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Conventional methods for measuring glomerular
filtration rate (GFR) and renal plasma flow (RPF) in man
are based on the renal clearance of inulin and p-
aminohippuric acid (PAH), determined by the laborious
constant infusion method, with which urine collections
are a major source of error. This thesis describes
alternative simpler methods using single injection
techniques with and without urine collections, using
appropriate pharmacokinetic analysis and a specific HPLC
assay for PAH and its acetylated metabolite (AcPAH).
The total body and renal clearances of inulin (70
mg/Kg) by the single intravenous injection technique
were similar to the renal clearance by the standard
constant infusion method, with sampling for the first
two hours. After this time the total body and renal
clearances of inulin declined progressively, following a
single injection in normal subjects, and patients with
renal impairment. The clearance of inulin was also
dependent on plasma concentration during constant
infusion at different plasma concentrations (35 to 187
mg/1). The renal clearance of creatinine remained
constant during these studies and the fall in inulin
clearance was therefore not due to renal changes in GFR.
In normal subjects the critical plasma concentration
below which the inulin clearances fell was about 100
mg/1, but was higher in patients with impaired renal
function. The fall in inulin clearance at low plasma
concentrations could be due to a lag in urinary
excretion or saturable tubular reabsorption. Selective
filtration of the high molecular weight polymers of
inulin was unlikely. The kinetics were consistent with
the saturable tubular reabsorption of inulin.
After a single injection of PAH (10 mg/Kg), the
total body and renal clearances of PAH also fell after
the first hour. The fall was even more dramatic than
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observed with inulin. About 17 % of the dose of PAH was
recovered in the urine as AcPAH. The renal clearance of
AcPAH was greater than the PAH clearance and it rose
after the first hour. The total body clearance of PAH
overestimated the renal clearance of PAH during both
constant infusion and after single injection, because of
metabolism to AcPAH. The renal clearance (but not the
total body clearance) of PAH varied directly with plasma
concentrations during constant infusion over the range 4
to 25 mg/1. The renal clearance of AcPAH was always
higher than the PAH clearance and was inversely related
to plasma PAH concentration. The data were consistent
with concentration-dependant renal acetylation of PAH.
The renal clearances of PAH during constant infusion and
for the first hour following single injection were
similar.
Estimation of GFR and RPF by the single injection of
inulin and PAH was quick, simple and easy. Using the
single injection methods, renal function in healthy
males was unaltered after administration of tenoxicam (a
new non-steroidal anti-inflammatory drug) for 10 days.
At low plasma concentrations, the renal clearances
of both inulin and PAH are plasma concentration
dependent. Further studies are required to reassess the
role of these compounds for measurement of the GFR and
RPF in man.
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STRUCTURE AND FUNCTION OF THE KIDNEY
The kidneys lie retroperitoneal^ on either side of
the vertebral column. Each consists of an outer cortex
and an inner medulla, leading into the renal pelvis and
ureters. The functional unit of the kidney is the
nephron, of which there are 1-1% million per kidney. A
nephron consists of the glomerulus and its capsule, a
proximal convoluted tubule, the loop of Henle and the
distal convoluted tubule. The nephrons are connected to
collecting ducts, which open at the calyx of the renal
pelvis, which in turn lead into the ureters and the
bladder. Juxtamedullary nephrons have a long loop of
Henle which extends deep into the medulla, while the
cortical nephrons have short loops which do not
penetrate far into the medulla (Fig 1.1).
Nephrons (a) Juxtamedullary. b) Cortical,
(from Tortora & Anagnostakos, 1984)
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Ultrafiltration of blood plasma occurs at the
glomerulus. The protein free filtrate enters the
proximal tubule and essential substances such as
glucose, electrolytes and amino acids are reabsorbed
here, together with 80% of the filtered water. The
proximal tubule cells can also secrete organic anions
and cations by specific active transport mechanisms. The
loop of Henle has a descending and an ascending limb,
and its main function is the concentration of urine in
conjunction with the medullary vasa recta and the
collecting ducts (the 'counter-current multiplier'). The
primary function of the distal tubule is facilitated
reabsorption of Na+ under the control of aldosterone,
and the secretion of H+, K+ and NH3". The collecting duct
reabsorbs water under the control of antidiuretic
hormone (Pitts, 1968; Guyton, 1986).
The kidneys receive their blood supply from the
abdominal aorta via the renal arteries. The renal artery
divides into anterior and posterior branches. The anter¬
ior branch supplies two thirds of the kidney. Segmental
arteries divide into interlobular arteries, from which
the specialised glomerular and peritubular capillary
beds arise. The latter are in close relationship to the
proximal and distal tubules, and long extensions supply
the loop of Henle (the vasa recta) (Brenner et al,
1987).
The function of the kidneys can be summarised as
filtration, reabsorption and secretion. They are
responsible for the maintenance of water and electrolyte
homoeostasis by varying the volume and composition of
urine, and the elimination of waste products (eg urea,
creatinine). The ability of the kidney to concentrate
and reabsorb constituents of the filtrate coupled with
its high blood flow (25% of cardiac output) and active
metabolism, make it a common site of drug toxicity (Rush
et al, 1984). Thus, it is essential to be able to
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monitor kidney function in man and various techniques
are available (Prescott, 1982a). Two important functions
that are commonly measured are the glomerular filtration
rate (GFR) and renal blood flow (RBF).
GLOMERULAR FILTRATION
The morphological studies of Bowman in 1842 provided
the basis for the understanding of the process of
glomerular filtration. He described the glomerulus as
ideal for the separation of water from plasma, but
thought that the urinary constituents were added by
secretion (Pitts, 1968). Ludwig in 1844 proposed that
the urine was formed by ultrafiltration at the
glomerulus to give a protein free filtrate containing
all urinary constituents, and that the filtrate was
reduced in volume by reabsorption (Pitts, 1968). Direct
evidence of glomerular filtration was subsequently
obtained by Richards (1934b) using micropuncture
techniques in amphibia, and urine was shown to be
derived from ultrafiltrate of plasma. This process was
confirmed in small mammals by Walker et 31/(1941).
Glomerular structure
The glomerular capsule is indented and envelops a
tuft of capillary loops, which spring from the afferent
arteriole and end in the efferent arteriole. The
glomerular capillary wall consists of three specialised
layers. On the blood side of the capillary lies, a layer
of endothelial cells separated by fenestrations or gaps
(500-1000 A0). These endothelial cells lie on an
acellular basement membrane composed of acidic glycos-
aminoglycans and a supporting matrix of collagen fibres.
On the urinary side of the basement membrane, lie a
layer of specialised epithelial cells (podocytes)
displaying a complex pattern of interdigitating foot
processes (pedicils) (Ryan, 1986).
- 4 -
Glomerular filtration dynamics
Filtration at the glomerulus is the first step in
the production of urine and approximately 180 litres a
day are filtered. The driving force for glomerular fil¬
tration is the hydraulic pressure gradient across the
capillary membrane. The glomerular filtration rate (GFR)
is dependant upon the balance of hydraulic (P), and
oncotic (11) pressure (Starling's forces) between the
capillary and the tubule. The oncotic pressure is
derived from the presence of proteins in the capillary
which are absent in the tubule fluid, therefore the
tubular oncotic pressure is essentially zero. Two other
important determinants are the intrinsic permeability of
the capillary wall (k), and the available surface area
(A) for filtration. Thus for a single nephron, the GFR
is determined by the relationship shown in equation 1
(Brenner & Humes, 1977; Baylis, 1986).
GFR = kA ( AP- All) (Equation 1)
( AP & All = mean difference in the hydraulic and
oncotic pressures between the capillary and tubule )
Alteration of the different components of equation
1, will have an effect on the single nephron GFR as
shown in Table 1.1. The glomerular capillary hydraulic
pressure is kept constant through a balance between the
afferent and efferent vascular resistance, and it is
always higher than the capillary oncotic pressure.
The GFR is maintained relatively constant over a
wide range of arterial blood pressures due to
autoregulation by intrinsic vascular responses of the
afferent and efferent arterioles. Vasoactive agents
involved in this process include angiotensin II, cate¬
cholamines (noradrenalin, dopamine), antidiuretic
hormone and prostaglandins. They act by modifying the
capillary resistance, capillary permeability and surface
area for filtration (Dworkin et al, 1983; Baylis, 1986;
Lote & Haylor, 1986).
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TABLE 1.1
A) Factors contributing to an increased GFR Examples Reason
1) increased mean hydraulic pressure hypertension AP
2) reduced plasma protein concentration malnutrition All
3) increased glomerular plasma flow rate Anaemia, pregnancy AH
B) Factors contributing to decrease GFk
1) reduced hydraulic pressure
2) increased plasma protein concentration
3) reduced glomerular plasma flow rate






(adapted from Brenner et al, 1987)
Glomerular filtration barrier
The glomerular capillary is very permeable to water,
but the ultrafiltrate normally contains very little
plasma protein or other macromolecules. The selectivity
of the glomerular barrier for filtration of large
molecules, is determined by their size, charge and
configuration (Deen et al, 1983). Molecules which have
an effective radius of 1.4 nm or less, are freely
filtered (fractional clearance = 1). As the effective
radius increases with increasing molecular size, the
fractional clearance diminishes progressively. It
approaches zero for serum albumin (effective radius 3.55
nm, MW 68000), but with neutral dextrans, the fractional
clearance does not approach zero until the effective
radius exceed 4.2 nm, possibly because of charge
selectivity. Albumin is anionic, and anionic dextran
sulphate shows a reduced fractional clearance compared
to neutral dextrans of the same effective radius. In
contrast, the fractional clearance of cationic dextran
is increased. This charge selectivity is due to the
presence within the capillary wall of fixed negative
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charges which are found in all regions of the capillary,
and are thought to impede the filtration of anionic
macromolecules (Bohrer et al, 1978; Brenner et al,
1978). The higher fractional clearances of neutral
dextrans could also be related to their linear polymeric
nature. These polymers are loose, randomly coiled,
hydrated spheres in free solution. These can unfold in
response to deforming forces of pressure and become
elongated, passing through the capillary wall by
reptation (wriggling end on through the interstices).
Such unfolding cannot occur with globular proteins such
as albumin because of the firm, internal cross-linking
or folded polypeptide chains (Ryan, 1986).
MEASUREMENT OF GLOMERULAR FILTRATION RATE
The measurement of GFR is important for the study of
changes induced by drugs, disease or physiological
factors. Clinically, it is used to assess renal function
in patients with nephro-urological disorders. Dosage
requirements for drugs which are excreted by the kidney,
and have a low therapeutic ratio, are based on the GFR.
If the renal clearance of a substance is greater than
the GFR, it must also be secreted, if it is less, then
reabsorption may be taking place (Brochner-Mortensen,
1985; Schuster & Seldin, 1985).
The single nephron glomerular filtration rate can be
measured directly in animals using micropuncture tech¬
niques, but this is not possible in man. The GFR can be
estimated for all functional glomeruli by measuring the
clearance of a suitable substance excreted by the kidney
(Levinsky & Levy, 1973). Clearance relates the concent¬
ration of a substance to its rate of elimination
(Rowland & Tozer, 1980) :-
rate of elimination = clearance x concentration
If an amount of such a substance is found in the
urine (Ax), then it must have been cleared from a volume
of plasma containing that amount. Thus, the renal
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clearance (Clr) can be conceived of as a proportionality
constant, relating the urinary excretion rate (dAx/dt),
to its plasma concentration (Cp). So it can be defined
as the virtual volume of plasma completely cleared of
that substance per unit time, and the renal clearance
can be estimated by comparing the amount of substance
excreted over time, to its concentration in plasma
(Gibaldi, 1984).
dAx/dt
Clr = (Equation 2)
Cp
In practice, the renal clearance of a substance x
(Clx) is calculated as follows :-
Ux V
Clx = ml/min (Equation 3)
Px
where Px and Ux are the concentrations of x in the
plasma and urine respectively, and V is the urine flow
rate in ml/min. Alternatively, the renal clearance can
be calculated from the slope of a plot of the urinary
excretion rate of a compound against the plasma con¬
centration, provided that' the renal clearance is
independent of the plasma concentration (Tucker, 1981).
The renal clearance can also be determined if the right





where the AUC is the area under the plasma concentra¬
tion-time curve for the corresponding time period. The
AUC is usually measured by the trapezoidal method
(Tucker, 1981).
These equations apply irrespective of the handling
of a substance by the kidney (ie, whether it is filtered
at the glomerulus, secreted or reabsorbed by the
tubules). It is therefore necessary to use a substance
which is cleared by the mechanism which represents the
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kidney function to be measured. For measuring GFR, an
ideal substances should have the following
characteristics (Smith, 1951)
It should be -
1) Non-metabolised and freely filtered by the
glomerulus.
2) Neither secreted nor reabsorbed by the tubules.
3) Neither bound to plasma proteins or stored in the
kidney.
4) Physiologically inert.
For such a test compound the renal clearance equals
the GFR.
Compounds used for measurement of the GFR
The clearance of urea was originally used as an
index of kidney function by Addis (1917), who showed
that the ratio of the rate of urea excretion per hour to
the blood urea concentration was constant, at maximal
urine flow rates. However, the rate of urea excretion is
dependent on the urine flow rate (Austin et al, 1921).
Moller, Mcintosh and Van Slyke (1929) introduced the
term 'clearance' in connection with urea excretion.
Rehberg (1926) chose creatinine as the index substance
because it was the urinary constituent which was
concentrated most, relative to plasma. Joliffe and Smith
(1931) extended the concept of clearance to creatinine,
and this principle is now widely used to define the
removal of substances from the body. Creatinine and urea
are unsatisfactory markers, because they are subject to
tubular secretion and reabsorption respectively.
Richards et al, (1934b) and Shannon and Smith,
(1935) compared the clearances of inulin, xylose and
creatinine and found that inulin appeared to best fit
the requirements for the ideal substance to measure GFR.
It has since become the universally accepted standard
marker (Schuster & Seldin, 1985).
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Inulin
Inulin was first isolated from artichoke tubers by
Rose in 1804 (McDonald, 1946). It is a polyf ructosan
(polysaccharide), which upon acid hydrolysis yields D-
fructose as the main product. It is insoluble in cold
water, but dissolves readily on heating to 80°C.
Supersaturated solutions may stay clear for 3 to 5 days,
before visable precipitation occurs (Phelps, 1965).
Inulin consists of an average of 30 fructofuranose
subunits in an unbranched chain which terminates with a




The structure of Inulin
The average molecular weight of inulin is about
5200, (Levinsky & Levy, 1973) with an average range of
4000 to 7200, depending on the method of determination,
and the time of year that the tubers are harvested
(Berglund, 1965; Phelps, 1965). However, inulin is not
homogeneous, and it consists of a complex mixture of
polymers, with a wide range of molecular weights up to
15,000 (Bassir, 1956; Mogensen, 1968). Commercial inulin
is composed of two fractions, an alkali labile fraction
of low molecular weight, which is hydrolysed by hot
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dilute alkali and an alkali stable fraction of high
molecular weight. The proportions of these fractions
vary from 1:12 to 2:1, in inulin from different sources
(Cotlove, 1954; Andreucci, 1978). However, their renal
clearances are reported to be similar. (Cotlove, 1954;
Walser et al, 1955).
The solvated inulin molecule is cylindrical, with a
semilength of 25 A0, a radius of 10 A0 (Middleton,
1977), and a diffusion coefficient of about 1.33 x 10"^
O
cmz/sec. This is consistent with a molecular weight of
about 15,000, and this discrepancy has been attributed
to an elongated configuration (Bunim et al, 1937;
Phelps, 1965).
Inulin clearance as a measure of glomerular filtration
Homer Smith (1951) has given a detailed account of
the validation of the inulin clearance as a measure of
GFR in animals and man. The urinary excretion rate of
inulin, is said to be proportional to its plasma
concentration over the wide ranges of 50-400 mg/100 ml,
(Shannon & Smith, 1935) and 5-90 mg/100 ml (Miller et
al, 1940). Thus, the renal clearance of inulin appears
to be independent of the plasma concentration (Fig 1.3a
& 1.3b). This suggests that inulin is freely filtered at
the glomerulus, and is neither reabsorbed or secreted by
the tubules. The renal clearances of substances which
are secreted (e.g. p-aminohippuric acid) or reabsorbed
(e.g. glucose) by the renal tubules approach the inulin
clearance when these mechanisms are saturated or
inhibited with phlorizin respectively.
Inulin is not bound to plasma proteins (Shannon,
1934; Richards et al, 1934a) or metabolised (Smith,
1951). It is nontoxic and inert, and has been given
intravenously in man for over 40 years in doses as high
as 160 g without reported ill effects. The only severe
reactions to inulin, have been associated with pyrogen
contamination (Shannon & Smith, 1935; Materson, 1971).
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FIG 1.3
The relationships between the rate of excretion (l.3a)
and clearance (1.3b) of inulin to plasma inulin concent¬
ration. (adapted from Pitts, 1968) Uin and Pin represent
the concentration of inulin in urine and plasma respect¬
ively. V is the urine flow rate
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Inulin does not affect the renal clearance of other
substances, (eg urea, xylose) and it is rapidly excreted
in the urine with quantitative recovery (Shannon & Smith*
1935; Schwartz et al* 1949; Ladefoged, 1969). Inulin
distributes slowly through the extracellular water, and
it has been used to determine the extracellular space.
Its volume of distribution is 13-16 % of the body weight
(Schwartz et al, 1949; Ladegaard-Pedersen, 1972). It is
thought that a small, but insignificant amount of inulin
is excreted in the bile (Smith, 1951).
The evidence that inulin is cleared at the rate of
glomerular filtration has been questioned by Berglund
(1965). He found that the renal clearance of poly¬
ethylene glycol (PEG 1000) in the rat was greater than
the inulin clearance, and suggested that the filtration




In man, the renal clearance of inulin has been
reported to decline, as its plasma concentration falls
(Ferguson et al, 1950; Barnard et al, 1955). However a
decline in the renal clearance of inulin after a single
injection was not observed by Alving & Miller (1940), or
during clearance measurements at different plasma
concentrations of inulin, produced by stepping up or
down the infusion rate (Kennedy & Kleh, 1953; Cole et
al, 1972). No evidence supporting either tubular
reabsorption of inulin or plasma concentration dependent
clearance, was found. In the rat, micropuncture studies
have shown that inulin is filtered freely at the
glomerulus, and urinary recovery is quantitative, after
an injection into the tubular fluid. Inulin was not
detected in the blood or urine from the contralateral
kidney (Gutman et al, 1965; Harris et al, 1974).
Mogensen (1968) infused inulin from different commercial
sources into normal subjects, and patients with renal
impairment. Sephadex gel filtration was used to separate
fractions of differing molecular weights in plasma and
urine, and the elution curves were identical, indicating
unrestricted filtration. Similar findings have been
reported in preterm babies (Coulthard & Ruddock, 1983).
Overall, the evidence strongly suggests that inulin
is cleared at the rate of glomerular filtration, and it
has become universally accepted as the standard marker
for measurement of GFR in both man and animals (Pitts,
1968; Schuster & Seldin, 1985).
Polyfructosan-S
This is an inulin analogue which was first isolated
from the bulbs of red squill by Schmeideberg in 1879
(Nitsch et al, 1979). It is a /3-D-fructan of the inulin
type, with branching at position 6. The molecular weight
distribution ranges from 800 to 16,000, with an average
of 3000 (Nitsch et al, 1979). Polyfructosan-S was intro¬
duced as an alternative to inulin because it is very
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water soluble and alkali stable (Materson, 1971; Nitsch
et al, 1979). Its renal clearance does not differ
significantly from that of inulin (Mertz, 1963; Levinsky
& Levy, 1973; Muller-Suur et al, 1983). Polyfructosan-S
is assayed in the same way as inulin after hydrolysis to
fructose (Materson, 1971), and it has been used to
measure GFR in both animals and man (Falbriard & Zender,
1964; Favre et al, 1968; Svenninigsen, 1975; Muller-Suur
et al, 1983).
CLEARANCE TECHNIQUES - INULIN
Constant infusion
Smith and his colleagues developed the standard
method for determining the GFR by measuring the renal
clearance of inulin at a constant plasma concentration.
An intravenous priming dose of inulin is administered to
achieve the required plasma concentration, and this is
followed by a continuous infusion, to maintain that
concentration. An equilibrium period of about one hour
is required to achieve steady state plasma concent¬
rations after which, accurately timed urine samples are
collected every 30 minutes for 3 hours. A plasma sample
is taken at the midpoint of each urine collection
period. The inulin clearance for each period is
calculated according to equation 3, and the mean value
is taken as the GFR (Smith, 1951). This method can be
accurate, but it depends critically on carefully timed
urine collections, and complete bladder emptying. This
requires bladder catheterisation and fluid loading to
ensure an adequate urine flow.
The normal mean values for inulin clearance compiled
by Smith (1951), and Wesson (1969), from numerous
investigators using the above technique, are 127-130
ml/min/1.73m^ for males, and 118-120 ml/min/1.73m^ for
females, aged 20 to 40 years. The inulin clearance is
about half the adult rate in the newborn, and it reaches
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adult levels by about 2 years of age. After 40 years of
age, there is a steady decline, and the decline in the
inulin clearance in the eighth decade is half that at 20
years (Davies & Shock, 1950a; Schuster & Seldin, 1985).
The normal range of inulin clearance is 72-176
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ml/min/1.73mz in males, and 81-137 ml/min/1.73mz in
females (Smith, 1951). Sources of variation include
experimental and analytical errors, and physiological
variation in the GFR. Experimental variability on the
day of measurement may produce a standard deviation of
about 9% (Kennedy & Kleh, 1953). Zender et al,(1968),
found an intra-assay coefficient of variation of 1.73%,
with an error in the measurement of urine flow rate of
7.1%. Urine collection is therefore an important source
of error. Davies & Shock (1950b) found greater variation
from day to day than in sampling periods on the same
day, and a day to day difference of 20 ml/min, repre¬
sented a 95% chance of a significant change in GFR.
Physiological influences on GFR include exercise,
pregnancy and stress. There is also a diurnal variation
in the inulin clearance, with the lowest values at 4.00
am and the highest at 2.30 pm. Thus, clearance measure¬
ments should be made at the same time of day (Wesson &
Lauler, 1961). A protein load increases the inulin
clearance in animals, and this also occurs in man, with
increases of up to 22% (Pullman et al, 1954).
Inulin clearance in disease
Measurement of the GFR has been described as "the
single best assessment of the severity and evolution of
renal failure" (Editorial, 1967), and the inulin
clearance has been widely used to measure the GFR in
patients with progressive renal failure (Skov, 1970;
Hagstam et al, 1974; Schnurr et al, 1980). However,
impairment of glomerular function may restrict free
filtration of inulin, and leakage may occur in the
presence of tubular damage (Smith, 1941). The former is
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unlikely as the renal clearance of hexitols, mannitol
and inulin are identical in patients with pre-eclamptic
renal failure and glomerulonephritis (Smith, 1941; Earle
et al, 1944). The inulin clearance is considered a
reliable index of glomerular filtration in patients with
diseased glomeruli and the nephrotic syndrome (Carrie et
al, 1980). The reliability of the inulin clearance has
been questioned in transplant patients and donors
(Rosenbaum et al, 1979), but the inulin, creatinine and
iothalamate clearances were similar in children
receiving renal transplants (Mak et al, . 1983).
Transtubular reabsorption of filtered inulin may occur
in experimental disease, tubular damage and nephro¬
toxicity induced by agents such as mercury (Bank et al,
1967; Biber et al, 1968). Thus, in patients with renal
impairment, there are still potential pitfalls in the
interpretation of the inulin clearance as a measure of
GFR.
Disadvantages of the constant infusion method for
measuring inulin clearance
This technique has come to serve as the reference
for other methods (Truniger et al, 1968). However, it is
tedious and cumbersome not only for the patient, but
also the investigator. Errors and problems arise because
of: -
1) INCOMPLETE BLADDER EMPTYING
2) IMMOBILISATION OF PATIENTS
3) DELAY TIME
1) INCOMPLETE BLADDER EMPTYING
The greatest single source of error is in the
collection of urine, and complete bladder emptying is
necessary for accurate estimations of GFR. In normal,
healthy young subjects, 1-2 ml of urine remain in the
bladder after micturition, so that at normal flow rates
of 1-2 ml/min, the error in a 30 minute collection
- 16 -
period could be as much as 7% (Tucker, 1981). Accurate
collections require bladder catheterisation with
washouts, but this carries the risk of urinary tract
damage and infection, and it is unpleasant. Errors due
to incomplete bladder emptying can be reduced by
A) Water diuresis, as the residual volume may then
be negligible, compared with the total volume excreted.
This in turn is a disadvantage, as fluid loading places
the kidney in an abnormal physiological state.
B) An increased period of collection. This in turn
prolongs the infusion period.
2) IMMOBILISATION OF THE PATIENT
The need for a continuous infusion to steady state
requires immobility for 3 to 4 hours. Also, the need for
at least four short urine collection periods with cathe¬
terization or fluid loading, makes the procedure a
trial, even for healthy subjects.
3) DELAY TIME
Its takes time for a substance to be filtered and
pass down the tubule, before it arrives in the bladder.
This delay time has two components, the time taken to
pass down the nephron, and the time for the new urine to
mix with that previously secreted (Nosslin, 1965). In
practice, this means that the rate of excretion lags
behind that appropriate for the plasma concentration at
a given moment. Thus, ideally the plasma should be
sampled between 2.5 and 5 minutes before the midpoint of
the urine collection period (Materson, 1971). In
patients with normal renal function, a delay time
correction factor can be determined from the urine flow
rate (Nosslin, 1965).
Due to these problems, the constant infusion method
for estimating GFR is impractical for routine clinical
use, and today it is employed mainly for research. The
need for urine collection and prolonged intravenous
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infusions, can be avoided by constant infusion without
urine collection and, single intravenous injections with
and without urine collection.
Constant infusion without urine collection
In this method, measurement of the plasma clearance
or total body clearance (TBC) of a test substance is
based on the assumption that, if steady state plasma
concentrations are achieved, the rate of infusion is
exactly equal to the rate of elimination. If, as with
inulin, the kidney is the only route of elimination the
rate of infusion equals the rate of excretion. The GFR
is equal to the rate of excretion divided by the plasma
concentration. Therefore, the total body clearance can
be determined simply by dividing the rate of infusion,





Earle and Berliner (1946), introduced this technique
with inulin to obviate the need for urine collections.
The results agreed well with values obtained using the
standard constant infusion method (Berger et al, 1948;
Cole et al, 1972; Schnurr et al, 1980). However, it is
not possible to establish whether steady state exists,
and the total body clearance of inulin determined this
way may be an overestimate of the simultaneously deter¬
mined renal clearance (Ladefoged, 1969; Rose, 1969).
These differences were attributed to incomplete bladder
emptying. The method has been reported to be the most
accurate in newborn babies, in which constant infusions
for 24 hours give the most reliable results (Coulthard,
1983).
The advantage of this technique is its simplicity.
All that is required is the infusion of inulin, and the
taking of one blood sample. The main disadvantage is
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that steady state plasma concentration has to be
achieved, and with normal renal function this takes
approximately 4 x the half life (Gibaldi, 1984), i.e.
about 5 hours for inulin. A much longer period is
required in patients with impaired renal function
although, this can be reduced somewhat with the use of a
loading dose. The patient is immobilised for a prolonged
period, and the method is of little use in dynamic
studies as, small changes in GFR will not be reflected
quickly by changes in the plasma concentration
(Materson, 1971; Cole et al, 1972).
Single injection without urine collection
This method also measures the total body clearance
(TBC) of a substance. If excretion is limited to the
kidney, and is solely by glomerular filtration, then the
TBC will equal the GFR (Wilkinson, 1987). After a single
intravenous bolus injection of a GFR marker such as
inulin, the plasma concentrations fall in a curvilinear
manner when plotted logarithmically against time. An
initial rapid decline in plasma concentration is due to
both distribution and elimination, and is followed by a
slower linear terminal phase due solely to elimination
(Notari, 1987). The clearance is calculated from the
plasma decay curve by relating it to the ratio of the
dose administered and, the area under the plasma
concentration-time curve (AUC) (Wilkinson, 1987). Plasma
concentration-time curves have been analysed and the
clearance calculated by three main pharmacokinetic
methods.
1) One compartment model (Slope-intercept method)
2) Open 2-compartment model
3) Model-independent analysis
1) In the one compartment model, the slope of
terminal linear elimination phase is extrapolated back
to zero time to give the initial plasma concentration.
It is incorrectly assumed that the inulin in plasma
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equilibrates rapidly with that in the extracellular
fluid. The terminal slope is taken to reflect removal by
GFR alone, (Newman et al, 1944) and the clearance is
calculated using the following formula:-
Dose Kl
TBC = (Equation 6)
B
Where Kl is the slope of the regression line and B is
the zero time concentration obtained by back extrapol¬
ation of the terminal linear slope to the Y axis. This
method requires few blood samples and is very easy.
However, the model is quite inappropriate as the whole
phase of distribution is ignored (Truniger et al, 1968;
Cohen, 1974), and it seriously overestimates the TBC.
Although it has been claimed that the one
compartment method using data obtained after a bolus
injection of inulin correlates well with the standard
inulin clearance, it is inevitable that the clearance
will be overestimated (Rosenbaum et al, 1973). Barnett
(1940) used a similar method and found a good
correlation between the slope of the terminal linear
phase, and the standard inulin clearance. A similar
approach has been used with Polyf ructosan-S, and the
results correlated well with the standard clearance.
(Falbriard & Zender, 1964; Zender & Falbriard, 1967;
Favre et al, 1968).
2) In the open 2-compartment model it is assumed
that the dose is injected into one central compartment,
and that it diffuses freely into a second peripheral
compartment with elimination from the central
compartment (Sapirstein et al, 1955). This is a commonly
used model for pharmacokinetic analysis. In practice,
the log plasma concentration-time curve is the resultant
of two simultaneous exponential processes, which can be
separated by curve peeling. The elimination phase is
derived from the terminal linear part of the graph which
is extrapolated back to the Y axis, giving a zero time
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concentration (B). The half life (t%/3 ) for this phase,
is calculated from the slope of the line using the
following relationship (Rowland & Tozer, 1980):-
LoglO 2
t\ = (Equation 7)
Slope
The rate constant for elimination is calculated by
dividing the natural log of 2 by the half life. The
early values of the original plasma concentration-time
curve exceed those of the back-extrapolated line, and
the differences yield a series of residuals. These are
plotted as a second straight line with an intercept on
the Y axis (A), and a half life (t%a ) (Fig 1.4). The
sum of A + B is equal to the maximum concentration at
zero time (Co).
This biexponential curve can be described using the
following equation:-
Co = Ae"a 1 + Be" & 1
where a and |S are the rate constants for distribution,
and elimination respectively. The total body clearance
(TBC) can be derived from the following relationship
between the area under the plasma concentration-time
curve (AUC), and the administered dose:-
DOSE
TBC = (Equation 8)
AUC o-c>£*
If the concentration-time curve is biexponential
(Notari, 1987):-
AUC O-OC = A/a + B/|(3 (Equation 9)
therefore:-
DOSE DOSE a J3
TBC = = (Equation 10)
A/a + B/jS a/3 + Ba
























This is the equation for TBC based on a two
compartment model (Cohen, 1974). The t%a = 0.693/q; and
the t% = 0.693/j3 where 0.693 is the natural logarithm
of 0.5. In reality, the situation is often more complex
with distribution into more than two compartments. In
such circumstances, the calculated clearance tends to be
overestimated (Chantler et al, 1969; Svenningsen, 1975).
The total body clearances of inulin and polyfructosan-S
have been measured using this model (Broberger, 1973;
Silkalns et al, 1973; Svenningsen, 1975; Fawer et al,
1979; Muller-Suur et al, 1983). It accounts for the
distribution of inulin after a bolus injection, and good
correlations were reported with clearances obtained by
the standard constant infusion method.
3) Model independent analysis requires no assumption
of the number of compartments or that the indicator is in
distribution equilibrium. The general form of the plasma
decay curve is not important, but it is assumed that all




TBC = (Equation 8)
AUC O-OO
In practice, it is not possible to measure the entire
plasma concentration time curve, and extrapolation from
the last data point to infinity is necessary to calculate
the area of the final "tail". The final AUC to infinity
can be calculated by dividing the last plasma concent¬
ration time point (P(t)), by the terminal elimination
constant ( /3 ).
P(t)
AUC t-OO = (Equation 12)
The curve may also be resolved into monoexponetial
functions by curve peeling, and the total area calculated
as the sum of the areas under each, i.e. for a two
compartment model, the AUC = A/CX + B/fi (see above). Thus,
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the appropriate compartmental analysis of the plasma con¬
centration time curve and model independent pharmaco¬
kinetic analysis reduce to the same terms, and are equiv¬
alent. The advantage of the model independent method is
no assumptions have to be made. If the compound is
eliminated completely by renal excretion, total body
clearance equals renal clearance.
Either method provides an absolute means of measuring
the GFR provided that 1) sufficient number of plasma
samples are taken to define the early part of the curve,
2) sampling is continued until the final slope is
attained and 3) the inulin clearance remains constant
during the sampling period. These methods are accepted as
the most accurate for measuring the TBC of a substance
after a single injection (Nosslin, 1965; Ladegaard-
Pedersen, 1972; Hall et al, 1977; Brochner-Mortensen,
1985). The total body clearance of inulin calculated by
the model independent method has been reported for inulin
in normal subjects (Ladegaard-Pederson, 1972), and in
patients with a single kidney (Rehling et al, 1984). The
latter author, also measured the renal clearance of
inulin at the same time and showed it to be significantly
less than the total body clearance.
Single injection with urine collection
Early investigators calculated the inulin clearance
from the terminal slope of the plasma concentration-time
plot using equation 3. It was assumed, that distribution
equilibrium had occurred between plasma and extracellular
water, and that the system conformed to a one compartment
model (Alving & Miller, 1940). This is not the case. The
renal clearance is more correctly estimated from the
amount excreted in a given time divided by the corres¬
ponding AUC (equation 4) (Notari, 1987). This gives a
time averaged value for the renal clearance, but urine
can be collected over a longer period of time. However,
collections must be complete. This technique is less
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sensitive to changes in renal clearance with time than
the constant infusion method (Tucker, 1981; Wilkinson,
1987). If venous blood is sampled, the renal clearance
may underestimate the true clearance if there are signif¬
icant differences between the arterial and venous plasma
concentrations (Brochner-Mortensen, 1985).
Alving and Miller (1940) introduced this method for
the clinical measurement of the inulin clearance. Robson
et al, (1950), doubted whether equilibration occurred
rapidly after a single injection and devised a formula to
correct for this, reporting good agreement with the
standard constant infusion method in 19 subjects (ratio
1.04 + 0.14). The same group also reported that the renal
clearance of inulin falls progressively after a single
injection, and suggested that inulin is reabsorbed by the
tubules (Ferguson et al, 1950). Some workers have report¬
ed a similar decrease in clearance (Josephson & Lindahl,
1943; Laake, 1954; Barnard et al, 1955), but others have
not (Alving & Miller, 1940; Carrie et al, 1980).
Denneberg et al, (1961), reported that the inulin
clearance can be calculated with reasonable accuracy by
dividing the 24 hour urine recovery of inulin, by the 0-2
hour plasma curve extrapolated to infinity. The
advantages and disadvantages of each technique for
measuring the GFR are summarized in Table 1.2.
Problems associated with single injection techniques
Objections to the use of single injection techniques
are related to errors associated with failure to take
distribution kinetics into account, adequate sampling,
arterial venous differences and the delay time (Smith,
1951). Some of these objections have been minimised by a
better understanding and application of pharmacokinetic
principles.
VOLUME OF DISTRIBUTION
Early investigators incorrectly assumed that inulin
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Table1.2
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measuresrenalcl ar ncdir ct y
needsurinecollection
is diluted instantaneously in the whole volume of distri¬
bution. However, equilibration between plasma and extra¬
cellular fluid takes a considerable time, as shown by the
progressive increase in the distribution volume (Levinsky
& Levy, 1973). In the 2 compartment and model independent
analysis, the distribution phase is taken fully into
account.
ADEQUATE SAMPLING PERIOD
The terminal elimination phase must be accurately
defined for measurement of the total AUC to derive the
total body clearance. In practice, this dictates the
sampling period and, if this is too short, the AUC to
infinity will be underestimated, and the total body
clearance overestimated (Chantler et al, 1969). The
sampling time may have to be greatly increased in
patients with renal disease or severe oedema and ascites,
due to an increased volume of distribution (Brochner-
Mortensen, 1985).
ARTERIAL-VENOUS DIFFERENCE.
Theoretically, the renal and total body clearances
should be estimated using arterial blood as, clearance is
defined as the volume of plasma flowing through the organ
of elimination completely cleared of inulin per unit
time, and this occurs from the arterial side. In
practice, venous blood is used, but this should not cause
large errors unless, there is a significant arterio¬
venous difference in concentrations (Wilkinson, 1987).
After an intravenous injection, uptake of the marker from
the circulation into tissues, means arterial concent¬
rations are initially high, but during the subsequent
post-equilibrium elimination phase, the venous concent¬
rations become greater due to reversal of this movement.
The clearance estimated from this venous plasma will be
lower than if calculated using arterial plasma (Brun et
al, 1949; Chiou & Lam, 1982).
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This is not a problem with the constant infusion
technique, where steady state plasma concentrations are
achieved (Smith, 1951), or with methods based on the
plasma concentration-time curve taken from zero time to
infinity, as the total area under the arterial and venous
plasma concentration-time curves should be identical
(Chiou & Lam, 1982).
DELAY TIME
This has already been discussed in the context of the
constant infusion method. In single injection techniques,
it only becomes a problem if urine is collected, but the
errors can be minimised by increasing the duration of the
collection periods (Pihl, 1973).
Inulin kinetics after a single injection
Following a rapid intravenous injection of inulin,
distribution equilibrium is thought to be reached within
40 to 60 minutes. There is net transport of inulin from
the plasma to interstitial fluid up to this time, after
which movement occurs in the opposite direction (Robson
et al, 1950; Schachter et al, 1950). Brun et al (1949),
found that venous concentrations of inulin were on
average 7% higher than the simultaneously determined
arterial concentrations in 4 subjects, two hours after an
intravenous bolus. Ferguson et al (1950), reported an
average arterial venous difference for 7 subjects of +1%
to -3% throughout the duration of the study over a
similar time period, while in another study in infants no
difference could be found (Broberger, 1973).
Inulin disposition appears to be consistent with a
two compartment model, in which distribution equilibrium
is attained between 40 to 60 minutes after the injection.
(Alving & Miller, 1940; Denneberg et al, 1961; Ladegaard-
Pederson, 1972; Broberger, 1973; Fawer et al, 1979;
Rehling et al, 1984). The same seems to apply to Poly-
fructosan-S (Falbriard & Zender, 1964; Muller-Suur et al,
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1983). However, Robson et al, (1950), observed a smooth
curvilinear concentration-time relationship after an
intravenous bolus of inulin, but in no subject did the
logarithm of the plasma concentration bear a linear
relationship to time.
The measurement of inulin clearance as a measure of GFR
today
The use of inulin to measure GFR is now limited to
research, except possibly in paediatrics. It is also used
in conjunction with the constant infusion method, as the
reference standard for validating other methods. Its
demise is due to two main reasons. 1) The chemical deter¬
mination of inulin is laborious and non-specific. (The
former problem has now been overcome, to a certain
extent, by the automation of the technique (Dawborn,
1964). 2) The constant infusion method is tedious and
cumbersome and therefore not clinically practicable
(Kampmann & Molholm-Hansen, 1981). Inulin is used in
research because it is the most reliable marker known for
the estimation of GFR, and the constant infusion is a
good method for studying dynamic changes over time
(Materson, 1971). Inulin has been replaced to some extent
by other endogenous and exogenous markers, not because
they more accurate than inulin but because their analysis
is easier.
ENDOGENOUS AND EXOGENOUS MARKERS
Urea
Urea is unsuitable for measurement of GFR because its
clearance depends on the urine flow rate (Schuster &
Seldin, 1985).
CREATININE
The endogenous creatinine clearance is measured most
extensively as an index of the GFR in clinical practice
(Schuster & Seldin, 1985). It is normally estimated from
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the creatinine content of a 24 hour urine collection, and
one blood sample. The creatinine clearance is influenced
by numerous factors including the rate of creatinine
synthesis, the method of analysis, and renal function.
Creatinine is produced by the spontaneous, non-
enzymatic dehydration of creatine and phosphocreatine.
About 2 7c of the creatine in muscle is converted to
creatinine daily (Borsook & Dubnoff, 1947), and patients
with decreased muscle mass (e.g. the elderly), have lower
rates of creatinine production (Cockcroft & Gault, 1976).
Depending on the method of analysis, errors may arise
because of interfering chromogens such as acetoacetic
acid and acetone in the blood (but not urine) (Kampmann &
Molholm-Hansen, 1981). The creatinine clearance
determined by autoanalyser methods, is comparable to the
inulin clearance, because the plasma creatinine
concentrations are overestimated (Healey & Graeme, 1968).
Creatinine is secreted by the renal tubules (Smith,
1951), and the 'true' ratio of the creatinine to inulin
clearance ranges between 1.01 to 1.68 (Healey & Graeme,
1968). Measurement of the creatinine clearance also
requires accurate urine collections. Although short urine
collection periods are convenient, and the midpoint
plasma sample is likely to be representative,
inaccurately timed collections and incomplete bladder
emptying can cause major errors, unless the subject is
supervised and hydrated (Doolan et al, 1962; Richardson &
Philbin, 1971). With a 24 hour collection period, the
clearance is not dramatically influenced by small errors
in timing or residual urine, and diurnal variation is
taken into account, but a single plasma sample may not be
representative (Camara et al, 1951; Pasternack &
Kuhlback, 1971). The plasma creatinine concentration
depends on physical activity and diet, the latter being
increased by eating cooked meat (Mayersohn et al, 1983).
The errors associated with diet, activity, diurnal
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variation and incomplete 24 hour collections produce a
day to day variation of 25% (Zender & Falbriard, 1967;
Brochner-Mortensen & Rodbro, 1976a). As renal function
declines in patients with renal disease, the creatinine
clearance progressively overestimates the GFR, as the
proportion secreted increases (Bauer et al, 1982; Shemesh
et al, 1985). Despite the many problems, nomograms and
formulae have been devised to take muscle mass, age and
sex into consideration. These allow the creatinine
clearance to be predicted from a single plasma creatinine
concentration (Cockcroft & Gault, 1976).
Exogenous markers
The majority of exogenous markers are radiolabelled
compounds, which are easy to measure. They include radio-
labelled inulin, vitamin B12, chelating agents, contrast
media, allantoin, mannitol, sucrose, thiosulphate, poly¬
ethylene glycol, dextrans, glucosamine and ferrocyanide
(Levinsky & Levy, 1973; Materson, 1971; Bianchi, 1972).
Today, the fashionable radiolabelled compounds are
iothalamate i^l) an(j Cr^^ ethylenediamine-
tetracetic acid (EDTA).
Iothalamate is not ideal, because it is secreted by
the tubules, and it also undergoes extrarenal clearance
(Odlind et al, 1985, Prueksaritanont et al, 1986).
Cr-^ EDTA is the most widely used alternative to
inulin. The renal and total body clearance of Cr-^ EDTA
correlates well with the inulin clearance, as measured by
the constant infusion method, although, it underestimates
it by about 5-15 % (Garnett et al, 1967; Heath et al,
1968; Chantler et al, 1969; Lavender et al, 1969; Hagstam
et al, 1974; Kampmann & Molholm-Hansen, 1981). It is
mainly used with the single injection technique, using
both one and two compartmental model analysis (Truniger
et al, 1968; Vogeli et al, 1971; Donath, 1971; Muller-
Suur et al, 1983). The latter, is the most accurate
method of determination, using the total area under the
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curve from zero to infinity (Brochner-Mortensen et al,
1969; Rehling et al, 1984). Simple methods which need
only two blood samples have been reported, and although
the GFR is overestimated, correction factors may be used
(Chantler et al, 1969; Brochner-Mortensen & Rodbro,
1976b).
Problems associated with the use of radiolabelled tracers
The use of radioactivity needs care and appreciation
of the associated dangers. The use of radioactivity is
deemed an unnecessary risk in children, and repeated use
in adults should be avoided. The potential risk of uptake
of iodine 125 & 131 into the thyroid, necessitates pre¬
medication with potassium iodide (Pearson, 1979). Iodine
131 & 125 and chromium 51 have short half lives, 8, 60
and 27.8 days respectively (Materson, 1971) and
therefore, their shelf lives are short. If any metabolism
or breakdown of the markers did occur, this would not be
not be readily detected.
MEASUREMENT OF RENAL BLOOD FLOW
The kidney is well perfused at a rate of about 4
ml/min/gm tissue. This rapid renal blood flow has three
major functions :-
1) to supply oxygen and nutrients.
2) to deliver metabolic waste for elimination.
3) to regulate renal function (e.g. glomerular filtra¬
tion, reabsorption, secretion, and concentration of urine
- the important events in urine formation).
90 % of the renal blood flow perfuses the cortex, and 10%
the medulla (Brenner et al,1987). The renal blood flow is
kept constant over a wide range of blood pressures by
autoregulation, which is maintained through intrinsic
vascular tone and vasoactive hormones such as, vaso¬
pressin and catecholamines (Pearson, 1979; Baylis, 1986).
Renal blood flow can be altered by disease states (e.g.
renal artery stenosis), physiological conditions (e.g.
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pregnancy) and drugs (e.g. non-steroidal anti-inflamm-
atories) (Pitts, 1968; Dunn, 1984).
Renal blood flow can be measured directly by renal
vein cannulation, and local thermodilution, but these
methods require general anaesthesia, and are not
practical for clinical use (Levinsky & Levy, 1973).
Indirect techniques are based on the Fick principle
(Brenner et al, 1987), where a quantity of a chemical
marker (Q), removed from the plasma by the kidney, is
equal to the amount present in the renal artery (Qa)
minus the amount present in the renal vein (Qv),
multiplied by the renal plasma flow, (RPF). Thus
Q = RPF x ( Qa - Qv ) (Equation 13)
If the marker is not synthesised, metabolised or
reabsorbed by the kidney, the quantity extracted Q, will
equal the amount excreted in the urine (Ux V), where Ux
is the concentration of x in the urine, and V is the
urine flow rate. So, by substituting and rearranging
equation 13
Ux V
RPF = (Equation 14)
(Qa - Qv)
If the marker is 100% extracted in one passage
through the kidney, then the amount of marker present in
the renal vein (Qv) will equal zero.
Ux V
So RPF = (Equation 15)
Qa
The renal blood flow can now be calculated, if the
proportion of blood to plasma is known from the
haematocrit, (HCT)) so:-
RBF = RPF/(1 - HCT) (Equation 16)
where the haematocrit is expressed as a fraction. In the
case of compounds that are not 100 % extracted, the renal
blood flow can be calculated from the following equation:
RBF = RPF/ Ex (1-HCT) (Equation 17)
where Ex is the extraction ratio of the compound being
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measured (Schuster & Seldin, 1985).
Historically, the first substance tested was phenol
red, but it had only a 70 % extraction (Marshall, 1931).
This was followed by hippuran, an iodinated hippuric acid
compound used in urography (Elsom et al, 1937). Smith et
al, (1938), realised that the plasma clearance of a sub¬
stance by the kidney must have an upper limit, which is
determined by the renal plasma flow, and they reported
that the clearance of diodrast could be used as a direct
measure of the RBF in man. It was later replaced by p-
aminohippuric acid as this was easier to assay (Smith et
al, 1945). p-Aminohippuric acid has since become the
standard for measuring renal blood flow.
p-Aminohippuric acid
p-Aminohippuric acid (PAH) is an organic anion of
molecular weight 194.2, with a pKa of 3.6. PAH is a
major metabolite of p-aminobenzoic acid, being
formed in the body by its conjugation with glycine. It is
freely soluble in water as the sodium salt (Beyer et al,
1945). PAH is partially plasma protein bound (10-20 %,
Taggart, 1951), and the free fraction is filtered by the
glomerulus. A further fraction is secreted across the
proximal tubule by active transport, via a specific
organic anion transport system (Pitts, 1968). The
secretion and uptake of PAH by the proximal tubule has
been widely studied, both "in vivo" and "in vitro"
(Moller & Sheikh, 1983; Weiner, 1985). The inhibition of
active PAH secretion reduces its clearance to the level
of the glomerular filtration rate. Metabolic poisons (e.g
2,4, dinitrophenol), direct competition for the transport
system (eg sulphonamides), disease states and saturation
of the transport system by PAH itself, all depress the
secretion of PAH (Moller & Sheikh, 1983; Weiner, 1985).
The saturation of PAH transport means that its clearance
is maximal at low plasma concentrations (below 30 mg/1).
At plasma concentrations of 400 to 600 mg/1, the tubular
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secretory capacity for PAH is saturated (Smith, 1951)
(Fig 1.5).
The extraction of PAH is decreased at plasma concent¬
rations above 30 mg/1 in patients with impaired renal
function (Chasis et al, 1945). Thus, the tubular
secretion of PAH is limited by a maximal rate (TmPAH),
and this can be measured to estimate tubular excretory
function in health and disease (Chasis et al, 1945;
Smith, 1951).
FIG 1.5
Relationship of PAH clearance to plasma PAH concentration
PLASMA PAH CONCENTRATION mg/l
The amount of PAH extracted (Epah) in one passage
through the kidneys, can be estimated if renal vein
catheterization is performed. In health this can vary
between 81% and 100% (mean 91 %) (Smith, 1951). Thus, the
PAH clearance underestimates the true renal plasma flow,
and can only be used as a measure of effective renal
plasma flow (ERPF). This can be corrected for if, the
extraction ratio is known. The extraction ratio will be
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affected by factors which interfere with the secretion of
PAH, as detailed above.
The clearance of PAH is only a measure of cortical
blood flow. Medullary blood flow is thought to make up
10-20% of the total (Berger and Herd, 1971), and this may
explain why PAH is only 90 % extracted. It has been
proposed, that the unextracted PAH fraction may be used
to calculate the medullary blood flow (Reubi, 1958), but
this is an overestimate (Levinsky & Levy, 1973). Any
diversion of blood from the renal cortex, will decrease
the extraction of PAH.
PAH clearance as a measure of renal plasma flow
The validity of PAH clearance as a measure of RBF
depends on the fulfilment of certain criteria (Cohen,
1974) :-
1) Complete elimination from the blood in one passage
through the kidney
2) No synthesis, metabolism or storage in the kidney.
3) It must be physiologically inert.
PAH is accepted as the best available compound for
measurement of the RBF as, it is almost completely
extracted during one passage through the kidney (90%) at
low plasma concentration, having a maximal constant
clearance with plasma concentrations between 7 and 30
mg/1 (Smith, 1951). In subjects with normal renal
function, the secretion of PAH is a linear function of
its concentration in plasma, until this is raised over 80
mg/1, at which level the secretory mechanism begins to
saturate. The maximal rate of PAH secretion (Tmpah) can
be estimated where Tm is equal to the maximal rate of net
transport, which is in the region of 80 mg/min/1.73m
(Pitts, 1968; Schuster & Seldin, 1985). It is not thought
to be taken up by erythrocytes (Smith et al, 1945). PAH
is thought to be eliminated solely by the kidney, and it
is easily analysed in plasma and urine using colorimetry
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or high performance liquid chromatography (Smith et al,
1945; Meerdink et al, 1981).
The use of PAH clearance as a reliable estimate of
RBF has been questioned, because PAH is metabolised to
some extent to the N4 acetyl derivative (Fig 1.6) both in
animals and man (Smith, 1951). This metabolic loss is
thought to be insignificant, and to occur extrarenally
(Smith, 1951; Pearson, 1979). However, there is other
evidence that PAH is metabolised in the kidney in animals
(Setchell & Blanch, 1961; Gyrd-Hansen & Rasmussen, 1970;
Malyusz et al, 1979; Carpenter & Mudge, 1980). In man,
kidney acetylation of PAH has been demonstrated "in
vitro", (Frindt & Vial, 1968) and may occur "in vivo",
(Newman et al, 1949; Grindt et al, 1974). The latter
investigators, have also reported that PAH is
deconjugated to p-aminobenzoic acid and its acetyl
derivative (Fig 1.5).
Despite these potential problems, the PAH clearance,
determined with the classical constant infusion technique
remains the standard reference method for measuring RBF
(Pearson, 1979; Brenner et al, 1987).
CLEARANCE TECHNIQUES-p-Aminohippuric acid
The standard method for measuring PAH clearance is
the classical infusion method of Smith (1951), as
described for inulin (page 14). The steady state plasma
concentration of PAH must be kept below 30 mg/1, to
insure maximum extraction. The problems with the constant
infusion of PAH are the same as with inulin, (eg the need
for complete accurately timed urine collections). Other
aromatic amines (eg sulphonamides, and procanamide),
interfere with the colorimetric analysis of PAH (Waugh &
Beall, 1974), and high plasma glucose levels depress the
PAH clearance by a direct effect on tubular transport or,
formation of a glucose-PAH complex, which may not be
detected (bote et al, 1985; Greene et al, 1987).
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Fig 1«6



























The average value for PAH clearance (effective renal
plasma flow), for the age range 20 to 40 years are 654 +
163 and 592 + 153 ml/min/1.73 , for men and women
respectively. Thus, the average effective renal plasma
flow shows a wide variability, with the 95 % confidence
limits for PAH clearance ranging from 328 to 980 in men,
and 268 to 898 ml/min/1.73 m^ in women. If it is assumed
that the average Epah is 0.9, then the renal plasma flow
will be in the range 364-1088 and 298-998 ml/min/1.73 m^
respectively. Again, taking an average haematocrit for
males as 45% and females 40%, the total renal blood flow
will be 662-1978 and 497-1663 ml/min/1.73 m^ respectively
(Smith, 1951; Wesson, 1969). Davies and Shock (1950b),
showed that the diodrast clearance (which has a similar
clearance to that of PAH), determined in a single person
on different days, would have to differ by more than 165
ml/min/1.73 m , to represent a significant change at the
5% level. There is also diurnal variation in the PAH
clearance as with inulin (Wesson, 1969), and age also
influences the PAH clearance. In infants up to three
months of age, the Epah is approximately 60%, whilst
after 50 years, the PAH clearance falls by 20 ml/min/
decade. (Davies and Shock, 1950a).
The use of PAH clearance as a measure of RBF in
patients with renal disease, depends on the extent of
extraction of PAH. In glomerulonephritis, and nonspecfic
nephropathies, the PAH extraction is reduced in some
patients (Brodwell, 1964). Therefore, when using PAH to
measure RPF in renal disease, it is necessary to know its
extraction ratio (Schuster & Seldin, 1985).
Simplification of the constant infusion method to
measure PAH clearance has been attempted, in the same way
as for measuring the clearance of inulin.
The constant infusion of PAH without urine collection
The renal plasma flow was first measured using this
technique by Earle and Berliner (1946). When the plasma
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samples were hydrolysed to determine total PAH (as a
small proportion of PAH is metabolised), a good corre¬
lation with the standard method was attained (Berger et
al, 1948). Without the hydrolysis step, the total body
clearance of PAH overestimated the simultaneous calcu¬
lated renal clearance by 20-30 %. This was thought to
represent the amount eliminated by metabolism (Cole et
al, 1972, Statius Van Eps, et al 1967). More recently,
Schnurr et al (1980), reported a good correlation between
the total clearance and renal clearance using this
method, but they did not state whether the analytical
method included hydrolysis. The disadvantages of this
technique have already been presented (page 18, and Table
1.2, p 26). One other potential source of error with this
method is, the possibility that products other than PAH
will be formed during hydrolysis, and that these will
give a positive reaction on analysis (i.e p-aminobenzoic
acid, Brown et al, 1976)
The single injection method
Single intravenous injection techniques have been
used to estimate PAH clearance both with, and without the
collection of urine. Early workers, used single injection
with urine collection and calculated the renal clearance
from the amount excreted divided by the midpoint plasma
concentration, taken from the semilogarithmic plot
against time (Landowne and Alving, 1947; Newman et al,
1949). The latter reported that in man (but not in dogs),
the clearance of PAH fell, as the plasma concentration
declined. Neither group validated their results by
comparison with the classical infusion method.
Tacket and Houck (1950), calculated the total body
clearance of PAH on the basis of a one compartment
pharmacokinetic model, and claimed that a semilogarithmic
plot of the plasma decay curve against time was linear,
50 minutes after the injection. With this model, they
only obtained a good agreement between the PAH clearance
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and the simultaneously calculated renal clearance, if the
distribution volume of mannitol was used, instead of that
of PAH. They also reported that the average renal clear¬
ance of PAH increased, as the plasma concentration
declined. Rosenbaum et al,(1973), used a one compartment
model, with plasma concentration data 30 to 45 and 45 to
60 minutes after the injection, and found that the plasma
clearance of PAH consistently overestimated the values
obtained by the standard infusion method. Similar find¬
ings were described in children, but the model was not
specified (Boineau et al, 1974).
Mandel et al,(1955), used a two compartment model in
dogs, and found good agreement in 11 of 15 studies, with
the PAH clearance estimated from a constant infusion.
PAH was apparently cleared by patients with no
kidneys after a single injection, using a one compartment
model (Rosenbaum et al, 1973), but this was not confirmed
in anuric patients, with a hydrolysis step during
analysis of the plasma (Tacket & Houck, 1950). The
clearance of PAH following a single injection is lower if
peripheral venous, rather then arterial plasma
concentrations are used (Newman et al, 1949; Tacket &
Houck, 1950). The venous clearance was 16 % lower than
those calculated using arterial clearance (Tacket &
Houck, 1950). The distribution of PAH is thought to be
complete by 30 to 50 minutes, after an intravenous bolus
injection (Tacket & Houck, 1950; Rosenbaum et al, 1973).
The potential problems with single injection techniques
have been mentioned previously (pages 25-28, and Table
1.2, p 26).
Other methods for the estimation of the PAH clearance
by single injection have been proposed, using intra¬
muscular, (Bucht, 1949) and subcutaneous (Brun, 1951)
routes. These methods cause pain on administration, and
the rate of absorption is variable.
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OTHER TEST COMPOUNDS
1 ? S 1 ? 1
Radiolabelled substances, including I and i-LJ-L
1 O -J
hippuran (ortho-iodohippurate) and jJ-j-l diodrast
(iodopyracet), have been introduced as alternatives for
PAH. Their clearances, after a single injection,
correlate well with the simultaneously determined PAH
clearance, during a constant infusion (Elwood et al,
1965; Maher et al, 1971; Silkalns et al, 1973; Pearson,
1979). Predictably, two compartmental pharmacokinetic
analysis is the most accurate model for determination of
1
hippuran clearance. Simplification, with reduction
in the number of blood samples and the use of a one
compartment model, overestimates the true clearance
(Taylor et al, 1985). The major disadvantage of the use
of radiolabelled iodinated compounds is, the risk of
uptake into the thyroid gland (Pearson, 1979). The
clearance of hippuran after single injection has a
coefficient of variation of 25% (Favre, 1978). The renal
clearance of radiolabelled iodohippurate has been shown
to decline with time, and falling plasma concentrations
(Pihl, 1973), and radiolabelled iodopyracet clearance is
reduced at low plasma concentrations, this being
attributed to increased plasma protein binding (Block &
Burrows, 1960).
Radioactive isotopes such as 131 Xenon have been used
for measuring renal blood flow, by the gas washout
technique (Pearson, 1979).
SUMMARY
Glomerular filtration is a major mechanism of renal
excretion, and the methods used for its measurement are
based on the clearance of a specific marker. The uni¬
versal standard is inulin, but measurement of its clear¬
ance by the constant infusion method is time consuming,
and subject to errors, because of inaccurate urine
collections. Single injection techniques are more
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practicable for routine use, but proper pharmacokinetic
analysis using either, open two compartment model or
model independent methods, are essential. The endogenous
creatinine clearance is the most widely used index of
GFR. It is convenient, and analysis are routine in most
hospitals, but it is far from ideal. Radiolabelled
markers have been used in some establishments, for the
S1
routine measurement of GFR. Cr L EDTA is a popular
replacement for inulin, but it underestimates the inulin
clearance by 5-15 %. Radiolabelled markers and creatinine
are only used because of ease of analysis.
Because of the problems associated with radio¬
activity, and the unreliability of the measurement of
creatinine clearance, the single injection of inulin has
been re-evaluated as a simple, safe, practicable and
reproducible method of estimating the GFR.
Measurement of the renal clearance of PAH by the
constant infusion method, is thought to be a good
estimate of the renal plasma flow, and has long been the
standard reference method. Due to its limitations, this
method is mainly restricted to research applications.
Radiolabelled hippuran and diodrast have been
introduced as clinically practicable substitutes for PAH.
Their clearances can be estimated using single injection
methods, and appropriate pharmacokinetic analysis.
Measurements of the PAH clearance have been attempted by
the constant infusion method without urine collection,
and by single injection. These methods estimate the total
body clearance of PAH, and this is an overestimate of the
renal clearance because there is significant extrarenal
elimination of PAH by acetylation. Thus, methods in which
urine PAH is not determined, will be inaccurate. There is
evidence that PAH is metabolised by the kidney, and this
raises the possibility that the measured renal clearance
of PAH, actually underestimates its true clearance.
The disposition and formation of acetyl PAH and its
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influence on the measurement of PAH clearance, has been
investigated following a single injection and during
constant infusion of PAH.
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CHAPTER TWO
SINGLE INJECTION METHOD FOR THE MEASUREMENT OF GLOMERULAR
FILTRATION RATE USING INULIN
- 45 -
SECTION I
Evaluation of a single injection technique for the
measurement of inulin clearance
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INTRODUCTION
Accurate measurement of the glomerular filtration
rate (GFR) is necessary to assess changes induced by
drugs, disease or physiological factors. Measurement of
the renal clearance of inulin during constant intravenous
infusion at steady state plasma concentrations, is the
reference technique. However, this technique is tedious
and cumbersome for both patient and investigator, and it
requires short, accurately timed complete urine collect¬
ions. This necessitates bladder catheterization, which is
unpleasant, and carries the risk of urinary tract infec¬
tion. In addition, the obligatory water diuresis places
the kidneys in an abnormal physiological state. These
factors, combined with lengthy immobilisation of the
patient, make this method impractical for routine
clinical use, and it is now reserved mainly for research
purposes (Kampmann & Molholm-Hansen, 1981). The
creatinine clearance is used as the standard clinical
indicator of GFR, however, it overestimates the true GFR
because of tubular secretion, and this disparity
increases with decreasing GFR (Bauer et al, 1982). More
convenient and accurate clinical assessments of GFR are
now being calculated from plasma concentration-time decay
curves, following single injection of radiolabelled
tracers (Brochner-Mortensen, 1985). The two most commonly
used are Cr^ EDTA and i^l iothalamate. Cr-^ EDTA
underestimates the inulin clearance by 5-15%, and the
suitability of iothalamate has recently been questioned,
because of evidence of tubular secretion and extrarenal
elimination (Brochner-Mortensen, 1985; Odlind et al,
1985). These techniques have become widely accepted for
clinical use, as urine collections are not required.
The measurement of the inulin clearance following a
single intravenous injection has been limited, even
though it is the standard marker for the estimation of
GFR. The early methods still required urine collections,
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and were based on inappropriate pharmacokinetic analysis;
some workers reported a fall in the inulin clearance
following a single injection (Josephson & Lindahl, 1943;
Barnard et al, 1955). More recently, the single injection
of inulin has been reported in children (Broberger, 1973;
Muller-Suur et al, 1983), but studies in adults are
limited, and results have not been compared with the
reference method (Ladegaard-Pedersen, 1972; Rehling et
al, 1984). With the increasing recognition of
pharmacokinetic principles and their correct application
for the estimation of clearance, the use of single
injection techniques is practical for the clinical
measurement of the GFR. As inulin is still the reference
standard, and the problems associated with analysis have
been partially overcome with the introduction of
automated methods (Dawborn, 1964), it seems that the
inulin single injection technique using appropriate
sampling and kinetic analysis, would be preferred for the
estimation of GFR in adults. The technique is simple,
safe and practical, and it obviates the need for accurate
urine collections, and the use of radioactive markers.
This is particularly important in studies with repeated
measurements.
METHODS
The inulin clearance was measured in 10 healthy male
volunteers, aged between 21-50 years (mean 26 + 9 years)
weighing 74 + 7 Kg (range 63-83 Kg) by both the trad¬
itional constant infusion method, and a single injection
technique. The methods were used in random order, and the
two studies were carried out within fourteen days.
Volunteers
The volunteers were medical students, department
staff and healthy males from Edinburgh, recruited by
newspaper advertisement. All underwent a physical examin¬
ation, and were screened for normal biochemical and
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haematological values. They gave informed consent before
participation, and the study was approved by the local
ethical committee.
Procedure
The volunteers fasted from 22.00 hr, and reported to
the department at approximately 8.30 am the next morning.
The fluid intake for both techniques was similar. The
volunteers drank 500 ml of water an hour before the
study, and thereafter they drank 100 ml (constant
infusion), or 130 ml (single injection) of water every
half hour, for 3-4 hours during the constant infusion,
and up to 8 hours on single injection days, to ensure an
adequate urine flow. On the "single injection" day,
subjects were allowed a light lunch at four hours. The
subjects remained supine for the first four hours on
single injection days, and for the duration (3-4 h) of
the constant infusion. The same batch of inulin (Kerfoot,
Barnsley. U.K.), was used for each individual, on both
study days. It was prepared by heating a 50 ml (10 % w/v,
5g) ampoule in a beaker of water at 80°C for 15 minutes,
until a clear supersaturated solution was obtained. The
solution was cooled before administration. p-Amino-
hippuric acid was also administered in the following
studies, and the results appear in chapter 3.
Constant infusion method
The inulin clearance was measured by the traditional
constant infusion method of Smith (1951), as modified by
Mackay et al, (1984). On arrival at the unit, the volun¬
teers emptied their bladder, and an aliquot of urine was
kept as a control blank. The subject was weighed, and
cannulae (Venflon, 1.2 mm O.D), were inserted into veins
in each forearm. A control blank blood sample (10 ml),
was drawn. One cannula was attached to an infusion pump
(Braun Perfuser) via an infusion line, and a loading dose
of 2.3 g of 10 % inulin solution was administered over 5
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minutes. The infusion was then commenced with a solution
containing inulin (18.1 mg/ml, 10 % solution) in 5 %
dextrose, given at a rate of 1 ml/min. After an equil¬
ibrium period of one hour, the bladder was emptied, and
four, half hourly timed urine samples were collected.
Venous blood (10 ml) was withdrawn at the start, and end
of each urine collection period, using the cannula not
used for the infusion. It was kept open by flushing with
1 ml of heparinised saline (10 units/ml), after taking
each blood sample.
Single injection technique
The initial procedure for this technique was as
described above. Inulin (70 mg/Kg, 50 ml, 10% w/v
solution), was given as an intravenous bolus injection.
The inulin was injected (Braun Perfuser) over five
minutes, after which the infusion line was flushed
through with normal saline. The cannula was then removed.
Blood samples were collected (10 ml) at 10, 15, 20, 30,
40, 50, 60, 75, 90, 120, 180, 240, 360 and 480 minutes
after the start of the injection. Urine was collected
hourly for the first four hours then at 6, 8 and 24 hours
(initially a 4-8 h sample was collected). The inulin
syringe was weighed full before and again empty after
administration, to allow calculation of the exact dose.
Sample preparation and storage
The blood samples were collected in 10 ml lithium
heparin tubes, and centrifuged at 1500 g for 10 minutes.
The plasma was removed, and stored in 5 ml plastic tubes
at 4°G. Urine volume and pH (Radiometer) were measured,
and a 20 ml aliquot was stored at 4°C. The plasma and





Plasma and urine inulin were determined by the method
of Heyrovsky (1956), adapted for automated analysis
(Dawborn, 1964).
Inulin is hydrolysed to fructose with hydrochloric
acid, and on incubation with 3-indolylacetic acid, a
purple colour develops.
STANDARDS
Aqueous standards were made by diluting inulin (5g,
10 % w/v solution, Kerfoot. Barnsley, U.K.), or "Inutest"
(5g, 25 % w/v solution, Lavevosan-Gesellschaft, Linz,
Austria), with distilled water to give solutions
containing 50-500 mg/1.
PROCEDURE
Plasma and urine samples were run under the same
conditions, using a Technicon Autoanalyser. Plasma
samples were estimated directly, and urine was diluted 1
in 10 with distilled water.
The plasma, urine and aqueous standards were diluted
1:2 with 0.5 N hydrochloric acid (BDH, Poole, U.K.), and
the inulin was hydrolysed by heating at 60°C for 10
minutes in a double-coil heating bath. The fructose was
separated from plasma proteins by dialysis across a
Cuprophane membrane (Altex, U.K.), for 7 minutes at 37°C.
The protein-free dialysate was then incubated with
concentrated hydrochloric acid and 3-indolylacetic acid
(BDH, Poole, U.K.) at 60°C for 8 minutes in the second
coil of the heating bath, and the colour intensity
estimated photometrically at 520 nm. The concentrations
of unknown samples were obtained by reference to a
standard calibration graph.
2) Creatinine
Creatinine was determined using a standard
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autoarialyser method (Gemstar Electro-Nucleonics, W.
Germany). The assay is based on the Jaffe reaction, in
which creatinine forms a yellow-orange compound with
picric acid in alkaline solution. The absorbance change
measured at 500 nm, is proportional to the concentration
of creatinine, after correction for the reagent blank.
Calculation of clearance
Constant infusion method
Inulin and creatinine clearances were calculated for
each half hour collection period using the formula:-
Ux V
Clx = (Equation 3)
Px
where Clx is the renal clearance of inulin or creatinine,
Ux and Px are the urinary and midpoint plasma concent¬
rations respectively, and V is the urine flow rate. The
midpoint plasma concentration was taken as the mean of
the concentrations at the beginning, and end of each
collection period. The clearances for each half hour
period were averaged, to give a mean value.
The coefficient of variation for the clearances
determined in each collection period, were calculated for
each individual by dividing the standard deviation by the
mean and multiplying by 100.
Single injection technique
The inulin clearance was calculated from the plasma
concentration-time data alone (total body clearance,
TBC), and also from the plasma concentration and urinary
excretion rate (renal clearance). The area under the
plasma concentration time curve (AUC), was calculated by
the trapezoidal method.
The TBC was calculated from the following
relationship:-
DOSE
TBC = (Equation 8)
AUC 0-OO
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The administered dose was estimated by weighing the
syringe full prior to, and empty after administration.
The weight of 1 ml of inulin was measured for each diff¬
erent batch used, and the dose (g) was calculated from
the following equation :-
Weight full - Weight empty
DOSE =
Weight 1 ml of inulin
Zero time for the calculation of the AUG was taken as
2.5 min after the start of the injection, i.e. the
midpoint of the period of administration. The time points
for calculation were therefore 7.5, 12.5, 17.5, 27.5,
37.5, 47.5, 57.5, 72.5, 87.5, 117.5, 177.5, 237.5, 357.5
and 477.5 minutes.
The total area under the plasma concentration time
curve was calculated by pharmacokinetic analysis, based
on an open 2 compartment model. A non-linear weighted
least squares algorithm (damping Gauss-Newton), was used
to obtain the parameters for the best fit of the experi¬
mental data, using the microcomputer programme of Yamaoka
et al, 1981. From the best fit parameters, the plasma
concentration at zero time (Co), and the terminal elimin¬
ation rate constant, were obtained. The total AUC was
obtained by adding the actual AUC (i.e 7.5-477.5 minutes)
to the AUC calculated from Co to 7.5 minutes, and the
area extrapolated from 477.5 minutes to infinity. This
latter area, was calculated by dividing the plasma
concentration at the last data point, by the terminal
elimination rate constant (Notari, 1987).
The renal clearance (Rcl) of inulin, was calculated
using the following relationship:-
amount excreted in urine tl-t2
Rcl = (Equation 4)
corresponding AUC tl-t2
where tl-t2 is the time of the collection period. The
actual AUC was calculated using the trapezoidal rule. The
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AUC from zero time (Co) to the first time point, was
calculated by back extrapolation to the y axis. The renal
clearance was calculated for each urine collection
period, except 8-24 hours, and the data for the periods
4-6 and 6-8 hours were combined, to give results for 4-8
hours.
Creatinine clearance was calculated for the same
collection periods using equation 3, except 0-1 hours.
The creatinine clearance was not calculated for the 0-1
hour collection period, as in the majority of
individuals, the timing of this collection period was not
always accurate. This did not affect the renal clearance
of inulin as, the time from the injection to the end of
the first collection period was known, and the
relationship of clearance to urinary excretion rate and
AUC, is described by equation 4.
All clearances were corrected for a body surface area
(SA) of 1.73 :"
CI x 1.73m^
Corrected clearance = = ml/min/1.73 m
SA
The surface area was estimated from body weight and
height by a nomogram (Du Bois & Du Bois, 1916).
Statistical methods
Statistical analysis was carried out using 2 way
analysis of variance (ANOVA) to test for differences in
clearances between collection periods, against time, and
plasma concentration. The significance between means was
also determined using a students two tailed "t" test. The
Wilcoxon nonparametric rank sum test, was used to deter¬
mine the statistical significance of differences in the
coefficients of variation. The null hypothesis was
rejected when p< 0.05. Correlation coefficients were





Steady state inulin plasma concentrations were
achieved in each subject. The mean plasma concentrations
after the equilibration period to the end of the study
ranged from 172 + 21 to 169 + 14 mg/1 (Fig 2.1.1).
Individual plasma concentrations are listed in Appendix
I.
Renal clearance of inulin and creatinine
The individual clearances for inulin and creatinine
are given in Table 2.1.1 & 2.1.2 respectively. The mean
renal clearances of inulin during the four collection
periods ranged from 89 + 14 to 87 + 11 ml/min/1.73 m ,
and the corresponding creatinine clearances ranged from
120 + 9 to 106 + 9 ml/min/1.73 m^ (Fig 2.1.1). There were
no significant differences in clearance between the
collection periods for inulin but, there was a
significant fall in the creatinine clearance between 1-1%
hours and 2%-3 hours (120 vs 106 ml/min/1.73 m^, p<
0.002)
The mean period to period coefficient of variation in
creatinine clearance was 7.7 %, and this was




Following intravenous bolus administration, the
plasma concentrations of inulin fell rapidly in all
subjects in a curvilinear manner, when plotted semi-
logarithmically against time (Fig 2.1.2). The plasma
concentration-time curve up to eight hours could be
fitted to a three compartment model, and was log-linear
only from 4 to 8 hours. Up to two hours it was possible
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Fig 2.1.1
Mean plasma inulin concentrations (top) and inulin and
creatinine renal clearances (bottom), during a constant

























































The renal clearance of inulin during constant infusion of inulin in
210 healthy males. The clearances are expressed as ml/min/1.73 m .
The mean JJ3D for each subject and each collection period are given
together, with the individual period to period coefficient of
variation (CV).
COLLECTION PERIOD (hours)
SUBJECT 1-1^2 l%-2 2-2i; 2^-3 MEAN + SD CV %
RM 84 81 84 86 84 2.1 2.5
LP 91 88 87 90 89 1.8 2.1
GC 84 85 79 80 82 2.9 3.6
JN 74 70 73 71 72 1.8 2.5
DM 97 92 100 98 97 3.4 3.5
MK 141* 114 92 97 101 11.5 11.4
CP 84 80 78 85 82 3.3 4.0
BH 72 85 88 83 82 7.0 8.5
BS 86 80 83 76 81 4.3 5.3
PL 109 110 107 103 107 3.1 2.9
MEAN 87 89 87 87 88 4.1 4.6
+SD 11 14 10 10 11 3.0 3.0
* Not included in mean due to incomplete bladder emptying at the
end of the equilibration period
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TABLE 2.1.2
The renal clearance of creatinine during constant infusion of
inulin in 10 healthy males. The clearances are expressed as
O
ml/min/1.73 m . The mean +_SD for each subject and each collection
period are given together, with the individual period to period
coefficient of variation (CV).
COLLECTION PERIOD (hours)
SUBJECT l-lh 1^-2 2-2\ 2^-3 MEAN + SD CV %
RM 136 123 128 124 128 5.9 4.6
LP 108 95 100 98 100 5.6 5.5
GC 124 115 109 107 114 7.6 6.7
JN 117 96 98 94 101 10.6 10.5
DM 124 111 119 108 115 7.3 6.3
MK 163* 119 99 102 107 10.8 10.1
CP 112 105 104 103 106 4.1 3.9
BH 113 142 122 113 122 13.7 11.2
BS 124 101 109 102 109 10.6 9.7
PL 125 131 132 110 124 10.2 8.2
MEAN 120 114 112 106 113 8.6 7.7
+SD 9 15 12 9 10 3.0 3.0
* Not included in mean due to incomplete bladder emptying at the











to fit the data to a two compartment model. The mean
plasma inulin concentrations declined from 686 + 95 mg/1
at 10 minutes, to 22 + 11 mg/1 at 480 minutes. Individual
plasma concentrations are listed in Appendix I.
Renal clearance of inulin
The individual renal clearances of inulin for each
collection period are given in Table 2.1.3. The mean
renal clearance of inulin was relatively constant over
the first two hours, but after this time there was a pro¬
gressive and significant fall (p< 0.01). The mean renal
O
clearances were 92, 94, 78, 69 and 48 ml/min/1.73 m over
the periods 0-1, 1-2, 2-3, 3-4, and 4-8 hours respect¬
ively. The 0-1 hour renal clearance of inulin was signif¬
icantly greater than at all times after 2 hours (P<
0.003) (Fig 2.1.3).
Total body clearance of inulin
The total body clearance of inulin (determined by
pharmacokinetic analysis of the plasma concentration-time
curve only), also showed a significant fall over time
(p<0.01). The total clearance determined from time points
after 2 hours, was significantly less (p< 0.02) than the
total clearance from 0-2 hours. The total body clearance
fell progressively up to 6 hours, and the mean clearances
were 101, 87, 82, 71 and 77 ml/min/1.73 m^ from 0-2, 0-3,
0-4, 0-6 and 0-8 hours respectively. Individual total
body clearances of inulin are given in Table 2.1.4.
Creatinine clearances
The mean creatinine clearances did not differ signif¬
icantly, and were 117, 113, 110 and 115 ml/min/1.73 m^
for 1-2, 2-3, 3-4, and 4-8 hours respectively (Fig
2.1.3). The individual creatinine clearances are given in
Table 2.1.5. The overall mean creatinine clearance was
114 ml/min/1.73 m^.




The renal clearance of inulin (ml/min/1.73 m ) at different time
periods following a single intravenous injection of inulin in 10
healthy male subjects.
COLLECTION PERIOD (hours)
SUBJECT 0-1 1-2 2-3 3-4 4-8 0-2
RM 87 108 76 78 43 92
LP 85 94 83 67 44 87
GS 87 76 62 48 44 83
JN 83 83 67 70 65 83
DM 108 104 74 56 39 106
MK 91 99 98 63 42 93
CP 90 90 69 73 58 90
BH 73 82 68 65 34 75
BS 96 93 76 74 44 95
PL 121 108 103 95 64 118
MEAN 92 94 78 69 48 92
+SD 14 11 13 13 11 12
* 0-2 hour renal clearance calculated from the 0-2 hour urinary




Mean inulin and creatinine renal clearances following
single intravenous bolus of inulin in 10 healthy ma
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Total body clearance of inulin (ml/min/1.73 m ) at different time
periods, following a single intravenous injection of inulin in 10
healthy male subjects
TIME (hours)
SUBJECT 0-2 0-3 0-4 0-6 0-8
RM 98 71 81 71 74
LP 91 92 83 53 77
GS 107 91 78 82 82
JN 98 88 87 75 90
DM 104 59 62 76 78
MK 108 108 95 99 96
CP 94 86 79 73 79
BH 92 77 80 38 39
BS 101 90 92 45 67
PL 114 108 85 93 93
MEAN 101 87 82 71 77




The renal clearance of creatinine (ml/min/1.73 m ) after a single
injection of inulin in 10 healthy males. The mean _+_ SD for each
subject and each collection period are given.
COLLECTION PERIOD (hour)
SUBJECT 0-1 1-2 2-3 3-4 4-8 MEAN +SD
RM NM 114 110 109 107 110 2.9
LP NM 97 105 99 105 102 4.1
GS NM 116 106 113 108 111 4.6
JN NM 118 96 110 113 109 9.4
DM 129 124 130 126 123 126 3.1
MK NM 125 127 102 87 110 19.2
CP 131 109 111 99 104 106 5.4
BH 146 119 103 108 105 109 7.1
BS 136 129 115 115 184 136 32.8
PL 151 123 125 123 115 122 4.4
MEAN 117 113 110 115 114 9.3 7.9
+SD 9 11 9 26 10 10 7
NM = Not measured
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infusion study, was virtually identical to that
determined on the single injection study day (113 + 10
and 114 + 10 ml/min/1.73 m respectively).
Comparison of inulin clearance measured by constant
infusion and single intravenous bolus injection
The mean 0-2 hour renal clearance of inulin measured
by the single injection method, was similar to that
determined during constant infusion (92 + 12 versus 88 +
11 ml/min/1.73 m ). The mean ratio of single injection to
constant infusion renal clearance was 1.05 + 0.09, this
5 7o overestimate is not significant. The clearances
determined by the two methods were significantly
correlated (r= 0.77, p< 0.01, Fig 2.1.4). However, the
clearance of inulin by constant infusion was signifi¬
cantly greater than the inulin clearance by single
injection, during the 2-3, 3-4 and 4-8 hour time periods
(p< 0.01, Fig 2.1.5). The absolute differences were 10,
19, and 40 ml/min/1.73
The total body clearance of inulin calculated from
the 0-2 hour plasma concentration data after single
injection, significantly overestimated the corresponding
0-2 hour renal clearance by single injection (9%, p<
0.02), and renal clearance by constant infusion (15 %, p<
0.002). There were significant correlations between the
0-2 hour total body clearance and the single injection
and constant infusion renal clearances (r= 0.69, p<0.05
and r= 0.65, p< 0.05 respectively) (Fig 2.1.6 & 2.1.7).
No significant correlation was found between the 0-3, 0-
4, 0-6 and 0-8 total body clearances and the constant
infusion clearance of inulin.
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Fig 2.1.4
Relationship between the renal clearances of inulin
determined by the constant infusion and single injection
methods, in 10 healthy male subjects.
Line of identity
Best fit line
70 80 90 100 110 120
CONSTANT INFUSION INULIN RENAL CLEARANCE ml /min/1.73 m2
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Fig 2.1.5
Mean inulin clearances during constant infusion, and at
different times after a single injection of inulin in 10



























Relationship between total body and renal clearances of
inulin, following single intravenous injection in 10
healthy male subjects.
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Fig 2.1.7
Relationship between the total body and renal clearances
of inulin determined by single injection, and constant
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DISCUSSION
The renal clearance of inulin measured by constant
infusion was consistent over the different periods.
However, the average clearances were low compared to the
currently accepted average values of 127-130 ml/min/1.73
O
m . The inulin clearances for each individual was
however, within the normal range (72-176 ml/min/1.73 m^,
Smith, 1951). The corresponding creatinine clearances
were greater than the constant infusion inulin renal
clearance, and the mean ratio was 1.28. This difference
may be explained by the partial tubular secretion of
creatinine (Bauer et al, 1982). The calculated variation
in creatinine clearance was greater than the
corresponding variation in inulin clearance, over the
different time periods. The creatinine clearance thus
appears to be a more variable index of the GFR, than the
inulin clearance. The mean coefficient of variation
between collection periods for the inulin clearance
during the constant infusion was 5%, and this is less
than previously reported (Smith et al, 1938; Kennedy &
Kleh, 1953). This variation could be due to a number of
factors including analytical errors, incomplete urine
collection and physiological changes in inulin excretion
rate (this is discussed in more detail in section II).
The collection of urine is the most important source of
variation with the constant infusion technique (Zender et
al, 1968).
The inulin clearance determined by the single
injection method compared well with that obtained by
constant infusion, but only over the first two hours. The
mean 0-2 hour renal clearance of inulin after single
injection, did not differ significantly from that during
constant infusion, but was 5% higher. This could possibly
be attributed to the fact that the two studies did not
occur on the same day. Davies and Shock (1950b), report
that the day to day variation in inulin clearance was
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greater than the period to period variation. In the only
other reported comparison of the renal clearance of
inulin following a single injection with that during
constant infusion, the latter gave values which were 4%
higher than the single injection clearance, with a
standard deviation of 14% in 19 subjects (Olbrich et al,
1950). However, in this study, the midpoint plasma
concentration for each collection period was estimated
from the semilogarithmic plot of the inulin plasma con¬
centration against time, and this is less accurate than
the method used in the present study (Notari, 1987).
The renal clearance of inulin following a single
injection fell progressively after two hours. As the
corresponding creatinine clearance did not decrease, a
true reduction in glomerular filtration rate during the
study seems unlikely. This phenomenon has been reported
previously (Josephson & Lindahl, 1943; Ferguson et al,
1950; Laake, 1954; Barnard et al, 1955), but the decline
was less marked, and the pharmacokinetic methods used for
estimating the clearance were inappropriate. The prog¬
ressive fall in inulin clearance after 2 hours could be
due to factors such as, changing differences in the
arterial and venous concentrations of inulin over time,
concentration-dependant inulin clearance due to tubular
reabsorption at low concentrations, or selective filtrat¬
ion of the lower molecular weight fractions of inulin.
These factors are discussed in detail in section III.
The major advantage of the single injection technique
is the ability to calculate the clearance from the plasma
concentration-time decay curve thus, obviating the major
errors associated with urine collection (Brochner-
Mortensen, 1985). The plasma inulin concentration-time
curve after a single injection showed an initial rapid
fall, followed by a slower decreasing rate of decline,
which did not appear to become linear until 4-8 hours.
The transition from the initial rapid to the slower
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phase, occurred at 30-50 minutes. The curvilinear concen¬
tration-time curve upto two hours, could be fitted to a
two compartmental pharmacokinetic model, as found by
other investigators (Broberger, 1973; Fawer et al, 1979;
Muller-Suur et al, 1983). However, after two hours, a
multi compartmental model is necessary for a proper fit
of the data. The total body clearance of inulin also fell
after two hours, and subsequent clearances were
significantly lower than the 0-2 hour clearance. The fall
in total body clearance of inulin after two hours has not
been reported previously, because sampling has not been
continued after two hours?except in patients with reduced
renal function. However, Ladegaard-Pedersen (1972) extra¬
polated data from the last 60 minutes of a 3 hour curve
in volunteers with normal renal function, but found no
change after 2 hours.
The pharmacokinetic model used for the calculation of
total clearance in this study requires that the clearance
stays constant during the period of measurement, and that
distribution is complete before extrapolation (Gibaldi,
1984). Distribution equilibrium is said to occur 40-60
minutes after rapid intravenous administration of inulin
(Schachter et al, 1950). The result from the present
study is in good agreement as the mean distribution half
life was 8 minutes. Distribution was therefore more than
95 7o complete after 48 minutes. This together with the
fall in the renal clearance of inulin after two hours,
suggests that the AUC from the 0-2 two hour plasma con¬
centration data extrapolated to infinity would give the
best estimate of the total body clearance of inulin. The
fall in the rate of elimination, and the total body
clearance of inulin after this time, reflects the
progressively decreasing renal clearance of inulin after
two hours.
The total body clearance of inulin from 0-2 hours was
essentially the same, as the 0-2 hour single injection
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renal clearance and the constant infusion clearance. The
rather weak correlation between the total body clearance
and the corresponding renal clearance is surprising, but
small numbers were involved. The correlation between the
total body clearance of inulin and the corresponding
renal clearance for all the single injection studies
(N=31) reported in section III, gave a correlation
coefficient r, of 0.96, and the regression line was
parallel to the line of identity (see Fig 2.3.9, section
III ). Overall the total body clearance overestimates the
renal clearance by 6%.
This overestimate implies limited extrarenal
clearance of inulin although, this has not been well
investigated. Biliary excretion is thought to be
insignificant, and metabolism is not thought to occur
(Smith, 1951). Other possible explanations are, under¬
estimation of the area under the plasma concentration-
time curve, or non linear-kinetics. One other explanation
for the higher total body clearance, is that the injected
dose of inulin was too small. This could occur if the
polyfructosan chains of the inulin were partially
hydrolysed to fructose during the heating, which was
necessary in preparation of the solution, prior to
administration. On the other hand, the renal clearance of
inulin may be an underestimate of the true clearance, due
to retention of inulin in the urinary tract. This could
occur with residual urine in the bladder. Incomplete
bladder emptying is established as the greatest single
source, of error, unless catheterization is performed
(Zender et al, 1968). For ethical and practical reasons,
this was not done in the present study. Rehling et al,
(1984), reported a 23 % overestimate of the total body
clearance compared to the renal clearance in patients
with one kidney, following a single injection, but no
catheterization was performed. Overestimation of the
total body clearance of inulin during a constant
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infusion, compared with the simultaneously measured renal
clearance, was also attributed to incomplete bladder
emptying (Rose, 1969). However, in studies in which cath¬
eterization was performed, the total body clearance of
inulin after a single injection did not overestimate the
renal clearance during constant infusion (Broberger,
1973; Boineau et al, 1974). In the present study, the
volunteers were water loaded, to reduce the effect of
residual urine, and incomplete bladder emptying.
Differences in the arterial and venous concentrations
of inulin, may be another factor. Venous blood was
sampled, but inulin is cleared by the kidney from
arterial blood. The venous plasma concentration may be up
to 7 % higher than the arterial concentration, two hours
after an intravenous injection (Brun et al, 1949;
Ferguson et al, 1950). However, as arterial concent¬
rations are higher during the distribution phase, these
differences are likely to be cancelled over the whole
period.
The rate of excretion of inulin into the bladder lags
behind the plasma concentration at a given moment, due to
a delay after filtration of the inulin, and its arrival
in the bladder. This is more of a problem where plasma
concentrations are changing rapidly (Tucker, 1981).
Errors can be minimised by, increasing the period of
collection and increasing the urine flow rate (Pihl,
1973). In the present study the urine collection periods
were an hour, and the mean flow rate for the second hour
was 5 ml/min. From the formula of Nosslin (1965), the
calculated delay time is 4.1 minutes, which in 60 minutes
represents a 7 % error. However, the blood was sampled up
to two minutes before the volunteer voided, thus reducing
the error to under 4 % .
SUMMARY
The single injection technique for measurement of the
total body or renal clearance of inulin, gave results
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which were similar to those obtained by the standard
constant infusion method, when sampling was restricted to
the first two hours. The total body clearance slightly
overestimates the renal clearance, probably because of
problems with urine collection. The ability to measure
the total body clearance simply and accurately, is a
distinct advantage, and a reason for the popularity of
single injection techniques using radioactive markers. In
healthy individuals estimation of the GFR by the inulin
single injection technique, is easy, and the risks
inherent with the use of radioactivity are avoided. The
technique is simple to carry out, lasts only two hours
and there is minimum discomfort. The only drawback, is
that numerous blood samples are needed to ensure an
accurate analysis of the concentration-time decay curve,
following a single injection.
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SECTION II
REPRODUCIBILITY OF THE SINGLE INJECTION TECHNIQUE FOR
ESTIMATION OF THE INULIN CLEARANCE
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INTRODUCTION
As described in the last section, inulin is suitable
for the measurement of GFR over the first two hours,
after a rapid intravenous bolus injection. The usefulness
of any technique for measurement of the GFR depends on
its reliability, accuracy and reproducibility (Brochner-
Mortensen & Rodbro, 1976a). The former was discussed in
the last section, and in this section the results of
repeated estimates of the GFR in the same individual over
time, are presented. Data obtained by the constant
infusion method over a similar period, were kindly
provided by Dr T. MacDonald, allowing a comparison be¬
tween the classical and the single injection methods.
METHODS
Single injection
Eight healthy male volunteers with a mean age 27+3
years (range 24-32 yrs) weighing 70 + 10 Kg (range 56-85
Kg) received inulin intravenously, by the single
injection technique, on 3 different occasions, at
intervals of 6 to 22 days between the first two study
days, and 7 days between the second and third studies.
The experimental conditions were similar to those
described on page 50 except that, the fluid intake was a
100 ml of water every half hour for the duration of the
study (2 h). The same batches of inulin (7 subjects) and
"Inutest", (one subject) were used for each volunteer, on
each occasion.
Constant infusion method
Nine healthy male volunteers with a mean age 30 + 5
years (range 22-36 yrs) weighing 69 + 7 Kg (range 56-81
Kg) received "Inutest", by the classical infusion method,
on 3 different occasions at intervals of 7 to 15 days
between the first two study days in eight subjects, and a
period of 5 months in one subject. The interval between
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the second and third studies, ranged from 4 to 28 days.
The experimental conditions were similar to those des¬
cribed on page 49 except that, the fluid intake was 200
ml every half hour for 3 hours, and the urine collection
periods were for one hour. The same batch of "Inutest"
was used for each volunteer on each occasion.
Sample collection and analysis for inulin were as
previously described (pages 50 & 51).
Data analysis
Single injection
The total body and renal clearances of inulin
following a single injection were calculated as described
previously (pages 52 & 53). The renal clearance was
estimated from the 0-2 hour plasma and urine data, whilst
the total body clearance was calculated from the 0-2 hour
plasma data, extrapolated to infinity.
Constant infusion
The renal clearance of inulin estimated by constant
infusion was calculated as described on page 52. The
values reported are the mean of the first two collection
periods after equilibration.
All clearances were corrected for surface area as
described on page 54.
Statistical methods
The coefficients of variation for the repeated
estimates were calculated for each subject, as described
on page 52. The statistical significance of differences
between mean clearances over the three studies, were
estimated by two way analysis of variance. A non-
parametric Wilcoxon rank sum test was used for differ¬
ences in the coefficients of variation of the two
methods. The null hypothesis was rejected when p< 0.05.
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RESULTS
The individual total body and renal clearances of
inulin following a single injection on three different
days are given in Tables 2.2.1A & B, and the results for
the constant infusion method are given in Table 2.2.2.
The individual plasma and urine concentrations for the
single injection are given in Appendix II.
The mean total body clearances of inulin following a
single injection for days 1, 2, and 3 were 106, 104, and
106 ml/min/1.73 and, the corresponding renal clear-
O
ances were 97, 98, and 98 ml/min/1.73 m respectively.
The mean renal clearances of inulin for the 3 days using
the constant infusion technique were 104, 99, 91
O
ml/min/1.73 m . There were no significant changes in the
mean clearances over the 3 days with any of the methods.
The reproducibility of each method on the 3 separate
days is expressed as the coefficient of variation. The
individual coefficients of variation are given in Table
2.2.1A & B for the single injection total body and renal
clearances, and Table 2.2.2 for the renal clearance by
constant infusion. The smallest mean and individual
ranges of variation, were found with the total body
clearance method (mean coefficient of variation 4.6%
range 1.0-8.7%). The variation in the mean renal
clearance by single injection was 7.5%, range 1.0-11.7%.
In contrast, the mean variation in clearance determined
by constant infusion was 15.1% (range 4.0-32.6%). The
coefficient of variation for the total body clearance of
inulin following single injection, was significantly less
than for the two renal clearance methods (p< 0.01). There





The total body clearance of inulin (ml/rain/1.73 m ) determined in
healthy male volunteers by the single injection technique, on
three different days
STUDY DAY
SUBJECT 123 MEAN +SD CV %
GM 97 95 96 96 1.0 1.0
EC 95 92 86 91 4.6 5.0
AB 114 97 106 106 8.5 8.0
RJ 114 96 103 104 9.1 •00
AD 117 120 122 120 2.5 2.1
JA 99 107 104 103 4.0 3.9
SA 117 116 124 119 4.4 3.7
MS 98 107 103 103 4.5 4.4
MEAN 106 104 106 105 4.8 4.6
_+ SD 9.9 10.4 12.5 10.0 2.7 2.7
TABLE 2.2.IB
O
Renal clearance of inulin (ml/min/1.73 m ) in the same subjects on
the same three days, as in Table 2.2.1A.
STUDY DAY
SUBJECT 123 MEAN +SD CV %
GM 84 96 86 89 6.4 7.3
EC 99 98 82 93 9.5 10.3
AB 98 80 81 86 10.1 11.7
RJ 103 85 103 97 10.4 10.7
AD 116 133 146 132 15.0 11.4
JA 95 103 99 99 4.0 4.0
SA 96 97 95 96 1.0 1.0
MS 85 90 90 88 2.9 3.3
MEAN 97 98 98 98 7.4 7.5




The renal clearance of inulin (ml/min/1.73 in ) determined in healthy
male volunteers by the constant infusion method, on three different
days
STUDY DAY
SUBJECT 1 2 3 MEAN +SD CV %
DM 121 102 100 108 11.6 10.8
BB 90 95 109 98 9.8 10.0
AD 97 94 114 102 10.8 10.6
DP 99 106 99 101 4.0 4.0
KH 70 93 102 88 16.5 18.7
AK 96 101 83 93 9.3 10.0
SM 81 96 97 91 9.0 9.8
BW 111 98 65 91 23.7 26.0
JM 175 108 99 127 41.5 32.6
MEAN 104 99 96 100 15.1 14.7
+ SD 30.4 5.4 14.5 12.0 11.3 9.2
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DISCUSSION
The reproducibility of the total body and renal
clearances of inulin on three separate occasions, using
the single injection method, has been evaluated and
compared with the renal clearances of inulin determined
by the constant infusion method, over a similar period.
The latter is the reference method, but it has many
disadvantages. A method for routine clinical use has to
be simple, accurate and reproducible; it is the latter
which was the concern of this study. The results show
that there was significantly less variation in the total
body clearance of inulin following a single injection,
than the renal clearances determined by both single
injection, and constant infusion methods. The renal
clearance by single injection also varied less than the
renal clearance during constant infusion, but the
difference was not statistically significant.
Variability in clearance measurements has three main
components, a) true variation in the GFR, b) analytical
variability, and c) errors in urine collection.
a) Glomerular filtration is maintained by auto-
regulation, at a relatively constant rate in healthy
individuals, over a wide range of arterial blood
pressures (Baylis, 1986). Certain physiological factors
such as stress, exercise and pregnancy alter GFR, and
there is also a diurnal variation (O'Connor, 1981). The
subjects in this study were not affected by these
factors, with the possible exception of stress, and they
were studied under the same conditions, at the same time
of day, on each occasion. Variation in the GFR itself is
unlikely to be the main contributing factor to the
differences between the methods, as both total body and
renal clearances would have been affected equally, after
a single injection.
b) Analytical variability is also unlikely to explain
the differences in variation between total body and renal
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clearance as, both plasma and urine concentrations of
inulin, were well above the limit of detection, and the
coefficient of variation of the method for repeated
samples carried out within the medical renal unit labor¬
atories, is about 5%.
c) Errors in urine collection are the most likely
explanation for the greater variability in the renal
clearance, than the total body clearance. These arise
mainly from inaccurate timing, and incomplete urine
collections. In another study, the inter-assay
coefficient of variation for the constant infusion was
1.7 %, while the error of measurement of the urine flow
rate was 7.1 % (Zender et al, 1968). Thus, urine
collection is likely to be the single greatest source of
variation in the measurement of the renal clearance of
inulin. Urine collection may be incomplete without
catheterization (as in this study) and this may
contribute to the wide individual range observed. Sudden
changes in urine flow may have a similar effect. Thus,
methods which do not depend on urine collection, are
likely to be more reproducible, than those which do.
The most widely used routine clinical measure of the
GFR is the endogenous creatinine clearance obtained,
using either 24 hour urine collections, or estimated by
nomogram, from the plasma creatinine concentration. These
methods have coefficients of variation of 25 % and 15 °L
respectively (Brochner-Mortensen & Rodbro, 1976a). The
coefficients of variation for the inulin clearance
following a single injection, were less in the present
study than reported for the creatinine clearance, and of
the same order as with radiolabelled markers (Brochner-
Mortensen, 1985). The day to day variation in the total
body clearance of inulin, was less than the period to
period variation, for the constant infusion method
(Kennedy & Kleh, 1953).
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SUMMARY
The total body and renal clearances of inulin,
following a single intravenous bolus, in 8 healthy male
volunteers, were estimated on three separate occasions in
the same person. This was compared to the renal clearance
of inulin, during constant infusion of inulin, over a
similar period. The inulin clearance measured by the
single injection technique is reproducible on repeated
estimations and less variable than the constant infusion
method. There is least variation with total body




MECHANISMS OF THE PROGRESSIVE FALL IN INULIN CLEARANCE
AFTER A SINGLE INTRAVENOUS INJECTION
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INTRODUCTION
The initial studies reported in section one showed
that, the mean renal clearance of inulin remains
relatively constant for the first two hours after an
intravenous bolus injection but, after this time, the
clearance of inulin falls progressively as the plasma
concentration declines. The corresponding creatinine
clearance did not show a similar decrease, and therefore,
a true reduction in GFR is unlikely. This was unexpected,
as the rate of excretion of inulin is thought to be
directly proportional to its plasma concentration over a
wide range of plasma concentrations (50 to 4000 mg/1;
Shannon & Smith, 1935; Miller et al, 1940).
However, a fall in the renal clearance of inulin has
been reported previously. Josephson and Lindahl (1943),
first noted that after an intravenous bolus of inulin,
the renal clearance estimated in the third collection
period, was significantly lower than the first two, and
similar observations were reported by Laake (1954).
Others have reported a fall almost immediately after the
injection (Ferguson et al, 1950; Barnard et al, 1955).
The reasons suggested for this decline in inulin clear¬
ance include, tubular reabsorption, selective filtration
(Ferguson et al, 1950; Barnard et al, 1955), and a
decrease in extracellular fluid tonicity and thus,
intrarenal pressure due to fluid loading (Laake, 1954).
Ferguson et al (1950), infused inulin at different rates,
and reported that at different plasma concentrations, the
clearance of inulin differed. However, a decline in renal
clearance has not been observed by others using single
injection methods (Alving & Miller, 1940; Carrie et al,
1980), or during clearance measurements at different
steady state plasma concentrations of inulin produced by
stepping up, or down the infusion rate (Kennedy & Kleh,
1953; Cole et al, 1972). There was no evidence to support
tubular reabsorption of inulin or plasma concentration
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dependant clearance.
The early studies which reported the fall in inulin
clearance used inappropriate pharmacokinetic analysis,
and there have been no subsequent reports using
appropriate kinetics which indicate a fall in inulin
clearance. This may be due to the fact that in the most
recent reports, the estimated clearance was based on the
total body clearance of inulin, or the studies have been
carried out in patients with reduced renal function
(Broberger, 1973; Muller-Suur et al, 1983; Rehling et al,
1984). It should be noted that, the validity of the
pharmacokinetic models used to calculate total body
clearance depends on the assumption that, the clearance
of the measured marker remains constant, throughout the
period of measurement (Gibaldi, 1984). The results pres¬
ented in section I clearly show a fall in the renal
clearance of inulin and therefore, measurements of the
total body clearance made during the period of declining
renal clearance, are invalid.
The fall in inulin clearance could be due to a number
of factors including, 1) changing differences between the
arterial and venous plasma concentration of inulin over
time, 2) concentration dependant inulin clearance due to
tubular reabsorption, 3) selective filtration of the low
molecular weight fraction of inulin or 4) an increasing
proportion cleared extrarenally, at low plasma
concentrations.
The possible role of these factors has been
investigated by further analysis of the results of
studies in 23 males with normal renal function, and 8
patients with reduced renal function following an
intravenous bolus of inulin. The renal clearance of
inulin was assessed in relation to, time, plasma
concentration, urine flow rate, and amount recovered in
24 hours. In addition, the renal clearance of inulin has
been investigated under steady state conditions, at
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different plasma concentrations in 8 male subjects with
normal renal function. The endogenous creatinine
clearance was also measured, to control for naturally
occurring fluctuations in GFR.
METHODS
Study one. Single injection in 23 healthy males.
Single injection studies were carried out in 23
healthy male volunteers aged 21-32 years (mean 26+3
yrs), weighing 57-89 Kg (mean 71+8 Kg). The protocol
and experimental conditions were the same as described in
section I (p 50), except that in 19 volunteers the fluid
intake during the study was reduced from 130 ml to 100 ml
every half hour, for 6-8 hours. Inulin (Kerfoot,
Barnsley, U.K., 5 g in 50 ml, 10% w/v) was used, except
in volunteers JN, RF, and MS who received "Inutest"
(Lavevosan Gesellschaft, Austria, 5 g in 20 ml, 25% w/v,
this was diluted with 28 ml of normal saline and
administered over 5 minutes).
Study two. Single injection in 8 patients with renal
impairment.
Single injection studies were carried out in 8
patients with decreased glomerular function (range 20-70
ml/min/1.73 m^), as assessed by an eight hour creatinine
clearance. 6 males and 2 females with a mean age of 59 +
7 years (range 46-65 yrs) weighing 61-88 Kg (mean 74 + 10
Kg) were entered into the study, which was approved by
the local ethical committee. The protocol and
experimental conditions were as described in section I (p
50) with the following exceptions:- a) The number of
blood samples were reduced by excluding the following
time points 40, 50, and 75 minutes. A 45 minute sample
was added, b) The fluid intake was at the rate of 150 ml
every half hour for the first four hours thereafter, it
was ad libitum. All patients received the same batch of
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"Inutest" (Lavevosan Gesellschaft, Austria. 5 g in 20 ml,
25% w/v). This was diluted with 28 ml of normal saline
and administered over 5 minutes.
Study three. Incremental infusion in 8 healthy males.
Eight healthy male volunteers aged between 25-42
years (mean age 30+6 yrs), weighing 55-77 Kg (mean 69 +
7 Kg), received two constant infusions of inulin
("Inutest"), in random order on different days. The same
batch was used throughout the study. The constant
infusion was intended to give a stepwise increase in
plasma concentrations of inulin on one occasion, and a
stepwise decrease on the other. The interval between the
two studies ranged between 7 and 22 days in seven
subjects, and was six months in the other. The volunteers
fasted from 22.00 hours and, on the morning of the study
drank 500 ml of water, an hour before the study
commenced, followed by 150 ml every half hour for 1\
hours. The subjects were supine for the duration of the
study, but stood to empty their bladder. No food or
caffeine containing beverages were allowed during the
study.
The initial procedure for the measurement of inulin
clearance by constant infusion, was as described in
section I (p 49). On "step up" days, the subjects were
given an initial loading dose of "Inutest" 375 mg (1.5
ml). The infusion contained "Inutest" (1679 mg/ml in 300
ml of 0.9% saline), which was given at the rate of 336
mg/min. After equilibration for an hour, the subjects
emptied their bladder and blood was drawn at the
beginning and end of three half hour urine collection
periods. At the end of the third period, another loading
intravenous injection of "Inutest" was administered (375
mg, 1.5 ml), and the infusion rate was increased to 672
mg/min. Four half hour urine collections were then made
with blood sampling, as described above. At the end of
the fourth collection period, another intravenous
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injection of "Inutest" was given (1125 mg, 4.5 ml) and
the infusion rate was increased to 2015 mg/min. Urine was
collected with blood sampling for 4 final half hour
periods, as before (Fig 2.3.1).
On "step down" study days, the volunteers received an
initial loading dose of "Inutest" (3000 mg, 12 ml), prior
to the infusion, which was maintained at a rate similar
to that at the end of the "step up" study (1913 mg/min).
Blood was sampled and urine collections were also made at
the same times, as during the "step up" study. However,
at the times when an intravenous bolus injection of
inulin was given in the "step up" study, the infusion was
stopped for 15 minutes, after which the infusion rate was
reduced to 638 mg/min for the middle, and 319 mg/min for
the final periods (fig 2.3.1).
The blood sampling cannula was kept open by flushing
with 1 ml of heparinised saline (10 units/ml), after the
withdrawal of each sample. Ten ml of the infused solution
was collected at the end of each study, for measurement
of the actual inulin concentration.
Sample collection and analysis
Blood and urine samples were collected as described,
and inulin and creatinine estimated by the same




The total body and renal clearances of inulin, and
the renal clearance of creatinine were calculated for the
same periods, and in the same way, as described in
section I (p 52-54). The mean distribution half life was
calculated from the constants obtained by pharmacokinetic
analysis of the plasma concentration-time curve, up to 2
hours. From the best fit of the data, using the "multi"
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non-linear regression analysis programme (Yamaoka et al,
1981), the rate constant was obtained for the initial
rapid fall in plasma concentration, which represents the
distribution phase. The mean half life of distribution
was then obtained by dividing In 2 by the distribution
rate constant.
The percentage of the dose recovered in each urine
collection period was calculated by dividing the amount
excreted by the administered dose x 100.
The midpoint plasma concentration for the plot of
urinary excretion rate against plasma concentration, was
calculated by dividing the actual area under the plasma
concentration time curve for each collection period by
the duration.
Study two.
The total body and renal clearances of inulin and the
renal clearance of creatinine were calculated, as
described in section I (p 52-54), and the mean
distribution half life was estimated, as described in
study one over four hours.
The percentage of dose recovered in each urine
collection period was calculated, as above, for the
period 0-8 hours, as no 8-24 hour collection was made.
Study three.
Because of the need to allow time for equilibration
after changing the rate of administration of inulin, the
results for the first urine collection period, after each
change of dose (Ul, U4, U5, U8, and U9 see Fig 2.3.1),
have been disregarded. The samples were pooled to
represent one hour periods from 1% to 2\ hours, 3\ to 4%
hours and 5% to 6% hours. In the "step up" study, these
successive time periods are referred to as "low", "mid",
and "high" dose infusions, and the reverse applies for
the "step down" study (Fig 2.3.1).
The renal clearance of inulin and creatinine were
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calculated, as described previously, for the constant
infusion method (section I, p 52).
The total body clearance of inulin (TBC) was
calculated from the following relationship
rate of infusion
TBC = (Equation 5)
Css
where Css is the steady state plasma concentration of
inulin calculated from the mean of the last two inulin
plasma concentration values, during each infusion step.
The percentage urinary recovery of inulin was
calculated by dividing the urinary excretion rate of
inulin of the last two periods in each infusion step, by
the infusion rate.
All clearances were corrected for body surface area
O
of 1.73 m^ as described on page 54 section I.
Statistical analysis
Statistical analysis were carried out between
collection periods, using two way analysis of variance
(ANOVA). In addition, the significance of differences
between means were determined using a students two tailed
"t" test, and the null hypothesis was rejected if p<




The plasma concentrations of inulin for each
individual in each study, are given in Appendix I, III &
IV for study one, two and three respectively.
Study one.
Following intravenous bolus administration, the
plasma concentrations of inulin fell rapidly in all
subjects in a curvilinear manner, when plotted
semilogarithmically against time (Fig 2.3.2). The plasma
concentration-time data up to two hours could be fitted
- 93 -
Fig 2,3,2
The mean plasma concentration-time curves following a
intravenous bolus of inulin in 23 healthy males, and
patients with impaired renal function.
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compartment model, but a terminal linear phase was not
seen. The mean plasma inulin concentrations declined from
736 + 92 mg/1 at 10 minutes, to 22 + 13 mg/1 at 480
minutes. The mean distribution half life was 7.7 minutes,
therefore distribution was on average greater than 95 %
complete, 46 minutes after the single injection.
Study two.
Following intravenous bolus administration, the
plasma concentrations of inulin fell again in all
subjects in a curvilinear manner, when plotted semilogar-
ithmically against time (Fig 2.3.2). The plasma data was
consistent with a three compartment model up to eight
hours, and the plasma concentration-time relationship
appeared to be log-linear from 4-8 hours. Up to four
hours, the data could be fitted to a two compartment
model. The mean inulin plasma concentrations declined
from 921 + 127 mg/1 at 10 minutes, to 111 + 46 mg/1 at
480 minutes. The mean distribution half life was 13.8
minutes, therefore, distribution was on average more than
95 % complete, 83 minutes after administration.
Study three.
The mean plasma concentrations of inulin during each
"step up" and "step down" infusion are shown in Fig
2.3.3. With the "step up" infusion, the plasma concent¬
rations appeared to reach steady state during the low,
mid, and high periods, at the times when the clearance of
inulin, was measured. The respective mean midpoint plasma
inulin concentrations were 35, 65.6, and 165 mg/1.
With the "step down" study, the mean midpoint plasma
inulin concentrations were 187 , 103.2, and 65 mg/1 but,




A plot of the mean inulin plasma concentrations achieved
during the step up and step down constant infusion of














The relationship between the renal clearance and plasma
concentration of inulin
Study one.
The individual renal clearances of inulin for each
collection period are given in Table 2.3.1. The mean
renal clearance of inulin over the first and second hours
was similar, but thereafter it fell progressively by 7,
14, 36, and 50 ml/min/1.73 m^ for 2-3, 3-4, 4-6, and 6-8
hour periods respectively, relative to the clearance
measured from 0-1 hours. The sequential mean renal
clearances of inulin were 97, 100, 90, 83, 61 and 47
ml/min/1.73 m^ (Fig 2.3.4). This fall in the renal clear¬
ance of inulin over time and, with falling plasma
concentrations, was statistically significant (p< 0.01).
The 0-1 hour renal clearance of inulin was significantly
greater than for any period after 2 hours (p< 0.03 for 2-
3 h and p< 0.001 for 3-4, 4-6, and 6-8 h).
A plot of the mean renal clearance of inulin against
the mean midpoint plasma concentration for each
collection period shows, that the clearance remained
relatively constant at plasma concentrations ranging from
150 to 480 mg/1. However, as the concentration of inulin
declined below 100 mg/1, the renal clearance fell
progressively (Fig 2.3.5).
Study two.
The individual renal clearances of inulin for each
collection period are given in Table 2.3.2A. The fall in
the mean renal clearance of inulin was not as dramatic as
in the healthy subjects. The clearance over the first and
second hours was similar, after which time there was a
small, but progressive fall of 6, 14, 14, and 19.4 % for
2-3, 3-4, 4-6, and 6-8 hours periods respectively,
relative to the clearance from 0-1 hours. The mean renal
clearances of inulin were 36, 37, 34, 31, 31, and 29




Renal clearance of inulin (ml/mim/1.73 m ) after a single intra¬
venous injection of inulin in 23 healthy male subjects
COLLECTION PERIOD (hours)
SUBJECT 0-1 1-2 2-3 3-4 4-6 6-8
PF 108 102 105 120 97 72
GS 87 88 79 72 41 26
JN 78 61 59 57 40 30
DM 109 104 74 56 39 37
MK 90 99 98 63 49 28
CP 89 90 69 73 66 44
BH 72 82 68 65 43 25
BS 94 93 76 74 53 34
PL 123 108 103 95 64 64
TM 110 117 105 100 82 44
GW 81 90 80 75 66 46
AT 106 146 123 101 81 128
EC 101 95 96 101 77 25
WW 93 90 92 85 64 75
AB 105 94 99 98 72 50
RJ 104 100 79 90 67 43
AD 117 113 115 106 68 51
JA 95 97 79 61 64 65
RF 108 102 85 92 70 43
PD 83 130 117 82 24 13
MS 87 78 76 70 49 55
SA 98 91 103 81 64 51
JG 104 132 88 86 71 38
MEAN 97 100 90 83 61 47
+SD 13 19 17 17 17 24
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Renal clearance of inulin (ml/rain/1.73 m ) following an intravenous
bolus of inulin in 8 renal impaired patients.
COLLECTION PERIOD (hours)
SUBJECTS 0-1 1-2 COICN] 3-4 4-6 6-8
JB 22 24 23 21 19 18
EC 17 25 22 22 18 23
AD 35 38 35 32 31 29
EH 30 28 27 25 22 22
WA 49 50 54 53 44 43
JH 58 55 51 46 41 37
CP 42 37 36 20 37 30
EB 33 38 22 25 33 29
MEAN 36 37 34 31 31 29
+SD 14 11 13 12 10 8
TABLE 2.3.2B
Total body clearance of inulin (ml/min/1. 73 m2) following an
intravenous bolus of inulin in 8 renal impaired patients.
COLLECTION PERIOD (hours■)
SUBJECTS 0-2 0-4 0-6 0-8
JB 34 24 19 21
EC 26 24 21 18
AD 27 35 30 25
EH 33 26 20 21
WA 56 50 44 43
JH 63 55 49 48
CP 37 43 38 34
EB 43 37 34 29
MEAN 40 37 32 30
+SD 13 12 11 11
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respectively (Fig 2.3.6). This fall was significantly
related to time and plasma concentration, up to 8 hours
(p< 0.05), but not up to 4 hours. The clearances during
the 4-6 and 6-8 hour periods were significantly lower
than from 0-1 hours (p< 0.05) and 1-2 hours (p< 0.005),
and the clearance from the 3-4 hour period was
significantly less than from 1-2 hours (p<0.05). A plot
of the mean renal clearance of inulin against the mean
midpoint plasma concentration for each collection periodj
showed there is a small fall in clearance as the plasma
concentration declines from 592 to 126 mg/1 (Fig 2.3.4).
Study three.
The renal clearances of inulin are shown in Table
2.3.3A and Fig 2.3.7. During the "step up" infusion the
mean inulin clearance increased progressively from 90, to
O
97 at low and mid, and to 114 ml/min/1.73 m at high
plasma concentrations. This rise in clearance was signif¬
icant over time and increasing plasma concentrations (p<
0.01), and the clearances at low and mid, were
significantly lower than that at the high plasma
concentration (p< 0.005). Similarly, the clearance at the
low period was significantly lower than that at the mid
period (p< 0.05).
Conversely, during the "step down" study, the mean
inulin clearances were 112, 114, and 94 ml/min/1.73 m
for high, mid and low plasma concentrations respectively.
This fall in clearance was significant over time and
declining plasma concentrations (p< 0.05), and the clear¬
ance at the low plasma concentration was significantly
less than that at the high (p< 0.002) and mid (p< 0.01)
plasma concentrations.
A plot of mean renal clearance of inulin against the
mean midpoint plasma concentrations (Fig 2.3.8) for each
period shows clearly that, in the "step up" study, the
clearances rise as the plasma concentration increases. At
both the low and mid periods, the mean plasma concent-
-102-
Fig 2.3.6
Renal clearances of inulin and creatinine following a
single injection of inulin, in 8 patients with renal
impairment. Bars = SD.
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inulin (ml/min/1.73 m ) following incremental
changes in the dose rate in 8 healthy male subjects
COLLECTION PERIOD
STEP UP STEP DOWN
SUBJECT LOW MID HIGH HIGH MID LOW
JN 100 105 136 92 86 76
GS 74 73 97 94 86 72
SB 99 96 110 119 133 114
AD 123 139 133 127 120 119
BB 91 95 121 122 119 86
WW 69 91 99 139 176 126
SM 80 87 103 87 80 68
BW 81 88 114 116 108 94
MEAN 90 97 114 112 114 94
+ SD 18 19 15 19 32 23
TABLE 2.3.3B
O
Total body clearance of inulin (ml/min/1.73 m ) during step up
constant infusion in 8 healthy male subjects
COLLECTION PERIOD
STEP UP
SUBJECT LOW MID HIGH
JN 117 111 154
GS 88 88 107
SB 114 109 135
AD 129 140 142
BB 85 94 117
WW 70 93 109
SM 80 87 104
BW 84 87 102
MEAN 96 101 121
+ SD 21 18 20
-104-
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Plot of inulin renal clearance against plasma
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rations are below 100 mg/1. In the "step down" study, the
renal clearance remains similar (in most cases) over the
mid to high concentrations, but falls in the low period,
when the plasma concentrations are below 100 mg/1 (Fig
2.3.8).
Total body clearance of inulin
Study one.
The individual total body clearances are given in
Table 2.3.4. The total body clearance of inulin showed a
significant fall over time and plasma concentration
(p<0.01). The total clearance determined from time points
after two hours was significantly less, than the total
clearance from 0-2 hours (p<0.001). The mean total body
clearances were 105, 93, and 82 ml/min/1.73 m^ for 0-2,
0-4, and 0-6 hours respectively.
Study two.
The individual total body clearances are given in
Table 2.3.2B. The total body clearance of inulin showed a
significant fall over time and plasma concentration
(p<0.01). The total clearance did not differ signi¬
ficantly between 0-2 and 0-4 hours, but after 4 hours the
clearance is significantly less (p<0.001). The mean total
body clearances were 40, 37, 32, and 30 ml/min/1.73 m
for 0-2, 0-4, 0-6 and 0-8 hours respectively.
Correlation between total body clearance and renal
clearance of inulin following a single injection.
A plot of the total body clearance of inulin against
the renal clearance is shown in Fig 2.3.9. This includes
data from both the 23 healthy subjects (0-2 hour data),
and the 8 patients with renal impairment (0-4 hour data).
The total body clearance significantly overestimated the
renal clearance of inulin (p< 0.005) by a mean of 6% (87




Total body clearance of inulin (ml/min/1.73 m ) after a single
intravenous injection of inulin in 23 healthy male subjects.
COLLECTION PERIOD (hours)
SUBJECT 0-2 0-4 0-6
PF 123 123 104
GS 105 84 54
JN 76 63 54
DM 104 62 76
MK 109 95 99
CP 94 79 79
BH 92 80 38
BS 101 92 45
PL 114 85 93
TM 112 107 99
GW 101 82 77
AT 127 113 113
EC 95 92 82
WW 101 85 82
AB 98 97 82
RJ 118 99 88
AD 117 109 97
JA 99 93 92
RF 113 103 93
PD 98 89 78
MS 103 88 81
SA 117 108 91
JG 98 100 96
MEAN 105 93 82
+SD 12 15 19
-108-
Fig 2.3.9
Relationship between inulin total body clearance and the
corresponding inulin clearance in 23 healthy male
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between the total body clearance, and single injection
renal clearance (r= 0.97, p< 0.001, Fig 2.3.9).
Study three.
The individual total body clearances are given in
Table 2.3.3B. The mean total body clearances in the "step
up" study were 96, 101, and 121 ml/min/1.73 m^' for low
mid and high plasma concentrations respectively. This
increase was significant over time and increasing plasma
concentration (p< 0.01). Both low and mid total body
clearances, were significantly lower than that for the
high plasma concentration (p< 0.005). The corresponding
mean values for the renal clearance of inulin were 90,
97, and 114 ml/min/1.73 m » and the ratios of the mean
total body clearances to the mean renal clearances were
close to unity (1.07, 1.04 and 1.06 respectively).
The total body clearance of inulin could not be
calculated for the "step down" studies as steady state
plasma concentrations were not achieved.
Creatinine clearance
Study one.
The individual creatinine clearances are given in
Table 2.3.5. The mean creatinine clearances were 130,
113, 117, 120, and 107 ml/min/1.73 m^> for the collection
periods 0-1, 1-2, 2-3, 3-4, 4-6 and 6-8 hours respect¬
ively (Fig 2.3.4). There was a significant change in
creatinine clearance over time (p< 0.05), with the 0-1
hour clearance being significantly greater than all other
collection periods, (p<0.01) except 4-6 hours. No
significant differences were found between the other
collection periods.
Study two.
The individual creatinine clearances are given in
Table 2.3.6A. The mean creatinine clearance showed a




Renal clearance of creatinine (ml/min/1.73 m ) during the 8 hours
after a single intravenous injection of inulin in 23 healthy male
subjects.
COLLECTION PERIOD (hours)
SUBJECT 0-1 1-2 2-3 3-4 4-6 6-8
PF 209 107 128 119 108 100
GS 120 113 106 108 109 102
JN 117 112 112 111 119 118
DM 129 124 130 125 131 114
MK * 125 127 102 113 61
CP 131 109 111 99 116 93
BH 146 119 103 108 98 110
BS 136 129 115 115 244 121
PL 173 123 125 123 105 126
TM 119 123 115 114 123 129
GW 105 79 114 113 109 102
AT 111 118 104 113 129 123
EC 124 111 111 115 108 49
WW 98 95 102 96 95 105
AB 126 113 118 125 123 136
RJ 109 108 109 110 129 113
AD 124 120 122 119 115 106
JA 122 112 113 105 no 126
RF 217 131 128 133 123 119
PD 99 82 125 106 115 33
MS 118 108 107 116 106 119
SA 124 114 139 120 109 122
JG 110 131 128 123 128 128
MEAN 130 113 117 114 120 107
+SD 31 14 10 9 29 26




Renal clearance of creatinine (ml/min/1.73 m ) following an
intravenous bolus of inulin in 8 renal impaired patients
COLLECTION PERIOD (hours)
SUBJECTS 0-1 1-2 2-3 3-4 4-6 6-8
JB 36 33 34 32 31 33
EC 33 33 30 31 26 34
AD 38 39 40 38 39 43
EH 38 38 39 38 35 37
WA 61 54 63 57 61 59
JH 65 66 62 61 63 61
CP 62 35 53 33 61 58
EB 46 48 33 33 47 47
MEAN 48 45 44 40 45 46
+SD 13 12 13 12 15 12
TABLE 2.3.6B
Urine flow rate (ral/min) following an intravenous bolus of inul
in 8 renal impaired patients
COLLECTION PERIOD (hours)
SUBJECTS 0-1 1-2 2-3 3-4 4-6 6-8
JB 3.9 3.9 4.7 4.5 3.0 2.8
EC 2.5 4.2 4.2 4.5 2.9 3.4
AD 6.4 5.7 5.0 4.2 3.0 3.4
EH 5.6 5.7 6.2 5.3 2.8 3.0
WA 6.3 5.7 00•vD 5.8 3.8 3.1
JH 7.4 5.7 5.8 5.0 2.2 2.3
CP 6.2 6.3 6.1 3.9 4.6 6.2
EB 6.9 6.9 4.4 4.1 4.5 4.5
MEAN vD•in 5.5 5.4 4.7 3.4 3.6
+ SD 1.6 1.0 1.0 0.7 0.9 1.2
-112-
2.3.6). The mean clearances were 48, 45, 44, 40, 45 and
46 ml/min/1.73 for 0-1, 1-2, 2-3, 3-4, 4-6 and 6-8
hours respectively. There was no significant change over
t ime.
Study three.
The individual creatinine clearances are given in
Table 2.3.1k. The mean creatinine clearances were similar
in all collection periods in the "step up" and "step
down" studies (Fig 2.3.7) (136, 141, and 135 ml/min/1.73
m^) for high, mid and low periods in the "step up" study,
and 137, 147, and 135 ml/min/1.73 m for the corres¬
ponding period during the "step down" study. There was no
significant change in creatinine clearance over time on
either day.
The relationship between the renal clearance of inulin
and creatinine and urine flow rate
Study one.
The individual urine flow rates for each period are
shown in Table 2.3.8. The mean urine flow rate fell,
progressively, from 7.1 to 2.7 ml/min from 0-1 to 6-8
hours. This was significant over 8 hours (p< 0.01). There
were no significant correlations between the renal clear¬
ances of inulin or creatinine and the corresponding urine
flow rates except, in the last collection period (r=
0.66, p< 0.001 and r= 0.45, p<0.05 for inulin and
creatinine respectively, Figs 2.3.10 A & B).
Study two.
The individual urine flow rates for each period are
given in Table 2.3.6B. The mean urine flow rate fell from
5.6 to 3.6 ml/min from 0-1 to 6-8 hours. This fall was
insignificant over 4 hours, but was significant over 8
hours (p< 0.01). A significant correlation was found be¬
tween the urine flow rate, and the corresponding renal




Renal clearance of creatinine (ml/min/1.73 m ) during incremental
changes in the inulin dose rate in 8 healthy male subjects
COLLECTION PERIOD
STEP UP STEP DOWN
SUBJECT LOW MID HIGH HIGH MID LOW
JN 119 128 117 117 120 117
GS 133 132 131 149 141 131
SB 135 128 130 141 167 180
AD 126 163 141 133 143 135
BB 124 128 126 130 141 132
WW 155 162 148 162 199 141
SM 169 158 150 126 131 134
BW 120 129 142 121 133 129
MEAN 135 141 136 135 147 137
+SD 18 17 11 15 25 19
TABLE 2.3.7B
Urine flow rate (ml/min) during incremental changes in the inulin
dose rate in 8 healthy male subjects
COLLECTION PERIOD
STEP UP STEP DOWN
SUBJECT LOW MID HIGH HIGH MID LOW
JN 7.2 7.9 8.8 9.6 5.9 10.1
GS 8.1 8.7 8.5 8.1 9.5 7.5
SB 9.6 4.4 9.6 4.1 4.8 7.6
AD 7.6 9.3 6.7 8.3 8.5 8.6
BB 11.0 9.5 10.0 9.4 7.0 8.5
WW 11.7 8.9 8.0 12.3 12.3 12.7
SM 7.8 7.0 6.8 8.6 6.9 8.4
BW 6.4 5.0 8.9 7.5 6.1 6.1
MEAN 8.7 7.6 8.4 8.5 7.6 8.7
+ SD 1.9 2.0 1.2 2.3 2.4 2.0
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TABLE 2.3.8
Urine flow rate (ml/min) during the 8 hours after a single
intravenous injection of inulin in 23 healthy male subjects.
COLLECTION PERIOD (hours)
SUBJECT 0-1 1-2 2-3 3-4 4-6 6-8
PF 12.7 5.5 3.7 2.4 5.3 3.5
GS 5.5 7.4 5.8 5.1 1.5 3.0
JN 6.0 7.3 6.8 7.2 3.2 5.6
DM 1.6 5.7 4.6 6.0 5.2 1.4
MK * 7.1 5.7 3.4 2.9 2.0
CP 0.6 1.7 8.3 6.1 7.5 1.1
BH 7.5 7.2 6.0 5.7 0.9 1.6
BS 10.7 6.3 4.3 5.0 1.7 1.4
PL 13.1 6.9 6.4 6.2 4.0 2.6
TM 8.6 5.1 5.8 4.3 4.2 2.0
GW 1.5 9.8 6.2 5.7 5.9 2.8
AT 6.0 4.8 7.4 6.3 3.0 6.4
EC 8.4 5.8 5.4 5.4 1.2 0.3
WW 8.4 4.3 5.8 3.8 3.0 4.0
AB 10.9 5.5 5.3 5.8 2.0 2.7
RJ 7.7 6.8 2.6 5.2 3.2 1.3
AD 7.5 4.8 4.9 6.3 5.0 2.0
JA 6.7 4.6 5.9 3.6 4.8 4.4
RF 4.3 8.5 3.6 7.3 2.7 1.3
PD 8.4 4.8 4.5 3.6 2.3 1.0
MS 7.9 5.6 5.1 5.0 3.5 4.7
SA 9.6 5.2 5.9 2.5 3.6 2.8
JG 9.3 7.0 4.9 5.5 4.6 3.3
MEAN 7.4 6.0 5.4 5.1 3.5 2.7
+SD 3.3 1.6 1.3 1.4 1.6 1.6
* clearance missing due to inaccuratly timed collection period
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Fig 2.3.10A
Relationship between the renal clearance of inulin and
urine flow rate (6-8 h) , after a single injection of
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Fig 2.3.10B
Relationship between the renal clearance of creatinine
and urine flow rate (6-8 h), after a single injection of
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0.84, p<0.01), 2-3 and 3-4 h (r= 0.75 and r= 0.72, p<
0.05, Figs 2.3.11 A, B, & C), and for the creatinine
clearance 2-3 h (r= 0.82, p< 0.01 Fig 2.3.11 D). There
was no such correlation for any other periods.
Study three.
The individual urine flow rates for each period are
shown in Table 2.3.7B. The mean urine flow rate for each
period during the two study days, were similar. No
correlation between the inulin or creatinine renal
clearance and the corresponding urine flow rate, were
found.
Urinary recovery of inulin
Study one.
Over 24 hours the mean percentage recovery of the
dose administered in the urine was 102 + 7 %. Of this, 50
% is recovered in the first hour, and 97 % is excreted
over eight hours. The individual recoveries are given in
Table 2.3.9.
Study two.
Over the eight hour study duration, the mean
percentage recovery of the dose administered in the urine
was 78 %. Of this, 50 % was excreted between 2 and 6
hours depending on the degree of renal failure. No 8-24
hour collection was made. The individual recoveries are
given in Table 2.3.10A.
Study three.
The mean urinary recovery of inulin in both studies
are given in Table 2.3.10B. For the "step up" study, the
percentage recovery of inulin relative to the amount
infused, was similar over the three periods (96 + 7, 98 +
7 and 98 + 8 % respectively). For the "step down" study,
the amount recovered exceeded the amount infused for the
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Fig 2.3.11
Relationship between the renal clearance of inulin (0-1 h
(A), 1-2 h (B), and 3-4 h (C), and creatinine (2-3 h (D)
with urine flow rate, after a single injection of inulin




Percentage urinary recovery of inulin after rapid intravenous
administration of inulin in 23 healthy male subjects
COLLECTION PERIOD (hours)
SUBJECT 0-1 1-2 2-3 3-4 4-6 001vD 8-24 TOTAL
PF 55 15 8 5 5 2 6 96
GS 50 19 9 6 6 3 7 100
JN 43 18 12 8 8 5 8 102
DM 53 20 10 7 6 3 8 107
MK 40 19 11 5 5 1 5 86
CP 50 20 9 7 8 3 5 102
BH 46 19 9 6 6 3 5 94
BS 49 19 10 6 7 3 9 103
PL 59 19 11 7 7 4 7 114
TM 56 20 10 6 7 3 8 110
GW 46 20 11 7 8 4 3 99
AT 52 23 10 5 5 3 10 108
EC 60 20 11 7 7 1 9 115
WW 55 18 11 6 6 4 5 105
AB 63 18 10 6 6 2 1 106
RJ 52 16 8 7 7 3 9 102
AD 65 18 10 5 4 2 5 109
JA 54 16 9 5 6 3 4 97
RF 57 18 9 6 6 3 5 104
PD 50 26 13 6 2 1 6 104
MS 52 16 9 6 5 4 6 98
SA 48 16 11 5 5 3 6 94
JG 57 23 9 6 6 2 4 107
MEAN 53 19 10 6 6 3 6 103
+SD 6 3 1 1 1 1 2 7
-120-
TABLE 2.3.10A
Urinary recovery of inulin as the percentage of dose administered
in 8 patients with renal impairment over 8 hours
COLLECTION PERIOD (hours)
SUBJECTS T—l1o 1-2 2-3 3-4 4-6 6-8 TOT
JB 18 13 10 8 12 9 68
EC 12 13 9 8 11 11 62
AD 27 16 12 8 13 9 85
EH 24 14 11 9 12 10 79
WA 35 16 12 9 11 8 91
JH 41 18 11 7 9 6 91
CP 29 16 7 4 12 7 75
EB 25 15 7 6 12 8 72
MEAN 26 15 10 7 11 8 78
+SD 9 2 2 2 1 2 11
TABLE 2.3. 10B
Percentage urinary recovery of inulin relative to <dose administered
in 8 males with normal renal function during incremental infusions
COLLECTION PERIOD
STEP UP STEP DOWN
SUBJECT LOW MID HIGH HIGH MID LOW
JN 89 99 92 110 178 196
GS 86 83 92 106 160 189
SB 84 89 83 102 192 228
AD 95 99 94 115 175 170
BB 108 98 104 112 186 174
WW 99 101 91 120 253 197
SM 100 100 100 101 149 172
BW 97 103 113 136 200 222
MEAN 95 97 96 113 187 194
+SD 8 7 9 11 32 22
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first period, and as the infusion rate was decreased, the
discrepancy increased. The mean recoveries were 114 + 11,
186 + 34 and 194 + 22 %, for high, mid and low periods
respectively.
The relationship between the urinary excretion rate and
inulin plasma concentration.
If the renal clearance of a substance is independent
of its plasma concentration, a plot of urinary excretion
rate against plasma concentration, should give a straight
line passing through the origin, and the slope should be
equal to the renal clearance (Tucker, 1981).
Study one.
The log-log plot of the mean urinary excretion rate
of inulin against the mean plasma concentration of
inulin, is shown in Fig 2.3.12. It has been assumed that
the first collection period gives an accurate estimate of
the GFR and therefore a straight line relationship should
exist between this point, and the origin, if the renal
clearance of inulin is independent of its plasma
concentration. This graph shows clearly that, at low
plasma concentrations the points deviate from linearity.
In Fig 2.3.13, the last four points are plotted on linear
graph paper, to show the deviation from the origin. If
the best straight line is drawn through these points, the
line cuts the x axis at 16 mg/1. In other words, at this
level, the renal clearance of inulin falls to zero. The
solid line in this graph represents the straightline
relationship between the first collection period, and the
origin.
Study two.
Similar plots of the urinary excretion rate against
plasma concentration in these patients, as in subjects
with normal renal function, are shown in Fig 2.3.12 & Fig
2.3.13. The slope of the line joining through the first
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Fig 2.3.12
Relationship between the mean urinary excretion rate of
inulin and the mean plasma concentration of inulin in 23
healthy males and 8 patients with renal impairment,
following a single injection. The lines represent the
straight line relationship between the highest clearance
periods and the origin for subjects with normal (- )
and impaired renal function (- ). Bars = + SD.
B.i* = S.D.
O NORMAL RENAL FUNCTION
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period and the origin, is shallower as would be expected
in subjects with reduced renal function. On drawing the
best straight line through the last four points, it is
found that the line cuts the x axis at 35 mg/1.
Study three.
The plot of mean urinary excretion rate against
plasma concentration for both the "step up" and "down"
studies are shown in Fig 2.3.14. If a line is drawn
through the points for the clearance periods when the
plasma concentration was highest and the origin, it can
be seen that there is a small deviation from this line
for the low and mid periods during the "step up", and
only for the low on the "step down". The divergence from




Relationship between the mean urinary excretion rate of
inulin and the plasma concentration of inulin during step
up and step down constant infusion studies, in 8 healthy
males. The solid line represents the straight line
relationship between the highest clearance periods and
the origin. Bars = + SD.
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Inulin clearance has been used for over 50 years as
the "gold standard" for measuring glomerular filtration
rate (Schuster & Seldin, 1985). Inulin best fulfils the
criteria for measurement of the GFR, as its urinary
excretion rate is thought to be proportional to the
plasma concentration, over a wide range 50 to 4000 mg/1,
and the clearance of substances, such as PAH and
glucose, after inhibition of tubular secretion and
reabsorption (by phlorizin and saturation) respectively,
are equal to that of inulin. Inulin is thought to be
freely filtered at the glomerulus, and to be neither
secreted or reabsorbed by the kidney tubules,
synthesised or metabolised by the body (Smith, 1951;
Pitts, 1968). The inulin clearance is therefore
considered to be independent of plasma concentration and
urine flow rate (Schuster & Seldin, 1985).
However, under the conditions of the present study,
both total body and renal clearances of inulin fell
progressively after a single injection with the passage
of time, declining plasma concentrations and falling
urine flow rates. The same effect were seen in subjects
with normal renal function and patients with impaired
renal function. This fall was most dramatic in healthy
subjects with normal renal function, after two hours.
There was no change in the simultaneously measured
creatinine clearance. In patients with renal impairment,
a progressive fall in inulin clearance was seen after
two hours, but this did not become statistically
significant until after four hours. Despite the apparent
decline in inulin clearance with time and decreasing
plasma concentrations, the single injection method gives
an adequate estimate of the GFR, if sampling is
continued for 2 hours in healthy subjects, and 4 hours
in patients with moderate impairment of renal function.
There was also a good correlation between the renal
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clearance and total body clearance of inulin (r= 0.96),
although the latter overestimated the former by about 6
7/o •
Similarly, a concentration dependant effect on the
renal and total body clearances of inulin were seen at
different steady state inulin plasma concentrations,
produced by, incremental stepping up or down the infus¬
ion rate, in subjects with normal renal function. Steady
state plasma concentrations were reached in the "step
up", but not "step down" study. In the latter study,
this was due to excessive input of inulin at a time when
extracellular concentrations were higher than the plasma
concentrations. This is reflected in the greater urinary
recovery than the infused dose, and therefore, the total
body clearance of inulin could not be calculated in the
step down study. No change in creatinine clearances were
seen as the inulin infusion rates were stepped up or
down.
The inulin clearance clearly changed significantly
in all three studies, and in each of these, three
associated variables:- time, changing plasma
concentration, and urine flow rate could have been
involved. These variables are now considered in turn.
1) The effect of time on the clearance of inulin.
Following a single injection of inulin, the
clearance of inulin fell significantly with time after 2
hours in patients with normal renal function, and after
4 hours in patients with renal impairment. During the
constant infusion step up studies, the clearance rose
significantly with time, whilst during the step down,
the clearance fell with time. These studies were carried
out at the same time of day, and the mean clearances of
inulin at the high plasma concentrations on both step up
and step down study days were similar, even though in
one study, the clearance was calculated in the 1% to 2%
hour period and the other, from 5% to 6% hours. Smith
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(1951), reported a systematic drift downwards in the
filtration rate during long constant infusion studies,
but gave no figures. In the constant infusion study
reported in section one there was no change in inulin
renal clearance over a four hour infusion period. Yet
four hours after a single injection of inulin, the
clearance had dropped significantly, in subjects with
normal renal function. The glomerular filtration rate is
subject to diurnal changes of + 10 %, with the lowest
rate at 4.00 am, and highest at 2.30 pm (Wesson &
hauler, 1961). Altogether these observations suggest
that the inulin clearance is not dependant on time,
although a small diurnal effect is possible.
Selective filtration of lower molecular weight
fractions of inulin with time, has previously been
suggested as one possible reason for the decline in
inulin clearance, following a single injection (Ferguson
et al, 1950; Barnard et al, 1955). This is considered
below:
Selective filtration
Inulin is a complex mixture of polymers, consisting
of some 30 fructofuranose subunits with an average
molecular weight of 5200. However, it is not
homogeneous, and it contains a wide range of polymers
with molecular weights up to 15,000. Different batches
and sources of inulin have different molecular weight
ranges (Bassir, 1956). "Inutest" is claimed to be more
homogeneous, but has a molecular weight range of 800 -
16,000 (Nitsch et al, 1979). Selective filtration of the
lower molecular weight polymers of inulin, would result
in retention of the higher weight species, which might
be filtered less effectively. Such an effect, would
produce a decreasing clearance with time (Barnard et al,
1955). Time is unlikely to be a crucial factor as
described above. There is evidence that inulin is not
freely filtered at the glomerulus in rats (Berglund,
-129-
1965), but this has not been confirmed by micropuncture
studies (Gutman et al, 1965; Harris et al, 1974). The
molecular weight patterns of inulin in plasma and
eluting in urine, were similar in normal subjects,
patients with renal impairment and pre-term babies
(Mogensen, 1968; Coulthard & Ruddock, 1983). Thus,
inulin appears to be freely filtered in man, and has
been used for the estimation of glomerular pore size
(Brenner et al, 1978)
2) The effect of urine flow rate on the clearance of
inulin
The results of the present study show that the
effects of urine flow rate on the inulin clearance in
subjects with normal renal function, is limited. Follow¬
ing a single injection, the inulin clearance falls
progressively, and so does the urine flow rate, but
there was no significant correlation until the last
collection period. The relationship between creatinine
clearance and urine flow rate was similar, but there was
no fall in the creatinine clearance until the last
collection period, which suggests incomplete bladder
emptying. There was also no correlation between urine
flow rate and inulin clearance in the constant infusion
studies, despite significant changes in the inulin
clearance. In the patients with renal impairment, there
was no significant change in urine flow rate over the
first 4 hours, but in 3 of the four collection periods
there were significant correlations with the inulin
clearance. However, the urine flow rate and inulin
clearance both fell after 4 hours, but were not
correlated. The urine flow rate was high (5 ml/min), and
as there was no correlation between the creatinine
clearance and urine flow rate for all but one of the
periods, incomplete bladder emptying seems unlikely. The
reason for these sporadic correlations is not known.
Accurate measurement of urine flow rate depends upon
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correct timing of the collection periods and complete
bladder emptying. In this study, care was taken to
minimalize errors by hydration and long urine collection
periods. In any event, normal variation in urine flow
rate is due to changes in water reabsorption, rather
than in filtration rate (Pitts, 1968). If there is no
tubular reabsorption of inulin (Gutman et al, 1965),
there should be no correlation between the inulin clear¬
ance and urine flow rate. The renal clearance of inulin
is said to be independent of urine flow rate over the
range of 1 to 14 ml/min (Chasis & Smith, 1938), but the
filtration rate may fall with dehydration and increase
with hydration. The latter effect is thought to be due
to an increase in extracellular space (Smith, 1951).
3) The effect of plasma concentration on inulin
clearance
The plasma concentration of inulin declined during
the single injection and "step down" studies, and rose
in the "step up" study. These changes were consistently
mirrored by the clearance of inulin. At first sight, the
changes in the inulin renal clearance during the
constant infusion "step up" and "down" studies, do not
seem as dramatic as those following a single injection
of inulin over a similar range of plasma concentrations.
However, the rise in clearance during the step up study
was about 27 %, with plasma concentrations increasing
from 35 to 165 mg/1, and over a similar plasma
concentration range after single injection, the fall in
the inulin renal clearance was 38 %. The fall in
clearance seen in the step down study was 16 "L as plasma
concentrations fell from 187 to 65 mg/1, and over a
similar plasma concentration range, following single in¬
jection, the fall in renal clearance was the same. In
patients with renal impairment, the change in renal
clearance as plasma concentrations fell from 550 to 130
mg/1, was 19 %. The changes in total body clearance of
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inulin over the same periods were 26, 22, and 25 % for
the step up and single injection studies, in subjects
with normal and impaired renal function respectively.
One possible reason for the difference in percentage
change in renal clearance of inulin over similar plasma
concentrations during the step up and single injection
studies in subjects with normal renal function, may be
arterio-venous differences in the latter, which should
be minimal in constant infusion studies (Chiou & Lam,
1982). As inulin is cleared from the arterial side of
the kidney but venous blood is sampled, there may be
differences in the arterial and venous concentrations of
inulin with continuously rising and falling plasma
concentrations. After an intravenous bolus, the arterial
concentrations of inulin are greater than venous
concentrations, as inulin moves from the circulation
into extracellular stores. When distribution is
complete, inulin moves in the reverse direction, and the
venous plasma concentrations are higher than arterial
concentrations. This distribution effect occurs slowly,
and over two hours, venous concentrations in one study
were 7.4% higher than arterial concentrations (Brun et
al, 1949). After two hours, this difference could be
greater, and accentuate the fall in renal clearance
after a single injection. Other investigators, have
discounted arterial-venous differences as a cause for
the fall in inulin clearance after a single injection
(Ferguson et al, 1950; Laake, 1954), and the results of
the present "step up" study, show a change in clearance
in circumstances where there is no significant arterial-
venous difference in concentrations. The percentage
change in the total body clearances of inulin in the
different studies were similar, and this is less likely
to be influenced by arterial-venous differences as,
after 2 hours the curve is extrapolated to infinity, and
the pre- and post- distribution effects will more or
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less cancel out (Nosslin, 1965).
In subjects with normal renal function, the renal
clearance of inulin fell when plasma concentrations
dropped below 100-120 mg/1. However, these studies
provide no evidence that the renal clearance of inulin
remains constant above this level, and the possibility
of "supra normal" clearance at much higher plasma
concentrations, cannot be excluded.
The renal clearance of inulin has previously been
reported to be independent of plasma concentrations
between 40 to 4000 mg/1, with both declining plasma
concentrations, and at different steady state levels
(Shannon & Smith, 1935; Miller et al, 1940; Kennedy &
Kleh, 1953; Cole et al, 1972). On the other hand, others
have reported a falling clearance of inulin after a
single injection, and different clearances at different
constant infusion levels (Josephson & Lindhal, 1943;
Ferguson et al, 1950; Barnard et al, 1955; Laake, 1954).
The reasons for these contradictory findings are
obscure, but it is certain that the renal clearance of
inulin is not as constant as claimed by many
investigators.
The more dramatic decrease in inulin clearance
observed in this study, compared to previous studies,
could be explained by longer sampling periods, and the
measurement of clearance at plasma concentrations lower
than those studied by most other investigators (Shannon
& Smith, 1935; Josephson & Lindhal, 1943; Ferguson et
al, 1950; Laake, 1954; Cole et al, 1972). Miller et al,
(1940), used the constant infusion technique in 3
subjects with normal renal function, and although there
was a difference in mean clearance between low (below
100 mg/1), and high inulin plasma concentrations (above
100 mg/1), this was dismissed by the author. In another
3 healthy subjects using a single injection technique,
they found a fall in clearance in one subject and a rise
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with the other two, as the plasma concentrations fell.
These results are difficult to interpret, because the
kinetic analysis was inappropriate, and samples were
inappropriatly timed. Ferguson et al,(1950), showed a
fall in inulin clearance following single injection and
constant infusion at different plasma levels, but these
were higher than 100 mg/1. Similar findings following
single injection were reported by Barnard et al, (1955).
Again, the methods of analysis were inappropriate, and
sampling was limited. Josephson & Lindhal (1943),
reported a fall in inulin clearance in the third urine
collection period after single injection, but no plasma
concentration data was given, so no inference on the
relationship between plasma concentration and renal
clearance can be drawn. The findings of Laake (1954),
were similar to those in the present study in healthy
subjects, and the clearance seemed to fall after the
plasma concentrations reached 100 mg/1. The author
concludes that this is due to a decrease in extra¬
cellular fluid tonicity, and thus intrarenal pressure
due to fluid loading. However Smith (1951), reports that
the filtration rate increases with hydration. Kennedy &
Kleh (1953), found no concentration dependant clearance
of inulin during constant infusions, in which plasma
concentrations of inulin were stepped up from 40 mg/1 to
900 mg/1.
The fall in inulin clearance in the patients with
renal impairment occurred at higher plasma concent¬
rations than in subjects with normal renal function, but
the actual change was much smaller. Similar findings
were reported by Ferguson et al, (1950), and Laake,
(1954). Thus, the critical plasma concentration
threshold seems to depend on renal integrity and
function. The simultaneous endogenous creatinine
clearance was not measured by other investigators, and
it is not known if the changes were due to natural
-134-
fluctuation in the GFR or incomplete bladder emptying.
The consistency of the creatinine clearance in the
present study, suggests that the fall in inulin clear¬
ance was not due to these factors. More recent studies
of the total body clearance of inulin have correctly
utilised two compartment or model independent kinetic
analysis, but no decline in the renal or total body
clearance of inulin, has been noted. This can probably
be explained by the measurement of plasma concentrations
above the critical level, or the use of patients with
reduced renal function, where small changes in clearance
may go unnoticed (Ladegaard-Pedersen, 1972; Broberger,
1973; Svenningsen, 1975; Fawer et al, 1979; Muller-Suur
et al, 1983 ; Rehling et al, 1984).
The results of the present studies are supported, in
part, by previous reports, and there seems no doubt that
the clearance of inulin is dependant on its plasma
concentration, below a certain level. The question
arises to the mechanisms involved, and possibilities
include increased extrarenal clearance of inulin, and
tubular reabsorption.
Extrarenal clearance
The total body clearance of inulin exceeded the
renal clearance by 6 %, in both single injection and
constant infusion studies, in subjects with normal and
impaired renal function. This excess represents either
extrarenal clearance of inulin, or residual storage of
inulin in the body. Inulin is not thought to be metabol¬
ised or cleared extrarenally, except possibly to an
insignificant extent by biliary excretion (2%) (Smith,
1951). In addition, the urinary recovery of inulin fol¬
lowing a single injection in subjects with normal renal
function, was also complete, as found by others (Shannon
& Smith, 1935). Therefore, any extrarenal clearance must
be insignificant.
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Tubular reabsorption of inulin
The possibility of tubular reabsorption of inulin at
low plasma concentrations was raised by Ferguson et al*
(1950), who found that a plot of urinary excretion rate
against plasma concentration, gave a line which did not
pass through the origin, but cut the y axis at a
negative ordinate. A straight line passing through the
origin would be expected if the urinary excretion rate
is proportional to the plasma concentration, as is
thought to be the case for inulin (Shannon & Smith,
1935). Similar analysis by Laake (1954), and Kennedy &
Kleh (1953), gave different results. Either there was no
deviation from the origin, or minor discrepancies were
disregarded as insignificant. Laake (1954), suggested
that the clearance falls as plasma concentrations
decline below 100 mg/1, but no critical point could be
determined. In the present study, the deviation from the
line of identity is accentuated by the use of a log-log
scale. The line crosses the x axis at a positive
intercept (as shown on the linear graph) indicating
that, at this plasma concentration the inulin clearance
falls to zero. This negative deviation from the line of
identity shows, that the rate of excretion of inulin
lags behind the plasma concentration (Tucker, 1981). One
explanation for this could be delay time; however, such
a mechanism does not explain the change in inulin
clearance during the "step up" and "step down" constant
infusion. It is possible that delay time accentuates the
fall following a single injection at low plasma concent¬
rations, due to a diminishing urine flow rate. Another
possible explanation is, that inulin is retained within
the kidney as residual volume, as the urine flow rate
diminishes, following a single injection. However, again
the changes in both total body and renal clearances of
inulin during the constant infusion study, in which
urine flow rates were high and constant, suggests that
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this is unlikely.
A more likely explanation for the concentration-
dependent clearance of inulin is tubular reabsorption.
If this occurs, reabsorption must either be saturable,
or possibly a very small proportion is removed contin¬
uously, as the clearance of inulin is affected only at
low plasma concentrations. The results are consistent
with, but do not prove, reabsorption of inulin. The
tubular reabsorption of inulin would also explain the
consistent overestimation of the inulin renal clearance
by the total body clearance of inulin in both single
injection, and constant infusion studies, and also why
the total body clearance of inulin rose, significantly,
during the "step up" infusion study. Reabsorption should
also be suspected if the renal clearance of a substance
falls below the level of the glomerular filtration rate
(Rowland & Tozer, 1980). The evidence against
reabsorption of inulin comes mainly from micropuncture
studies in rats (Gutman et al, 1965; Harris et al,
1974). These showed little (0.6-2.4 %) or no reabsorp¬
tion as assessed by excretion via the contralateral
kidney, and quantitative recovery of the amount
injected. However, renal uptake of inulin occurs in
animals (Balint & Forgacs, 1958; Gayer et al, 1961;
Barber & Bourne, 1971).
The mechanism of reabsorption is not easily
explained as, the molecular size of inulin excludes
diffusion through tubular cell membranes, and it is not
thought to be actively reabsorbed. In the rat, inulin
does not diffuse through the plasma membrane of
hepatocytes but, it undergoes endocytosis. Of this
amount, 80 % was returned to the plasma, 18% was
retained intracellularly, and 2 % was excreted in the
bile (Scharschmidt et al, 1986). Any suggestion that
renal tubular cells transport inulin in a similar way
would be pure speculation, however, the ability to
-137-
internalize extracellular material appears to be a
property shared by most cells (Scharschmidt et al,
1986). It has been reported that after administration of
carbohydrates in large doses, vesiculation and swelling
of the proximal tubule epithelium occurs (Maunsbach,
1973) and this has been described for inulin in rabbits
(Simon et al, 1964). Although mechanisms cannot be
identified, saturable tubular reabsorption of inulin
cannot be excluded, and it is probably the most
plausible explanation for the concentration-dependant
decline in inulin clearance.
SUMMARY
The total body and renal clearances of inulin,change
significantly with changes in plasma concentration, time
and urine flow rate following a single injection in
subjects with normal renal function, and patients with
renal impairment. The clearance of inulin also changes
over time and plasma concentration during constant
infusion at different plasma levels. The creatinine
renal clearance remained constant throughout each study,
and therefore changes in inulin clearance were not due
to changes in GFR. The passage of time and changes in
urine flow rate are unlikely to account for all of the
changes in the clearance of inulin. The fall in inulin
clearance, seems to be plasma concentration dependant
below a critical point. In subjects with normal renal
function, this critical level was about 100 mg/1, but in
patients with impaired renal function, it was much
higher. The inulin clearance may fall at low plasma
concentrations because the urinary excretion of inulin
lags behind the plasma concentration, with increasing
retention or reabsorption by the kidney. The higher
total body than renal clearance of inulin could also
conceivably be explained by reabsorption in the kidney.
The mechanisms involved cannot be deduced from the
present data, but the kinetics of the concentration-
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dependent clearance of inulin are consistent with
saturable tubular reabsorption. A reassessment of the






A single injection method for measuring the
clearance of inulin was investigated and validated
against the standard constant infusion method.
The results obtained and conclusions drawn are
summarised below.
1) Over the first two hours following single
intravenous administration of inulin (70 mg/Kg over 5
minutes in 10 healthy males), both the total body and
renal clearances of inulin were similar (101 and 92
ml/min/1.73 m^ respectively). They agreed well with the
renal clearance of inulin during constant infusion (88
ml/min/1/73 m^) in the same subjects.
2) With the single injection method, the total body
and renal clearances of inulin decline progressively,
and significantly after two hours, (a mean fall of 48 %
over eight hours in the case of the renal clearance) and
the correlation and similarity between the single
injection and constant infusion methods, is lost.
3) The creatinine clearance does not show a similar
fall, and a real alteration in GFR is therefore
unlikely.
4) This depression in inulin clearance was
investigated further following a single intravenous
injection in 23 males with normal, and 8 patients with
impaired renal function. The clearance of inulin was
also investigated at different steady state plasma
concentrations in 8 normal subjects by the use of "step
up" and "step down" constant infusions.
5) In all three studies, there were significant
changes in the clearance of inulin. This could have been
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related to three variables, time, urine flow rate and
plasma concentration.
6) The changes in inulin clearance are unlikely to
be due to the effects of time, urine flow rate or
arterial-venous differences, as significant changes were
found in the "step up" and "step down" constant infusion
studies, where these factors were reduced to a minimum.
7) The results of the present studies show that the
inulin clearance depends on the plasma concentration
below a certain level. This critical level is about 100
mg/1 in normal healthy subjects, but is higher in
patients with renal impairment.
8) Three significant factors are relevant to the
mechanism behind the fall in clearance.
A) The inulin clearance falls to well below the
glomerular filtration rate (creatinine clearance).
B) The total body clearance of inulin consistently
overestimates its renal clearance, and the total body
clearance also falls as the renal clearance declines. As
the recovery of inulin in the urine is quantitative,
major extrarenal clearance is unlikely.
C) The plot of inulin urinary excretion rate
against plasma concentration indicates that, the
urinary excretion rate of inulin lags behind the plasma
concentration, as concentrations fall below 100 mg/1.
Therefore, the fall could conceivably be due to relative
retention of inulin in the urinary tract. This could
occur by, 1) delay time error, 2) incomplete bladder
emptying or 3) tubular reabsorption of inulin.
The first two factors do not adequately explain the
results. However, the progressive and significant
decline in inulin clearance below the GFR as the plasma
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concentration declines, and the higher total body-
clearance than renal clearance of inulin, would be
consistent with tubular reabsorption of inulin, which
only becomes significant at low plasma concentrations.
Saturable tubular reabsorption is the most plausible
explanation for the observed concentration-dependent
decline in inulin clearance.
9) The clearance of inulin following single
intravenous administration over the first two hours, is
similar to that found during the standard constant
infusion method. Over this period, the single injection
method was reproducible on repeated estimations, and the
total body clearance of inulin varied less than the
renal clearance of inulin as determined by single
injection or constant infusion methods.
10) The single injection of inulin for measuring GFR
is accurate and reproducible. It is also quick, easy and
causes minimum discomfort to the patient, while the
risks inherent with the use of radioactive compounds are
avoided. However, the clearance of inulin is
concentration dependent at low plasma concentrations,
and at these levels, both the injection and constant




SINGLE INJECTION METHOD FOR MEASUREMENT OF RENAL BLOOD
FLOW USING p-AMINOHIPPURIC ACID
-144-
INTRODUCTION
At low plasma concentrations p-aminohippuric acid
(PAH) is almost completely extracted during a single
passage through the kidney by active tubular transport,
consequently, its renal clearance is widely used as a
measure of renal plasma flow.
p-Aminohippuric acid was first used to measure renal
plasma flow (RPF) in 1945 (Smith et al, 1945), and it
has since become the standard for this purpose. The
renal clearance of PAH is usually measured at steady
state plasma concentrations, during constant intravenous
infusion. As noted previously (p 47), this technique is
tedious and cumbersome for both patient and investi¬
gator, and accurately timed complete urine collections
are required. These problems limit this technique mainly
to research applications. Radiolabelled substances such
1 ? 5 1^1
as z hippuran and IL-J-L diodrast have been introduced
as alternatives for clinical use, and their clearances
have been calculated from plasma concentration-time
decay curves, following single intravenous bolus admin¬
istration. The total body clearance of hippuran is less
than the simultaneously measured renal clearance of PAH,
and it falls with time (Pihl, 1973; Pearson, 1979).
Radioactive iodine is potentially hazardous, although
uptake into the thyroid gland can be inhibited by prior
administration of unlabelled iodine (i.e potassium
iodate). A simple method for the measurement of renal
blood flow is required, which does not have the problems
associated with radioactivity.
Simplification of the measurement of the renal
clearance of PAH to allow a clinically practicable
method has been attempted using constant infusion
techniques without urine collection, and single
injection techniques with, and without urine collection.
These have not been successful. The total body clearance
of PAH is significantly greater than the corresponding
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renal clearance (Statius Van Eps et al, 1967; Cole et
al,1972). This has been attributed to metabolism of PAH
as, the total body and renal clearances became equal
after hydrolysis of the samples (Berger et al, 1948).
PAH is metabolised to some extent to the N4 acetyl
derivative (AcPAH) in animals and man (Smith, 1951), but
this metabolic loss is considered to be insignificant,
and to occur extrarenally. Thus it should not interfere
with the estimation of RPF using the constant infusion
method, or techniques in which urine PAH is determined
(Smith et al, 1945; Pearson, 1979). However, if
metabolism occurs in the kidney, the clearance and RPF
will be underestimated. The renal metabolism of PAH has
been reported in many mammals (except the dog), both "in
vivo" and "in vitro" (Setchell & Blanch, 1961; Gyrd-
Hansen & Rasmussen, 1970; Malyusz et al, 1979; Carpenter
& Mudge, 1980). In man, "in vitro" metabolism of PAH has
been shown to occur in kidney cortical slices (Frindt &
Vial, 1968), and it may also occur "in vivo" in healthy
individuals (Newman et al, 1949) and patients with
various disorders (Grindt et al, 1974). The methods used
for analysis of PAH in these studies were not specific,
and the need for hydrolysis of AcPAH before estimation
as total PAH in plasma and urine, make these results
unreliable (Brown et al, 1976). There is no information
on the kinetics of AcPAH after a single injection or
constant intravenous infusion of PAH in normal





High Performance Liquid Chromatographic estimation of p-
aminohippuric acid in plasma and urine.
p-Aminohippuric acid (PAH) is routinely determined
by the Bratton & Marshall method (1939), with modific¬
ations (Smith et al, 1945; Harvey & Brothers, 1962). The
method depends on the reaction of N-(-l-napthyl)
ethylenediamine dihydrochloride with diazotizable aryl
amines (i.e PAH, sulphonamides, p-aminobenzoic acid) to
form azo dyes, which are measured colorimetrically. The
reaction of primary aromatic amines with p-
dimethylaminobenzaldehyde to form shiff bases, has also
been utilised (Brun, 1951). These colorimetric methods
are not specific (Waugh & Beall, 1974). They are also
time consuming due to the need for multiple steps, which
require careful timing (Shoup & Kissinger, 1975).
More specific techniques became possible with the
development of high performance liquid chromatography
(HPLC). Methods for the assay of PAH using HPLC with
ultraviolet absorbance detection of PAH have been
reported (Brown et al, 1976; Carpenter & Mudge, 1980;
Meerdink et al, 1981; Prueksaritanont et al, 1984;
Baranowski & Westenfelder, 1986), as well as with
electrochemical detection (Shoup & Kissinger, 1975). A
capillary gas chromatographic method has also been
described (Libeer et al, 1981). The majority of these
techniques are designed to measure not only PAH but also
iothalamate, p-aminobenzoic acid and creatinine.
Consequently, ultraviolet absorbance at 230 nm and 254
nm have been measured, but the maximum absorbance of PAH
is at 280 nm (Moffat et al, 1986). The method described
below is specific for PAH in plasma and urine, p-
Aminobenzoic acid is used as an internal standard, and
absorbance is measured at 280 nm.
Materials
Sodium aminohippurate (20% w/v) was obtained from
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Merck Sharp & Dohme, Hoddesdon, p-aminohippuric acid
from Sigma, Poole, Dorset and potassium nitrate (KN03),
p-aminobenzoic acid (PABA), perchloric acid (HC104),
gentisic acid and sulphanilamide were all purchased from
British Drug House, Poole, Dorset. Acetonitrile (HPLC
grade) was obtained from FSA Laboratory Supplies,
Loughborough and glacial acetic acid, from Thornten &
Ross Ltd, Huddersfield. The mobile phase was degassed
using Helium gas, obtained from the British Oxygen
Company.
Ins trumentation
The HPLC system consisted of a solvent delivery pump
(Altex 110), a WISP 710 B (Waters Intelligent Sample
Processor) auto sample injector. A filter and a Waters
"Guard-PAK" precolumn packed with the same material as
the analytical column, was fitted between the injector
and the column. The analytical column was an 8 mm x 10
cm Waters "Radial-PAK" Cartridge containing a reverse
phase, 5 p or 10 p C18 bonded spherical silica support
in a Waters RCM-100 Radial Compression Module. A Waters
series 441 ultraviolet (UV) absorbance detector or a
Perkin-Elmer Model LC-75 detector, were used at 280 nm.
The UV detector output was passed to a chart recorder or
a Shmadzu (C-R1B) integrator, to produce chromatograms
and peak heights.
Plasma p-aminohippuric acid assay
Chromatographic conditions
Plasma p-aminohippuric acid was estimated (5 p
column) under the following chromatographic conditions:
Mobile Phase : 0.005 M potassium nitrate containing 2 %








Preparation of standards and samples
Serial dilutions of a stock solution of p-
aminohippuric acid in fresh blank plasma were prepared
to give concentrations ranging from 1-50 mg/1, to run
with the unknown samples. To 250 pi of plasma in a
plastic tube, 250 pi of aqueous internal standard
containing 20 mg/1 p-aminobenzoic acid was added. (500
mg/1 of gentisic acid in aqueous solution can be used as
an alternative internal standard). Fifty pi of 24 %
perchloric acid was then added with continuous mixing
(Whirlimix, Jencons Scientific), to precipitate the
plasma proteins. The samples were centrifuged at 1400g
for 10 minutes and up to 40 pi of clear supernatant was
injected onto the column.
Calculation of results
The peak height ratios (PAH divided by p-amino¬
benzoic acid) were measured for the standards, and
plotted against the known standard concentrations. The
peak height ratios of the unknown samples were read off
the standard plot, to give a concentration in mg/1.
Results
Chromatograms from drug-free plasma, and from plasma
obtained 10 minutes after an intravenous bolus injection
of sodium aminohippurate are shown in Fig 3.1.1. The
retention times of p-aminohippuric acid, p-aminobenzoic
acid and gentisic acid were 2.92, 4.39 and 7 mins
respectively. The limit of detection for p-aminohippuric
acid was less than 1 mg/1 and no interference was
observed with the drugs used in the reported studies.
Validation
The linearity and precision were determined by
replicate analyses of the standard solutions of p-amino-
hippuric acid on 5 occasions, over a period of one week.
The results are shown in Table 3.1.1 and Fig 3.1.2.
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Fig 3.1.1
Chromatograms obtained from the assay of:-
A) Drug free plasma (25 pi injection)
B) Plasma sample obtained 10 minutes after an intra¬
venous bolus dose of 723 mg of sodium aminohippurate.
The sample contained 21.82 mg/1 p-aminohippuric acid (P)
plus 20 mg/1 p-aminobenzoic acid (internal standard
(IS)), and 500 mg/1 gentisic acid (G), (20 pi injection),
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Fig 3.1.2
Calibration plot of the mean peak height ratios obtained
following repeated analysis (N=5) of plasma containing
p-aminohippuric acid in the concentration range 1-50
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The coefficients of variation ranged from 10.8 % at 1
mg/1 to less than 4 % for concentrations of 5 - 50 mg/1.
The calibration plot calculated using linear regression
was linear over the concentration range 1-50 mg/1, and
passed close to the origin.
The mean recoveries of p-aminohippur ic acid from
spiked plasma compared with aqueous solution at
concentrations of 30, 15 and 5 mg/1 were 95, 93, and 97%
respectively (Table 3.1.2).
p-Aminohippuric acid urine assay
Chromatographic conditions
The conditions tend to be varied to change the
retention times of PAH and the internal standard, to
avoid interfering peaks in the urine. p-Aminohippuric
acid was determined in urine, using the same column as
for plasma with the following chromatographic
conditions:
Mobile Phase : 0.01 M potassium nitrate containing 1%
Preparation of standards and samples
Serial dilutions of a stock solution of p-
aminohippuric acid in blank urine were prepared to give
concentrations ranging from 50 - 800 mg/1, and these
were run with the unknown samples. To 250 pi of approp¬
riately diluted urine, 250 pi of aqueous internal
standard was added containing 200 mg/1 p-aminobenzoic
acid. (200 mg/1 sulphanilamide can be used as an
alternative aqueous internal standard). The samples were
mixed (Whirlimix, Jencons Scientific), and up to 15 pi
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Calculation of results
The peak height ratios (PAH divided by p-amino-
benzoic acid) were measured for the standards and
plotted against the known standard concentrations. The
peak height ratios of the unknown samples were read of
the standard plot to give concentrations in mg/1.
Results
Chromatograms from drug-free urine, and from urine
obtained 2-2% hours after the start of a constant intra¬
venous infusion of sodium aminohippurate, are shown in
Fig 3.1.3. The retention times of p-aminohippuric acid,
p-aminobenzoic acid and sulphanilamide were 3.5, 5.5
and 2.8 minutes respectively. The limit of detection of
p-aminohippuric acid depended on the presence of
interfering peaks in the urine.
Validation
The results of 5 replicate analyses of standard
solutions of p-aminohippuric acid in urine over a period
of one week, are shown in Table 3.1.3 and Fig 3.1.4. The
coefficients of variation were below 3 % for all
concentrations. The calibration plot was linear over the
concentration range studied, and passed close to the
origin.
Discussion
p-Aminohippuric acid in plasma and urine was estimated
directly by HPLC, using ultraviolet detection at 280 nm.
The assays are rapid, simple and precise. p-Aminobenzoic
is a potential metabolite of PAH. To rule out this
possibility as a cause of error, samples also contained
gentisic acid and sulphanilamide, as alternative
internal standards for plasma and urine respectively. In
no cases was there evidence for the presence of p-
aminobenzoic acid other than as the internal standard.
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Fig 3.1.3
Chromatograms obtained from the assay of:-
A) Drug free urine (15 pi injection)
B) Urine collected 2-2% hours after the start of a
constant infusion of sodium aminohippurate (15 mg/min).
The sample contained 1280 mg/1 p-aminohippuric acid (P),
plus 200 mg/1 p-aminobenzoic acid (IS) and 200 mg/l
sulphanilamide (S), (8 pi injection)
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TABLE3.1.3
Replicateanalysisofp-aminohippuricc di urine(1-50g/1)bHPLC p-AminohippuricPeakH ightRatio(PAH/PABA)Standa dCoefficient acidof Cone,mg/1Run12345MeanDeviationVari ti(%) 500.212.0 552.6 1000.434. 2. 084.9 2000.87895151. 4001.684716. 570 028. 6002.46549.3870 058. 8003.292356. 00 0591.8
Fig 3.1.4
Calibration plot of the mean peak height ratios obtained
following repeated analysis (N=5) of urine containing p-
aminohippuric acid in the concentration range 50-800
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High Performance Liquid Chromatographic estimation of
acetyl p-aminohippuric acid in plasma and urine.
Acetyl p-aminohippuric acid (AcPAH) is the major
metabolite of PAH and, it has usually been determined as
PAH (see p 148) after removal of the acetyl group by
hydrolysis, with concentrated hydrochloric acid at 96°C
for 1 to 3\ hours (Smith et al, 1945; Newman et al,
1949; Statius Van Eps, 1967; Grindt et al, 1974). The
AcPAH is represented as the difference in PAH
concentrations before, and after hydrolysis. Treatment
of AcPAH with hydrochloric acid also produces secondary
products such as p-aminobenzoic acid, which also give a
positive colour reaction and hence, a false estimate of
AcPAH concentrations (Brown et al, 1976). Specific HPLC
assays for AcPAH have therefore been developed, to
overcome these problems (Brown et al, 1974; Meerdink et
al, 1981; Stolk et al, 1985). The method of Brown et
al, (1974), is not sensitive enough to detect AcPAH in
plasma following intravenous administration of PAH. The
other methods can measure AcPAH and PAH simultaneously,
but this is impractical because of the large concent¬
ration differences in plasma. The HPLC method described
here, can measure AcPAH without hydrolysis at low
concentrations in plasma and urine.
Materials
Sodium aminohippurate, potassium nitrate, p-
aminobenzoic acid (PABA), perchloric acid, acetonitrile,
glacial acetic acid, and helium were obtained, as
described previously (p 149). Anthranilic acid and
hippuric acid were purchased from British Drug House,
Poole, Dorset.
Acetyl-p-aminohippuric acid was synthesised by
reacting PAH with acetic anhydride (May & Baker,
Dagenham, U.K.) using the method of Newman et al, 1949.
A 20 X solution of sodium aminohippurate was diluted
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with an equal volume of distilled water. 2 mols acetic
anhydride, was added whilst stirring to 1 mol PAH. The
solution was allowed to stand at room temperature for 30
minutes, with occasional shaking, before the mixture was
cooled in an ice bath, and filtered through a Bruchner
funnel by suction. The precipitate was washed several
times with ice cooled distilled water, and then with 95
7o ethyl alcohol. The precipitate was left to dry
protected from light. The AcPAH was a creamy crystalline
substance, with a melting point of 243.3°C to 247.6°C.
This was similar to the melting point of 242°C reported
by Stolk et al, (1985) but higher than 209 to 228°C
described by Statius Van Eps et al, (1967). The identity
of the AcPAH was confirmed by infra red spectrophoto¬
metry, nuclear magnetic resonance and mass spectrophoto¬
metry (MW = 235), at the Chemistry Department of
Edinburgh University. Only one peak was observed on
HPLC.
Ins trumentation
The HPLC system was as described on page 149.
Acetyl-p-aminohippuric acid plasma assay
Chromatographic conditions
Plasma acetyl-p-aminohippuric acid was estimated
using a Radial-PAK, C18, 5 p column under the following
chromatographic conditions:
Mobile Phase : 0.01 M potassium nitrate containing 1%
Preparation of standards and samples
Serial dilutions of a stock solution of acetyl-p-
aminohippuric acid in blank plasma were prepared in the









solutions were run with the unknown samples. To 250 ^jl
of plasma in a plastic tube, 100 ^il of aqueous internal
standard containing 250 mg/1 hippuric acid was added.
(2.5 mg/1 of aqueous p-aminobenzoic acid may be used as
an alternative). 50 pi of 24% perchloric acid was added
with continuous mixing (Whirlimix, Jencons Scientific)
to precipitate the plasma proteins. The samples were
centrifuged at 1400g for 10 minutes and up to 90 pi of
clear supernatant was injected onto the HPLC column.
Calculation of results
The peak height ratios (AcPAH divided by hippuric
acid) were measured for the standards and plotted
against the known standard concentrations. The peak
height ratios of the unknown samples were read off the
standard plot to give concentrations in mg/1.
Results
Chromatograms from drug-free plasma and from plasma
obtained 2 hours after the start of a constant infusion
of sodium aminohippurate are shown in Fig 3.1.5. The
retention times of AcPAH, hippuric acid and p-amino-
benzoic acid were 8, 11.5 and 5 minutes respectively.
The limit of detection for AcPAH was less than 0.5 mg/1
and no interference was obtained from tenoxicam used in
the studies.
Validation
The linearity and reproducibility for the plasma
assay were determined by replicate analysis of standard
solutions of AcPAH on 5 occasions, over a period of one
week (Table 3.1.4 and Fig 3.1.6). The coefficients of
variation were below 3 % for all concentrations. The
calibration plot was linear over the concentration range
studied, and passed close to the origin. The mean
recoveries of AcPAH, from spiked plasma, compared with
aqueous samples containing 0.5, 1 and 5 mg/1 were 89,
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Fig 3.1.5
Chromatograms obtained from the assay of:-
A) Drug free plasma (55 pi injection)
B) Plasma sample obtained 2 hours after the start of a
constant infusion of sodium aminohippurate (15 mg/min).
The sample contained 2.8 mg/1 acety1-p-aminohippuric
acid (A) plus 250 mg/1 hippuric acid (IS), 2.5 mg/1 p-
aminobenzoic acid (PB), and p-aminohippuric acid (P) (40
jul injection).

























































Calibration plot of the mean peak height ratios obtained
following repeated analysis (N=5) of plasma containing
acetyl-p-aminohippuric acid in the concentration range
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82, arid 89 % respectively (Table 3.1.5).
Acetyl-p-aminohippuric acid urine assay
Chromatographic conditions
Acetyl-p-aminohippuric acid was determined in urine
using a Radial-PAK, C18, 10 }i column, under the
following chromatographic conditions:
Mobile Phase : 0.01 M potassium nitrate containing 1%
acetic acid : acetonitrile (92:8 V/V)
Flow Rate : 1.9 ml/min
Pressure : 1000 psi
Wavelength : 280 nm (detector)
Preparation of standards and samples
Serial dilutions of a stock solution of acetyl-p-
aminohippuric acid in blank urine were prepared to give
concentrations ranging from 50 - 250 mg/1. These were
run with the unknown samples. To 250 pi of appropriately
diluted urine, 175 pi of aqueous internal standard
containing 50 mg/1 p-aminobenzoic acid was added. (1250
mg/1 aqueous anthranilic acid may be used as an alter¬
native). The samples were mixed (Whirlimix, Jencons
Scientific), and up to 20 jil injected directly on to the
HPLC column.
Calculation of results
The peak height ratios (AcPAH divided by p-
aminobenzoic acid) were measured for the standards, and
plotted against the known standard concentrations. The
peak height ratios of the unknown samples were read off
the standard plot, to give concentrations in mg/1
Results
Chromatograms from drug-free urine, and from urine
obtained 2-2% hours after the start of a constant
infusion of sodium aminohippurate, are shown in Fig
3.1.7. The retention times of AcPAH, p-aminobenzoic acid
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TABLE3.1.5
Meanr l tiveco ryofacetyl-p- miriohippuricdfr spikedplasma










Chromatograms obtained from the assay of:-
A) Drug free urine (20 pi injection)
B) Urine collected 2-2^ hours after the start of a
constant infusion of sodium aminohippurate (19 mg/min).
The sample contained 229 mg/1 acety1-p-aminohippuric
acid (A) plus 50 mg/1 p-aminobenzoic acid (IS), 1250
mg/1 anthranilic acid (AA), and p-aminohippuric acid (P)
(20 jul injection).
Detection was at 280 nm (0.1 AUFS), and 0 indicates the
time of injection.
-168-
and anthranilic acid were 4.5, 3.4 and 8.1 minutes
respectively. The limit of detection for AcPAH depends
on the presence of interfering endogenous peaks.
Validation
The standard solutions of AcPAH in urine were run
through the procedure 5 times, and the results are shown
in Table 3.1.6 and Fig 3.1.8. The coefficients of
variation were below 3 % for all the standards. The
calibration plot was linear over the concentration range
studied and passed close to the origin.
Discussion
The method allows rapid, direct, simple and precise
assay of acety1-p-aminohippuric acid in plasma and
urine, without the need for prior hydrolysis. AcPAH was
found to disappear slowly, in the presence of perchloric
acid, after 10 hours (data not shown). Samples must
therefore be processed within this time, after the
addition of perchloric acid. p-Aminobenzoic and hippuric
acid are potential metabolites of PAH. To rule out this
possibility as a cause of error, urine samples also
contained anthranilic acid, as an alternative internal
standard. However, in no cases was there evidence for
the presence of p-aminobenzoic acid or hippuric, acid
other than as the internal standard.
-169-




























































Calibration plot of the mean peak height ratios obtained
following repeated analysis (N=5) of urine containing
acety1-p-aminohippuric acid in the concentration range







I I I I I
50 100 150 200 250
ACETYL-p-AMINO HIPPURIC ACID (mg/l)
-171-
SECTION II
THE DISPOSITION AND KINETICS OF PAH FOLLOWING A SINGLE
INTRAVENOUS INJECTION AND AFTER CONSTANT INFUSION
-172-
INTRODUCTION
The object of this study was to investigate the
disposition and kinetics of PAH and AcPAH after a single
injection, and during constant infusion of PAH in
healthy male volunteers, using a direct and specific
assay of PAH and AcPAH. It was also hoped to be able to
develop a single injection technique for the estimation
of RPF, without dependence on urine collections. The
clearance of PAH following single injection and during
constant infusion was compared in the same individuals.
METHODS
Single injection
The total body and renal clearances of PAH and AcPAH
renal clearances were measured in 26 healthy male
individuals, with a mean age 27 + 6 years (range 21-50
yrs) weighing 71 + 7 Kg (range 57-89 Kg), following a
single intravenous bolus injection of PAH.
The initial procedure was described in chapter two
(p 50). Sodium aminohippurate (10 mg/Kg, 5 ml, 20 % w/v
solution, Merck Sharp & Dohme, Hoddesdon, UK) was given
as an intravenous bolus injection over 1 minute, prior
to inulin administration (p 50). Venous blood samples
(10 ml) were collected at 3, 5, 10, 15, 20, 30, 40, 50,
60, 75, 90, 120, 180, 240, 360 and 480 minutes, after
the end of the injection. Urine was collected hourly for
the first four hours, then at 6, 8 and 24 hours. The
syringe used to give PAH was weighed full before, and
again empty after administration, to allow calculation
of the exact dose.
Constant infusion
The PAH and AcPAH renal clearances were measured in
ten healthy male volunteers, aged between 21-50 years
(mean 27+8 yrs) weighing 57-78 Kg (mean 71 + 7 Kg) who
received PAH by constant infusion. The single injection
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and constant infusion methods were used, in random
order, and the two studies were carried out within
fourteen days of each other, except in the case of
volunteer RJ, in whom the interval was 8 months.
The initial procedure was as described on page 49
chapter 2. A loading dose of Sodium PAH (440 mg, 2.2 ml,
20 % solution) was administered over one minute,
followed by a maintenance infusion containing PAH (19
mg/ml) in 5 % dextrose, which was given simultaneously
with inulin (p 49), at a rate of 1 ml/min. After an
equilibrium period of one hour, the bladder was emptied
and 4 half hourly timed urine samples were collected.
Venous blood was drawn at the start and end of each
urine collection period using the cannula which had not
been used for the infusion.
Sample storage and analysis
The blood samples were collected in 10 ml lithium
heparin tubes, and centrifuged at 1500 g for 10 minutes.
The plasma was removed, and stored in 5 ml plastic tubes
at -20°C, until analysed. Urine volume and pH
(Radiometer) were measured, and a 20 ml aliquiot stored
at -20°C until analysis.
Plasma and urine were analysed for PAH and AcPAH
using HPLC as described in section I (p 147).
Data analysis
Single injection
The exact dose of sodium PAH was calculated by
syringe weighing, as for inulin (chapter 2, p 53). The
dose of sodium aminohippurate was then converted to the
PAH equivalent by applying a correction factor of 1.113,
based on the molecular weights of sodium aminohippurate
(216), and PAH (194). The dose administered will
subsequently be referred to as the amount of PAH.
The total body clearance of PAH was calculated from
the plasma concentration-time data alone, in the same
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manner as described for inulin (chapter 2, p 52), using
data at 3, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, and
120 minutes following the end of the PAH injection. In
some cases, the three minute data was ignored as
concentration were lower then at 5 minutes. After two
hours, both plasma PAH and AcPAH concentrations were
below the limit of measurement. The total body clearance
was calculated using equation 8 (p 52) i.e. the
administered dose divided by the area under the plasma
concentration time curve (AUC), extrapolated to
infinity. The total body clearance was calculated from
0-1 and 0-2 hours.
The renal clearances of PAH and AcPAH were estimated
from equation 4 (p 53) i.e. the amount excreted divided
by the corresponding AUC. The renal clearances of PAH
and AcPAH were calculated for the 0-1 and 1-2 hour
periods.
The percentage recovery of the dose of PAH was
calculated for each urine collection period up to four
hours, and summed to give the total recovery of PAH. The
percentage recovery as AcPAH was calculated, after
converting AcPAH to the PAH equivalent, by dividing by
1.216. This correction factor was obtained by dividing
the molecular weight of AcPAH (236) by that of PAH
(194). The recovery was calculated for each urine
collection period up to eight hours, and summed to give
the total percentage of the dose recovered as AcPAH.
The distribution half life for PAH was estimated in
a similar manner to that described previously for inulin
(chapter 2, p 90) for the 0-1 hour data. The plasma half
life values of PAH and AcPAH (t\) were calculated from
the linear elimination phase of the plasma concentration
time curve, using the following relationship:-
j- =
slope
the half lives were estimated for each subject from 30
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to 60 minutes for PAH, and 30 to 120 minutes for AcPAH.
Constant infusion
The renal clearances of PAH and AcPAH were
calculated as described previously for inulin (chapter
2, p 52), for all urine collection periods.
All clearance values for PAH and AcPAH were
O
corrected for a body surface area of 1.73 m .
Statistical methods
The significance of differences between means were
determined using 2 way analysis of variance. The null
hypothesis was rejected if p<0.05. Correlation coeffic¬
ients were determined by linear regression.
RESULTS
Plasma concentrations
Individual PAH and AcPAH plasma concentrations are
listed in Appendix I.
Single Injection
p-AMINOHIPPURIC ACID
Following intravenous bolus administration of PAH,
the plasma concentration fell rapidly in all subjects in
a curvilinear manner when plotted semilogarithmically
against time (Fig 3.2.1). The plasma concentration time
curve did not show a terminal linear phase but, the data
up to one hour could be fitted to a two compartment
model. The mean distribution half life calculated was
4.6 minutes, and therefore, distribution was on average
more than 95 % complete 28 minutes after the intravenous
injection. The mean elimination half life for PAH
estimated from the 30 to 60 minute data was 21.9 + 2.8
minutes (range 17-28 min) (Table 3.2.1). The mean PAH
plasma concentration fell from 50.4 + 13 mg/1 at 3
minutes to 1.1 + 0.4 mg/1 at 120 minutes.
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Fig 3.2.1
Mean plasma concentrations of
intravenous bolus injection
healthy males. Bars = SD.
PAH and AcPAH following an





Following an intravenous bolus administration of
PAH, AcPAH was already present in plasma at 3 minutes,
and a mean peak plasma concentration of 1.66 + 0.4 mg/1
was achieved by 20 minutes. Plasma concentrations
declined progressively in a linear fashion after 40
minutes when plotted semilogarithmically against time
(Fig 3.2.1). The mean elimination half life (t%)
estimated from the terminal linear elimination phase was
48 + 10 minutes (range 33-76 min) (Table 3.2.2).
Constant infusion
p-AMINOHIPPURIC ACID
Steady state plasma concentrations were achieved in
all subjects within l%-2 hours of starting the infusion.
The mean plasma concentrations after equilibration
ranged from 26.4 + 3 mg/1 at 1 hour to 30.5 + 2 mg/1 at
3 hours (Fig 3.2.2).
ACETYL-p-AMINOHIPPURIC ACID
Plasma concentrations of AcPAH increased during the
constant infusion of PAH, and became constant at 2 hours
after the start (Fig 3.2.2). The mean plasma concent¬
rations ranged from 2.7 + 0.4 mg/1 at 1 hour, to 3.3 +
0.5 mg/1 at 3 hours. These are some 10 times lower than
the corresponding PAH plasma concentrations.
Clearances
Single injection
p-AMINOHIPPURIC ACID - RENAL CLEARANCE
The individual renal clearances of PAH for each
collection period are given in Table 3.2.1. The mean
renal clearance of PAH fell by 54 % during the first two
hours. This fall was significant with respect to time,
and plasma concentration (p<0.01). The mean renal
O
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The total body and renal clearances of PAH (ml/rain/1.73 m )
following a single intravenous bolus injection of PAH in 26
healthy males. The elimination half life t\ is also given.
RENAL CLEARANCE (h) TOTAL BODY CL (h)
SUBJECT 0-1 1-2 0-1 0-2 t\ (rain)
GM 479 233 581 528 20.7
AT 619 347 717 714 18.5
EC 526 233 612 571 21.9
WW 495 148 554 516 21.8
AB 540 257 535 552 19.8
RJ 600 196 631 631 18.2
JG 649 257 700 673 20.2
AD 803 258 836 817 16.8
AH 545 177 580 562 22.8
SB 476 165 575 520 21.2
JA 605 277 641 591 20.6
PD 451 165 531 476 27.9
SA 623 204 625 602 20.7
RF 513 198 586 554 27.5
MS 533 135 634 537 23.0
PF 581 278 669 605 17.2
TM 589 201 646 608 21.3
MK 451 599 602 575 19.7
DM 532 277 642 632 26.4
JN 478 210 585 540 23.4
BH 414 337 482 508 23.5
BS 415 262 456 482 23.8
GS 460 305 573 539 20.8
LP 497 255 640 601 22.9
RM 420 122 526 497 23.3
CP 384 178 451 416 24.5
MEAN 526 241 600 571 21.9
+ SD 92 94 83 81 2.8
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period 0-1 and 1-2 hours respectively (Fig 3.2.3).
p-AMINOHIPPURIC ACID - TOTAL BODY CLEARANCE
The individual total body clearances of PAH are
given in Table 3.2.1. The mean total body clearance of
PAH also fell from 0-1 to 0-2 hours, but only by 5 %.
This fall was also significant with respect to time and
plasma concentration (p<0.01). The mean total body
o
clearances were 600 and 571 ml/min/1.73 m for 0-1 and
0-2 hours, respectively (Fig 3.2.3).
Comparison of total body and renal clearance of PAH.
The 0-1 hour total body clearance of PAH exceeded
the 0-1 hour renal clearance of PAH by a mean of 14 %
(p<0.01; 600 vs 526 ml/min/ 1.73 m^). There was a
significant correlation between the 0-1 hour, total body
and renal clearances of PAH (r=0.903, p<0.001, Fig
3.2.4) but not between 0-2 hour total body clearance and
1-2 hour renal clearance.
ACETYL-p-AMINOHIPPURIC ACID - RENAL CLEARANCE
The individual renal clearances of AcPAH following
an intravenous bolus injection of PAH are given in Table
3.2.2 and the mean clearances were 806 and 891 ml/min/
1.73 m^ for 0-1 and 1-2 hours respectively, (Fig 3.2.3).
The mean increase in clearance of 10 °L was significant
(p<0.05) over time, and declining PAH plasma concent¬
rations
COMPARISON BETWEEN THE CLEARANCES OF PAH AND AcPAH
The renal clearance of PAH fell from 0-1 to 1-2
hours whilst the renal clearance of AcPAH rose. Over
both time periods, the PAH renal clearance was
significantly lower than the AcPAH renal clearance
(p<0.01) (526 v 806 and 241 v 891 ml/min/1.73 m^
respectively). Similarly the 0-1 hour total body
clearance of PAH was significantly less than the 0-1
hour AcPAH renal clearance (p<0.01; 600 v 806 ml/min/
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Fig 3.2.3
The mean renal clearances of PAH and AcPAH (0-1 & 1-2 h)
and the total body clearance of PAH (0-1 & 0-2 h),
following a single intravenous injection of PAH, in 26
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Fig 3.2.4
Relationship between the 0-1 h renal clearance of PAH
and the corresponding 0-1 h total body clearance of PAH






The renal clearance of AcPAH (ml/min/1.73 m ) following a single
intravenous bolus injection of PAH in 26 healthy males. The
elimination half life t\ is also given.
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MEAN 806 891 48.0
+SD 181 223 10.2
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1.73 m^). A weak, but statistically significant correl¬
ation was found between the 0-1 hour renal clearances of
PAH and AcPAH (r=0.48, p<0.05, Fig 3.2.5) but not
between the 1-2 hour renal clearances.
Constant infusion
p-AMINOHIPPURIC ACID
The individual renal clearances of PAH in ten
healthy male subjects for each collection period are
given in Table 3.2.3.
The mean renal clearance of PAH for each urine
collection period were 461, 445, 437 and 430 ml/min/1.73
m^ for 1-1%, l%-2, 2-2% and 2%-3 hours respectively (Fig
3.2.6). The mean values show a tendancy for a fall in
PAH clearance over time, but this was not statistically
significant. The mean PAH clearance was 444 + 66 ml/min/
1.73 m^.
ACETYL-p-AMINOHIPPURIC ACID
The individual renal clearances of AcPAH for the ten
healthy male subjects for each collection period are
given in Table 3.2.4.
The mean renal clearances of AcPAH were 566, 558,
563 and 589 ml/min/1.73 m^ for 1-1%, l%-2, 2-2%, and 2%-
3 hours respectively (Fig 3.2.6). There was no stat¬
istically significant change over time, and the mean
AcPAH clearance was 569 + 108 ml/min/1.73 m^.
COMPARISON BETWEEN THE RENAL CLEARANCE OF PAH AND AcPAH.
The PAH renal clearance was significantly lower
than the corresponding AcPAH renal clearance on every
occasion (Fig 3.2.6) and the overall difference was 22 %
(444 v 569 ml/min/1.73 m^; p< 0.01). There was no




Relationship between the 0-1 h renal clearances of PAH
and AcPAH following single intravenous administration of




The renal clearance of PAH (ml/min/1.73 m ) during constant
infusion of PAH in 10 healthy males.
COLLECTION PERIOD (hours)
SUBJECTS i-ih l%-2 2-2% 2%-2> Mean +SD
MK 621 538 452 481 523 75
DM 509 480 514 474 494 20
JN 492 451 464 411 455 34
BH 395 482 465 419 440 40
BS 401 333 316 324 344 39
GS 327 416 371 393 377 38
LP 459 359 442 437 429 47
RM 480 500 513 496 497 14
CP 367 343 356 369 359 12
RJ 561 553 475 494 521 43
MEAN 461 445 437 430 444
+SD 91 80 67 58 66
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The renal clearance of AcPAH (ml/min/1.73 m ) during constant
infusion of PAH in 10 healthy males.
COLLECTION PERIOD (hours)
SUBJECTS 1-1*5 1*5-2 2-2*5 2*5-3 Mean _+SD
MK 616 529 502 542 547 49
DM 657 683 748 778 717 56
JN 543 535 551 551 545 8
BH 433 510 485 494 481 33
BS 500 481 477 485 486 10
GS 632 610 591 556 597 32
LP 572 491 627 652 586 71
RM 478 451 366 518 453 64
CP 463 481 508 517 492 25
RJ 765 805 774 797 785 19
MEAN 566 558 563 589 569
+SD 103 111 126 114 108
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The effect of urine flow rate 011 the renal clearance of
PAH and AcPAH.
Single injection
The individual urine flow rates are given in Table
3.2.5.
The urine flow rate fell from 7.00 to 6.00 ml/min
from 0-1 to 1-2 hours, but no significant correlation
was found between urine flow rate and the renal
clearances of PAH or AcPAH.
Constant infusion
The individual urine flow rates are given in Table
3.2.6.
The mean urine flow rates were similar, over all
collection periods (6.7, 6.4, 6.0, and 6.0 ml/min for 1-
1%, l%-2, 2-2%, and 2%-3 hours respectively). There was




The individual urinary recoveries of PAH and AcPAH
are given in Tables 3.2.7 and 3.2.8 respectively.
The mean urinary recovery of the administered dose
of PAH in the first four hours was 82.4 +6 % (range 75-
92 %) (Fig 3.2.7) and 92 % of this was excreted in the
first hour.
The mean urinary recovery of AcPAH over 8 hours was
17.1 + 2 % (range 13-23 %) (Fig 3.2.7), and 51 "L of this
was excreted in the first hour.
Constant infusion
The mean urinary recoveries of PAH and AcPAH in each
urine collection period expressed as a percentage of




Urine flow rate (tnl/min) following a single intravenous































* = Urine collection period not timed
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TABLE 3.2.6
Urine flow rate (ml/min) during constant infusion of PAH in 10
healthy males
C01LECTI0N PERIOD (h)
SUBJECTS i-ih ih-2 2-2\ 2\-3 Mean jfSD
MK 9.3 9.0 4.5 8.2 7.8 2.2
DM 7.6 6.6 4.0 7.1 6.3 1.6
JN 7.7 4.3 3.8 5.0 5.2 1.7
BH 4.9 4.9 6.5 5.5 5.4 0.7
BS 5.8 3.6 6.1 7.0 5.6 1.4
GS 7.0 8.1 4.4 4.5 6.0 1.8
LP 9.6 8.8 4.5 4.8 6.9 2.6
RM 7.8 7.0 11.7 8.5 8.8 2.0
CP 2.3 7.0 7.0 7.1 5.8 2.4
RJ 4.6 4.2 7.5 2.6 4.7 2.0
MEAN 6.7 6.4 6.0 6.0 6.3
+SD 2.3 2.0 2.4 1.9 1.2
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TABLE 3.2.7
The urinary recovery of PAH (% of dose) following a single
intravenous bolus injection of PAH in 26 healthy males.
Collection periods (h)
SUBJECT 0-1 1-2 2-3 3-4 Total (0-4)
GM 72.4 6.4 1.5 0.7 81
AT 76.9 4.0 0.8 0.5 82
EC 76.4 3.7 1.1 0.6 81
WW 80.0 3.1 1.1 0 84
AB 86.4 3.4 1.2 0.7 92
RJ 85.5 2.7 0.7 0.4 89
JG 83.9 3.2 0.8 0.6 88
AD 89.7 2.2 0.7 0.4 93
AH 83.4 3.6 0.8 0.6 88
SB 76.1 3.1 1.0 0.3 80
JA 84.6 4.2 1.2 0.4 90
PD 73.2 3.6 0.8 0.9 79
SA 85.3 3.8 0.9 0.3 90
RF 74.7 4.1 0.8 0 78
MS 73.2 3.3 0.6 0.1 77
PF 00 1—* • 4> 2.5 0.4 0.1 84
TM 74.5 3.8 0.8 0.3 86
MK 66.8 10.7 2.2 0 80
DM 70.3 5.0 1.4 0.6 77
JN 69.6 4.9 0.9 0.4 76
BH 70.7 6.2 1.0 0.4 78
BS 70.3 5.9 1.1 0.5 78
GS 71.1 6.3 0.6 0 78
LP 69.4 4.9 0.8 0.2 75
RM 70.8 3.0 0.6 0.2 75
CP 72.4 5.9 1.2 0.1 80
MEAN 76.5 4.4 1.0 0.3 82
+ SD 6.5 1.8 0.4 0.3 6
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TABLE 3.2.8
The urinary recovery of AcPAH (% of dose of PAH) following a single
intravenous injection of PAH in 26 healthy males.
Collection period (h)
SUBJECT 0-1 1-2 2-3 3-4 4-8 total(
GM 6.1 4.3 2.1 1.3 1.6 15.4
AT 8.8 5.2 1.4 0.6 0.4 16.4
EC 8.6 4.2 2.0 1.0 1.2 17.1
WW 9.8 5.0 2.2 1.0 1.0 19.0
AB 7.6 3.7 1.8 0.8 0.8 14.7
RJ 9.6 4.7 2.0 1.0 0.8 18.2
JG 8.3 4.8 2.0 0.8 0.6 16.4
AD 9.1 3.5 1.4 0.6 0 14.6
AH 8.5 4.4 2.1 0.9 1.0 16.9
SB 9.9 4.6 2.1 1.1 1.3 18.9
JA 6.9 3.6 1.5 0.7 0.4 13.0
PD 8.5 4.0 3.7 1.5 1.4 19.0
SA 9.0 4.7 2.4 0.8 1.0 17.9
RF 8.8 4.6 2.1 1.1 1.4 18.0
MS 8.0 3.9 2.0 1.0 1.2 16.1
PF 7.7 3.1 1.4 0.7 0.5 13.4
TM 7.3 4.6 1.8 1.1 1.0 15.8
MK 7.5 4.6 2.5 0.9 1.0 16.5
DM 9.4 5.9 2.6 1.1 1.0 20.0
JN 8.2 5.8 2.5 1.4 1.9 19.7
BH 6.9 4.4 2.0 1.1 1.3 15.8
BS 6.9 5.7 2.5 1.2 1.5 17.8
GS 8.0 4.7 2.3 1.2 1.3 17.5
LP 8.8 4.9 2.5 1.0 1.6 18.7
RM 6.9 3.9 1.7 1.1 0.7 14.3
CP 8.8 7.1 3.9 1.9 1.6 23.3
MEAN 8.2 4.6 2.2 1.0 1.1 17.1
+ SD 1.0 0.8 0.6 0.3 0.5 2.3
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Fig 3.2.7
The mean urinary recovery of PAH and AcPAH, (percentage
of the PAH dose) for each urine collection period,
following a single intravenous injection of PAH in 26
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Comparison of clearances in 10 healthy males who
underwent both constant infusion and single injection of
PAH
The individual clearance data for PAH and AcPAH are
given in Table 3.2.9.
p-Aminohippuric acid
The mean 0-1 hour renal clearance of PAH following a
single injection was similar to that determined during
constant infusion (465 + 65 vs 444 + 65 ml/ min/1.73
m^), and the difference between these values was not
statistically significant. However, the mean 1-2 hour
renal clearance of PAH after single injection was sign¬
ificantly lower than the mean clearance determined
during constant infusion (274 v 444 ml/min/1.73 m ; p<
0.01) (Fig 3.2.8). The 0-1 hour total body clearance of
PAH overestimated the renal clearance of PAH, determined
during constant infusion, by 20.6 % (559 vs 444 ml/min/
1.73 m^; p<0.01). There was a weak, but significant
correlation between the total body clearance of PAH
following single injection, and the renal clearance dur¬
ing constant infusion (r= 0.65, p<0.05, Fig 3.2.9), but
not between the renal clearance determined by the two
methods.
Acetyl-p-aminohippuric acid
The clearance of AcPAH following single injection of
PAH was significantly greater than during constant
infusion of PAH, (p< 0.01), 773 and 848 ml/min/1.73m^
for the 0-1 and 1-2 hour periods after single injection,
compared with 569 ml/min/1.73m^ during the constant
infusion (Fig 3.2.8). There were significant
correlations between the renal clearances following
single injection, and constant infusion for both 0-1
hour (r= 0.817, p<0.01, Fig 3.2.10a) and 1-2 hour (r=




The clearances of PAH and AcPAH (ml/min/1.73 m ) during constant
infusion and following a single injection of PAH in 10 healthy
males.
CONSTANT INFUSION SINGLE INJECTION
Renal CI Total CI Renal CI
PAH AcPAH PAH PAH PAH AcPAH AcPAH
SUBJECTS mean mean 0-1 1-2 0-1 0-1 1-2
MR 523 547 451 599 602 782 611
DM 494 717 532 277 642 1258 1290
JN 455 545 478 210 585 755 904
BH 440 481 414 337 482 601 750
BS 344 486 415 262 456 458 689
GS 377 597 460 305 573 913 863
LP 429 586 497 255 640 725 851
RM 497 453 420 122 526 417 624
CP 359 492 384 178 451 837 903
RJ 521 785 600 196 631 983 996
MEAN 444 569 465 274 559 773 848
+SD 66 108 65 131 75 250 201
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Fig 3.2.8
The mean renal clearances of PAH and AcPAH following a
single injection and during constant infusion of PAH, in
10 healthy males. The total body clearance of PAH
following a single injection of PAH in these subjects is














0-1h 0- 1h 1-2h CI CI 0-1 h 1-2h collection
period
SI SI SI si SI
p-AMINOHIPPURIC ACID ACETYL-p-AMINOHIPPURIC ACID
RENAL CLEARANCE CONSTANT INFUSION (CI)
RENAL CLEARANCE | SINGLE INJECTION
TOTAL BODY CLEARANCE / (SI)
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Fig 3.2.9
The relationship between the mean renal clearance of PAH
during constant infusion and the 0-1 h total body
clearance of PAH following a single intravenous





















Relationship between the renal clearances of AcPAH (0-1
h (A) and 1-2 h (B)) after a single injection and during





















































60Q 800 1000 1200
























































400 600 800 1000 1200
RENAL CLEARANCE OF AcPAH DURING A CONSTANT INFUSION
OF PAH ml/min/ 1.73m
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DISCUSSION
The acetylation of p-aminohippuric acid (PAH) is
known to occur in animals and man, but investigations in
man are limited, and the assay unreliable. About 20 % of
a dose of PAH is converted to AcPAH and, as a result,
simple methods for estimating PAH by single injection
and constant infusion without urine collection, give a
substantial overestimate of the renal clearance. In the
present study, the disposition and kinetics of PAH and
AcPAH have been investigated in healthy male subjects,
using specific assays for PAH and AcPAH.
Following single intravenous injection of PAH,
plasma concentrations initially fall rapidly, followed
by a slower decreasing rate of decline. The transition
between rapid and slow phases occurred after 20 to 30
minutes* and the distribution rate constant calculated
by 2 compartment pharmacokinetic analysis indicated
greater than 95 % distribution in 30 minutes. However,
plasma concentrations and the rate of elimination of PAH
decreased progressively over time, reflecting the
progressive fall in its renal clearance. The plasma
concentration time data could be fitted to a two
compartment model over the first hour, and the total
body clearance was calculated on the assumption that the
clearance during this period, was maintained. In
previous studies, the distribution of PAH following a
single injection was reported to be complete within 20
to 50 minutes (Tacket & Houck, 1950; Rosenbaum et al,
1973). These authors reported that the plasma con¬
centrations of PAH declined in a linear fashion after
distribution, but others report a linear decline almost
immediately following the intravenous bolus injection
(Newman et al, 1949). The striking difference in the
disposition of PAH observed in the present study, can
probably be accounted for by infrequent sampling in the
early studies. In the present study, numerous samples
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were taken to properly define the plasma decay curve of
PAH. The plasma concentration-time decay curve of PAH
has been reported to be consistent with an open two
compartment pharmacokinetic model in the dog (Mandel et
al, 1955), but appropriate pharmacokinetic modelling of
PAH does not seem to have been reported in man. The mean
plasma half life of PAH estimated from the 0-1 hour
plasma data was 22 minutes, and this is double that
reported by Moffat et al, 1986.
AcPAH was detected in the plasma 3 minutes after a
single injection of PAH, and the plasma concentration of
this metabolite rose slowly to reach a maximum at 20
minutes, before declining in a linear fashion. The rate
of elimination of PAH was more than double that of
AcPAH, and since the renal clearance of AcPAH is greater
than that of PAH, this implies that AcPAH has a larger
volume of distribution. Plasma concentrations of AcPAH
following a single intravenous injection of PAH have not
been reported previously in subjects with normal renal
function, although Newman et al, (1949) estimated that
the renal clearance of AcPAH was 800 ml/min, following a
single injection of PAH. Statius Van Eps et al, (1967)
described a rapid decline in plasma concentrations of
PAH, followed by a slow appearance of AcPAH with the
plasma concentrations peaking around 10 hours, following
a single injection of PAH in patients with renal
impairment.
During constant infusion of PAH, both PAH and AcPAH
plasma concentrations appeared to reach steady state,
but the latter were an order of magnitude less than
those of the parent compound. Plasma concentrations of
AcPAH during constant infusion of PAH, have not been
reported in subjects with normal renal function, due to
low levels (Brown et al, 1974). High concentrations of
AcPAH have been detected in patients with renal
impairment, and renal artery stenosis (Grindt et al,
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1974). These authors also measured renal venous blood,
and found that p-aminobenzoic acid and acetyl p-
aminobenzoic acid concentrations were greater, than in
mixed venous blood. The method of assay used by these
workers was not specific. P-aminobenzoic acid was not
detected in the present study.
Following a single intravenous injection, PAH was
rapidly excreted into the urine, as would be expected of
a substance cleared at the rate of the renal blood flow,
but only 82 °/a of the administered dose was recovered in
the urine as PAH. Most was excreted in the first hour,
and elimination was essentially complete by four hours.
AcPAH could be measured in the urine up to eight hours,
and 17 °L of the administered dose of PAH was recovered
as AcPAH. Virtually the total dose of PAH was recovered
as PAH plus AcPAH, suggesting that, renal excretion is
the sole route of elimination of PAH and AcPAH. Under
the conditions of this study, AcPAH appeared to be the
sole metabolite of PAH.
The renal clearance of PAH is universally accepted
as a reliable estimate of the renal plasma flow but, it
is only 90 % extracted in one passage through the
kidney, and the term effective renal plasma flow (ERPF),
should be used (Smith, 1951). As the extraction ratio
and haematocrit vary between individuals, the clearance
values in this study are taken to represent ERPF. As PAH
is actively secreted by a specific proximal tubular
transport system, its extraction decreases at high
plasma concentrations, because of saturation (Weiner,
1985). Depression of the PAH clearance occurs at plasma
concentrations above 80 mg/1 in healthy subjects, with
complete saturation occurring above 100 mg/1 (Schuster &
Seldin, 1985). The plasma concentrations of PAH in the
present study were about 30 mg/1, during constant
infusion, which is within the recommended range for
maximal extraction of PAH and thus, maximal and constant
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clearance (Smith, 1951). Following single intravenous
bolus administration, the maximum plasma concentrations
of PAH were about 60 to 70 mg/1, but these fell rapidly
to less than 30 mg/1 by 15 minutes. The mean midpoint
plasma concentration during the first hour was 15 mg/1,
this is well below those achieved during the constant
infusion. Thus, after a single intravenous injection,
the concentrations of PAH were in the range where the
clearance of PAH should have been maximal and constant.
Following a single intravenous injection, the renal
clearance of PAH showed a highly significant fall over
time and plasma concentration. The renal clearance
during the second hour were only about 54% of that
during the first hour. This dramatic fall in PAH
clearance was surprising, as by all previous accounts
the PAH plasma concentrations were well below the levels
associated with saturation of active transport, and
constant maximal clearances were expected. During the 1-
2 hour period, the mean plasma concentrations of PAH
were less than 7 mg/1, and the PAH clearance was grossly
reduced and, not constant. The 0-1 hour total body
clearance of PAH was significantly greater than the
renal clearance of PAH by 14 %, and this can be
accounted for by the metabolism of PAH to acetyl PAH.
The dramatic fall in PAH clearance following single
intravenous injection is not consistent with the
findings of Landowne & Alving, (1947) and Tacket &
Houck, (1950). These investigators did not observe a
fall in the renal clearance of PAH following a single
injection and indeed, the latter even reported a rise in
the renal clearance of PAH, with time. Tacket & Houck,
also compared the total body and renal clearances of
PAH. However, they used an inappropriate one compartment
model. They could only obtain constant results by using
the volume of distribution of mannitol, and carrying out
hydrolysis of the plasma and urine samples. Newman et
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al, (1949) reported a fall in the renal clearance of PAH
in man, but not in dogs. In these reports, the renal
clearance of PAH was estimated by dividing the amount
excreted by the midpoint plasma concentration, taken
from a semilogarithmic plot against time. This is not
correct because the distribution of PAH is ignored
(Notari, 1987). Newman et al, (1949), also reported that
the clearance of AcPAH was greater than the PAH
clearance, following a single injection of PAH. They
calculated the clearance of AcPAH by estimating the
difference in PAH content of plasma and urine before,
and after hydrolysis. This indirect method of estimating
AcPAH is subject to interference from endogenous
substances, which also give a positive reaction (Brown
et al, 1976). Despite this, their estimate of the AcPAH
clearance after PAH administration was similar to that
found in the present study.
The mechanism of this striking fall in the PAH
clearance is unknown, and may be due to factors such as
time, arterial-venous plasma concentration differences,
delay time or urine flow dependant clearance. However,
no correlation between urine flow and clearance of PAH
and AcPAH was found in the present study, and a time
effect also seems unlikely as the fall in the clearance
of PAH during the constant infusion studies was minor,
and can probably be attributed to failure to reach
steady state conditions.
Arterial-venous differences and delay time may cause
errors, when plasma concentrations are rapidly
decreasing (Brun et al, 1949). Arterial plasma concent¬
rations were not estimated in this study but, in
previous literature reports, the mean venous renal
clearance of PAH was only 16 % less than the arterial
clearance (Tacket & Houck, 1950). Similar findings were
reported by Newman et al, (1949), but they also showed
that the arterial renal clearance of PAH fell in the
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same manner as the venous clearance, over two hours.
Higher venous than arterial concentrations are unlikely
to account completely for the low clearance. Delay time
can also cause significant errors because the excretion
rate lags behind the plasma concentration. In the
present study, long collection periods and water
diuresis were used to reduce this error. Using the
formula of Nosslin, (1965) the correction time in the
first hour with a mean urine flow rate of 7 ml/min, was
4 minutes. In 60 minutes this represents an error of 6.6
7o and, as the subjects voided urine at least two minutes
after the plasma samples were taken, this error was
reduced to only 3 %. Similar errors could be anticipated
for the second hour, and this therefore, cannot explain
the fall in PAH clearance.
The fall in PAH clearance was quite clearly plasma
concentration-dependant. However, it is generally
believed that PAH clearance is maximal and constant, at
low plasma concentrations. In the present study, the
plasma concentrations of PAH following a single
injection, were much lower in the second hour than in
any previous investigation, and at these levels the PAH
clearance was highly dependant on plasma concentrations.
One possible explanation for this could be acetylation
of PAH within the kidney. This would also explain the
significantly higher clearance of AcPAH, than that of
the parent compound. Newman et al, (1949), suggested
that the declining renal clearance of PAH was due to
renal conjugation to the acetyl derivative but, Mandel
et al, (1955) attributed the fall seen by these authors
to inappropriate kinetic analysis. In the present study,
the amount of conjugated PAH in the urine increased over
time. However, an increase in the urinary excretion of
acetyl PAH with time, would in any event be expected
since its formation is delayed, and its half-life was
much longer than that of PAH. Other possible factors
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include a decrease in renal extraction, due to increased
plasma protein binding. This has been reported for other
compounds used for measuring renal blood flow such as,
diodrast (Block & Burrows, 1960). Increased uptake into
red blood cells at low concentrations or renal tubular
competition, could also account for a reduced
extraction. One other strong possibility is tubular
reabsorption of PAH, as reported to occur at low plasma
concentrations in dogs (Cho & Cafruny, 1970). These
possible mechanisms for the decline in PAH clearance are
discussed, in more detail, in the next section.
Comparison of the clearance of PAH using the single
injection and constant infusion methods in the same 10
individuals, gave virtually identical results for the
mean values but, there was no significant correlation
between the individual clearances for the two methods.
During the first hour after single intravenous
administration, the mean total body clearance of PAH
consistently overestimated the renal clearance during
constant infusion by 20 %, and a similar discrepancy has
been observed by others in man (Rosenbaum et al, 1973;
Boineau et al, 1974), but not in dogs (Mandel et al,
1955). This is not surprising, as dogs cannot acetylate
drugs (Newman et al, 1949). The renal clearance of AcPAH
was significantly greater following a single injection
of PAH than during constant infusion, and this would be
consistent with some renal acetylation of PAH which is
greater at low rather than high concentrations of PAH,
since concentrations were lower on average, following a
single injection than during constant infusion. This is
discussed in more detail in section 3.
The use of the single injection method with PAH for
measuring the renal plasma flow seems, on the face of
it, to be limited. The renal clearance of PAH falls
progressively as plasma concentrations decline, and the
total body clearance is an overestimate due to
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metabolism. However, the renal clearance of PAH
determined by the single injection method over the first
hour gives the same results, as that found with the
constant infusion method. It can therefore be used as a
quick, simple measure of the PAH clearance, and repeated
measurements could be made on the same day. The major
disadvantage is that urine collections are still needed.
Although errors are involved in urine collection (Zender
et al, 1968), it may only be necessary to determine the
fractional conversion to AcPAH, if the administered dose
is known. However, this assumes that PAH is not
acetylated in the kidney and the total body clearance
could then be corrected for the fraction metabolised.
There is a good correlation between the renal clearance
and total body clearance of PAH, but a simple universal
correction factor cannot be used, because of individual
differences. There is also more extensive and variable
acetylation of PAH in patients with impaired renal
function (Statius Van Eps et al, 1967). In addition
acetylation of some compounds are genetically controlled
and the population can be divided into fast and slow
metabolisers (Weber & Hein, 1985). In the present study,
there was no evidence of separate groups of slow and
fast acetylators, but formal testing of acetylator
status in the volunteers, was not carried out.
SUMMARY
The disposition and kinetics of PAH and AcPAH have
been investigated following intravenous administration
of PAH by constant infusion, and single rapid injection.
Following a single injection of PAH, a mean of 82 % of
the dose administered was recovered in the urine as PAH
and the remainder, as AcPAH. The total urinary recovery
as these two compounds, was essentially complete. The
total body clearance of PAH was significantly greater
than the renal clearance, and this can be attributed to
the acetylation of PAH. The renal clearances of PAH
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following a single injection fell dramatically over
time, as plasma concentrations decreased after the first
hour. The clearance of PAH appears to be plasma concent¬
ration dependant, when these are low. AcPAH appears to
be the sole metabolite of PAH, and its clearance is
significantly greater than that of PAH during constant
infusion and, following single intravenous administ¬
ration of PAH. Possible explanations for these results
are a reduced extraction of PAH compared to AcPAH,
saturable tubular reabsorption of PAH, or PAH is
metabolised in part within the kidney.
The renal clearance of PAH during the first hour
following a single intravenous injection was similar to
that during constant infusion, and the method can be








In the last section the disposition and kinetics of
p-aminohippuric acid (PAH) were investigated, and it was
found that 17 % of the dose following single injection
was metabolised to acety1-p-aminohippuric acid (AcPAH).
The total body and renal clearances of PAH fell dramat¬
ically after the first hour, whilst the AcPAH renal
clearances rose. The plasma concentrations of PAH
achieved after the single injection were well below
those at which tubular transport is saturable and there¬
fore, the clearance of PAH should be independent of the
plasma concentration (Smith, 1951). This depression in
the renal clearance of PAH has been reported previously
by Newman et al, (1949). Smith (1951), also cited
Hamburger and Ryckewaert, who observed very low PAH
clearance at plasma concentrations below 10 mg/1 after a
single injection and during constant infusion. These
authors suggest that this may be due to tubular conjug¬
ation or high plasma protein binding of PAH, or tubular
"inertia". Smith (1951), argued against significant
renal metabolism at low PAH plasma concentrations.
Others have not reported any decline in PAH clearance
after administration of PAH by single injection
(Landowne & Alving, 1947; Tacket & Houck, 1950).
However, the PAH clearance may become dependant on its
plasma concentration at low concentrations.
The object of this study was to investigate the
relationship between clearances of PAH and AcPAH at
different steady state plasma concentrations of PAH, to
the plasma concentrations of PAH. PAH plasma con¬
centrations were therefore incrementally increased and
decreased, in a steplike manner.
METHODS
8 healthy male volunteers mean age 30 + 6 years
(range 25-42 yrs) weighing 55-77 Kg (mean 69+7 Kg)
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received two constant infusions of PAH in random order
on different days. The constant infusions were intended
to give a stepwise increase in plasma concentrations of
PAH on one occasion, and a stepwise decrease on the
other. The interval between the two studies ranged
between 7 and 22 days in seven subjects, and six months
in the other. The same batch of sodium aminohippurate
(20 % w/v, Merck Sharp and Dohme, U.K.) was used
throughout.
The procedure was as described previously in Chapter
two, section III (p 89) for the infusion of inulin. On
the "step up" study days, the subjects were given
loading doses of sodium aminohippurate of 200 mg (1 ml),
200 mg (1 ml) and 400 mg (2 ml) over 1 minute, prior to
the increase in the infusion rate for the low, mid and
high periods respectively. The infusion fluid contained
sodium aminohippurate (12.67 mg/ml in 300 ml of 0.9 %
saline) and the low, mid and high dose rates were 2.5, 5
and 15 mg/min respective. On "step down" study days, the
subjects received an initial loading dose of sodium
aminohippurate (500 mg, 2.5 ml) over 1 minute, followed
by infusion of 14.4, 4.8 and 2.4 mg/min for the high,
mid and low periods respectively. The times of urine
collection, blood sampling and changes in the infusion
rate for both step up and down studies were the same as
for inulin (p 89) (Fig 3.3.1). Ten ml of the infused
solution was collected at the end of each study for
measurement of the PAH concentration.
Sample collection
Plasma and urine samples were collected and analysed
for PAH and AcPAH as described in section II (p 174).
Data analysis
Because of time needed for equilibration after
changing the rate of administration of PAH, the data for
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the first urine collection period after each dose change
(Ul, U4, U5, U8, and U9, Fig 3.3.1) have been
disregarded. The samples were pooled, to represent the
periods from 1% to 2%, 3% to 4% and to 6% hours. In
the "step up" study, these successive periods are
referred to as "low", "mid", and "high" dose infusions
and the reverse applies for the "step down" study (Fig
3.3.1).
The renal clearances of PAH and AcPAH were
calculated, as described previously for the constant
infusion method (chapter 2, p 92).
The total body clearance of PAH (TBC) was calculated
from the following relationship :-
rate of infusion
TBC = (Equation 5)
Css
where Css is the steady state plasma concentration of
PAH calculated as the mean of the last two
determinations of the plasma PAH concentration, during
each infusion step.
The % urinary recovery of PAH was calculated as
described previously for inulin (chapter 2, p 93). AcPAH
is expressed in terms of corrected PAH equivalents as
described in section II, p 175, and % recovery was
determined as described for PAH.
All clearances were corrected for a body surface
O
area of 1.73 m
Statistical analysis
The statistical significance of differences between
means was determined using 2 way analysis of variance.
The null hypothesis was rejected if p< 0.05. Correlation





The plasma concentrations of PAH and AcPAH during
each "step up" and "step down" infusion of PAH are given
in Appendix IV, and the mean plasma concentrations are
shown in Fig 3.3.2.
p-aminohippuric acid
During the "step up" infusion, the plasma
concentrations appeared to reach steady state during the
low, mid, and high periods. The respective mean mid¬
point plasma PAH concentrations were 4.4 + 1, 8.5 + 2
and 25.2 + 5 mg/1.
With the "step down" study the mean midpoint plasma
PAH concentrations were 22.8 + 5, 9.6 + 2 and 5.0 + 1
mg/1 for high, mid and low periods respectively. Steady
state was not achieved during the mid and low periods.
Acetyl-p-aminohippuric acid
The mean AcPAH concentrations showed a similar trend
to those of PAH, but at a much lower concentration.
During the "step up" infusion, the plasma concentrations
reached steady state during the low, mid, and high
periods and the respective mean midpoint concentrations
were 0.69 + 0.2, 1.2 + 0.4 and 2.6 + 0.8 mg/1.
With the "step down" study, steady state was not
attained, and the mean mid-point plasma AcPAH concent¬
rations were 2.97 + 0.7, 1.7 + 0.4 and 0.9 + 0.2 mg/1
for high, mid and low periods respectively.
The ratio of the concentrations of the metabolite to
the total plasma concentrations (PAH + AcPAH) decreased
as the PAH plasma concentrations increased, and the mean
values for the step up infusion were 11.5, 10.9, and 7.6
% and for the step down 12.9, 12.2, and 9.7 % for low,
mid, and high periods respectively.
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Fig 3.3.2
Mean plasma concentrations of PAH and












The individual renal clearances of PAH are given in
Table 3.3.1 and the mean clearances in Fig 3.3.3. During
the "step up" infusion, the mean PAH clearances
increased progressively from 405 to 468 at low and mid
O
and to 509 ml/min/1.73 m at high plasma concentrations
(Fig 3.3.3). This rise in clearance was significant over
time and increasing plasma concentrations (p< 0.01), and
the mean clearances for the low and mid periods were
significantly lower than that at high plasma con¬
centrations (p<0.01). Similarly, the mean clearance at
the low period was significantly lower than that at the
mid period (p<0.05).
Conversely, during the "step down" study the mean
PAH clearances were 517, 506 and 379 ml/min/1.73 m for
high, mid and low plasma concentrations respectively
(Fig 3.3.3). This fall in clearance was not
statistically significant over time and declining plasma
concentrations but, the mean clearance at the low plasma
concentration was significantly less than at the high
plasma concentration (p<0.01). Subject WW has an
exceptionably high renal clearance for the middle period
(1171 ml/min/1.73 m^). With omission of the data from
this subject, the mean renal clearances of PAH were 476,
o
412 and 344 ml/min/1.73 m for high, mid and low periods
respectively (Fig 3.3.3). This fall in clearance was
significant over time and plasma concentration (p<
0.01).
A plot of the mean renal clearance of PAH against
the mean mid point plasma concentrations for each period
shows clearly that in the "step up" study, the clearance
rose steeply as concentrations increased from the low to
mid to the high period (Fig 3.3.4). The converse applied
to the "step down" study but the renal clearance was




The renal clearance of PAH (ml/rain/1.73 m ) during step up
and step down constant infusions of PAH in 8 healthy males.
STEP UP INFUSION STEP DOWN INFUSION
SUBJECT LOW MID HIGH HIGH MID LOW
PERIODS PERIODS
JN 392 386 395 393 403 375
GS 408 425 478 406 365 313
SB 394 437 495 441 380 363
AD 448 582 616 588 505 413
BB 437 436 449 526 491 326
SM 354 361 420 425 353 328
WW 474 681 689 807 1171 629
BW 330 436 529 551 384 288
MEAN 405 468 509 517 507 379
jfSD 48 108 100 137 274 108
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The relationship between the mean renal clearances of
PAH (A) and AcPAH (B) and plasma concentrations of PAH
during the step up constant infusion of PAH in 8 healthy
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Fig 3.3.5
The relationship between the mean renal clearances of
PAH (A) and AcPAH (B) and plasma concentrations of PAH
during the step down constant infusion of PAH in 8





























The individual renal clearances of AcPAH during the
"step up" and "step down" infusions of PAH are given in
Table 3.3.2 and the mean clearances are shown in Fig
3.3.3. During the "step up" infusion, the mean AcPAH
clearance decreased progressively from 1334 to 1069 at
O
low and mid to 782 ml/min/1.73 m at high plasma PAH
concentrations. This fall was significant over time and
increasing PAH plasma concentrations (p<0.01), and the
clearances at the low and mid periods were significantly
higher than that at the high period (p<0.01). Similarly,
the clearance at the low period was significantly higher
than at the mid period (p<0.01).
Conversely during the "step down" study, the mean
AcPAH clearances were 600, 845 and 1009 ml/min/1.73 m^
for high, mid and low plasma concentrations respect¬
ively. This rise in clearance was also significant over
time and declining PAH plasma concentrations and the
clearances at low PAH plasma concentrations were
significantly higher than at high plasma PAH concent¬
rations (p<0.01). In subject WW, the AcPAH clearance was
also very high during the mid period (1733
o
ml/min/1.73m ) but when the data from this subject was
omitted, the rise in clearance is still significant.
A plot of the mean renal clearances of AcPAH against
the mean midpoint plasma PAH concentrations for each
period shows that in the "step up", study the renal
clearance of AcPAH fell steeply from low to mid plasma
PAH concentrations, with a slower decline at the high
concentrations (Fig 3.3.4). The opposite effect occurred
in the "step down" study. The renal clearance of AcPAH
increased as the plasma concentrations of PAH decreased
from high to mid concentrations, and then rose steeply





The renal clearance of AcPAH (ml/min/1.73 m ) during step up
and step down constant infusions of PAH in 8 healthy males.
STEP UP INFUSION STEP DOWN INFUSION
SUBJECT LOW MID HIGH HIGH MID LOW
PERIODS PERIODS
JN 642 547 478 341 576 739
GS 1216 954 700 478 631 872
SB 1643 1126 826 516 672 1154
AD 1552 1375 992 768 1023 1244
BB 1156 849 632 685 775 779
SM 896 845 628 494 639 830
WW 2195 1834 1157 867 1733 1471
BW 1370 1019 845 652 708 987
MEAN 1334 1069 782 600 845 1009
+ SD 478 391 219 173 384 258
mean data after removal of WW 562 718 943
146 149 193
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Total body clearance of PAH
The individual total body clearances of PAH are
given in Table 3.3.3. The mean total body clearances in
the "step up" study were 559, 601, and 590 ml/min/1.73
O
for low mid and high plasma concentrations
respectively (Fig. 3.3.3). There were no significant
differences with time or increasing plasma PAH
concentrations.
During the "step down" study the total body
clearance of PAH could not be measured as steady state
conditions were not reached.
Comparison of clearances
The renal clearance of AcPAH was significantly
greater than the corresponding renal clearance of PAH
for all plasma PAH concentrations on both "step up" and
"step down" studies (p<0.01).
A comparison of the mean renal clearances of PAH and
AcPAH are shown below:-
STEP UP
low mid high
PAH CLEARANCE 405 468 509 ml/min/1.73 m2
AcPAH CLEARANCE 1334 1069 782 ml/min/1.73 m2
STEP DOWN
high mid low
PAH CLEARANCE 517 506 379 ml/min/1.73
AcPAH CLEARANCE 600 845 1009 ml/min/1.7 3
Significant correlations were found between the
renal clearances of AcPAH and PAH for "step up" mid and
high, (r= 0.87, r=0.98, p<0.001) and for "step down" low
(r= 0.79, p<0.05), and mid and high (r= 0.97 and 0.92
respectively, p<0.001) periods respectively (Figs 3.3.6,
and 3.3.7). There was no significant correlation between
clearances for the low period in the "step up" study.




The total body clearance of PAH (ral/min/1.73 m ) during step
up constant infusion of PAH in 8 healthy males.
STEP UP INFUSION
SUBJECT LOW MID HIGH
PERIODS
JN 591 544 526
GS 571 528 577
SB 619 615 627
AD 665 710 670
BB 513 526 507
SM 472 452 500
WW 631 883 769
BW 411 555 551
MEAN 559 602 591
+SD 87 136 93
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Fig 3.3.6
The relationship between the renal clearances of AcPAH
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of PAH was significantly higher than the renal clearance
(559 v 405; 602 v 468 and 591 v 509 ml/min/1.73 m^) for
the low, mid and high plasma PAH concentrations respect¬
ively, (p<0.01) but it was significantly less than the
AcPAH renal clearance (559 v 1334; 602 v 1069 and 591 v
782 ml/min/1.73 m^) for low, mid and high plasma
concentrations respectively, (p<0.01).
Urine flow rate
The individual urine flow rates for each period
during the two study days were similar (Table 3.3.4).
There were no significant correlations between the PAH
or AcPAH renal clearances and the corresponding urine
flow rates.
Urinary recovery
The urinary recoveries of PAH and AcPAH for both
studies are given in Table 3.3.5.
p-aminohippuric acid
For the "step up" study, the mean percentage
recovery of PAH relative to the amount infused increased
from 72+6 to 78 + 5 and 85 + 7 % for the low, mid and
high periods respectively (Fig 3.3.8). For the "step
down" study, the recoveries of PAH were 82+8, 95+18
and 79 + 9 % for high, mid and low periods respectively
(Fig 3.3.8). The mean amounts of PAH excreted as
percentages of the total (PAH + AcPAH) were 72+5, 80 +
3 and 89 + 2 % for the "step up" and 71+4, 80+2 and
89 + 1 % for the "step down" studies in the low, mid and
high periods respectively. Thus during the corresponding
time periods, the total recoveries were virtually
identical in both studies.
Acetyl-p-aminohippuric acid
For the "step up" study, the mean percentage
recoveries of AcPAH relative to the amount infused,
decreased progressively from the low to mid to high
-228-
TABLE 3.3.4
Urine flow rate (ml/min) during step up and step down constant
infusions of PAH in 8 healthy males.
STEP UP INFUSION STEP DOWN INFUSION
SUBJECT LOW MID HIGH HIGH MID LOW
PERIODS PERIODS
JN 7.2 7.9 8.8 9.6 5.9 10.1
GS 8.1 r^•00 8.5 8.1 9.5 7.5
SB 9.6 4.4 9.6 4.1 4.8 7.6
AD 7.6 9.3 6.7 8.3 8.5 8.6
BB 11.0 9.5 10.0 9.4 7.0 8.5
WW 11.7 8.9 8.0 12.3 12.3 12.7
SM 7.8 7.0 6.8 8.6 6.9 8.4
BW 6.4 5.0 8.9 7.5 6.1 6.1
MEAN •00 7.6 8.4 8.5 7.6 8.7
+ SD 1.9 2.0 1.2 2.3 2.4 2.0
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TABLE 3.3.5.
The percentage urinary recoveries of PAH and AcPAH relative to dose
administered in 8 healthy males during step up (A) and step down (B)
constant infusions of PAH.
A)
STEP UP
SUBJECT LOW MID HIGH
PAH AcPAH PAH AcPAH PAH AcPAH
JN 65.2 26.6 70.4 18.4 74.8 10.3
GS 71.8 24.7 80.3 15.7 83.0 7.8
SB 63.0 39.8 69.8 27.7 77.5 13.3
AD 73.0 30.0 82.0 22.7 95.0 12.2
BB 83.0 27.3 84.3 20.8 85.1 11.3
SM 75.0 25.2 79.3 19.9 85.0 10.9
WW 71.6 29.1 82.9 19.0 85.6 9.1
BW 73.9 24.1 78.6 16.7 94.4 10.5
MEAN 72.1 28.4 78.5 20.1 85.1 10.7
+ SD 6.1 5.1 5.5 3.8 7.1 1.7
B)
STEP DOWN
SUBJECT LOW MID HIGH
PAH AcPAH PAH AcPAH PAH AcPAH
JN 67.4 8.8 83.7 22.5 78.1 29.7
GS 73.2 9.0 79.4 19.8 71.4 28.7
SB 84.0 11.9 98.2 25.1 94.9 48.1
AD 88.0 11.8 87.0 23.9 74.0 32.7
BB 90.0 11.5 103.4 22.7 74.1 26.8
SM 81.4 8.8 88.4 19.5 87.5 30.0
WW 89.7 8.4 134.9 28.7 84.5 24.8
BW 83.6 9.7 82.3 20.6 66.4 34.8
MEAN 82.2 10.0 94.7 22.9 78.9 32.0
+ SD 8.1 1.5 18.2 3.1 9.4 7.2
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(28 +5, 20+4 and 11 + 2 % respectively; Fig 3.3.8).
For the "step down" study, the mean recoveries of
AcPAH were 10+2, 23 + 3 and 32 + 7 % for the high, raid
and low periods respectively (Fig 3.3.8). The recoveries
of AcPAH as a percentage of the total amount excreted
(PAH + AcPAH), were 28+5, 20+3 and 11 + 2 % for the
"step up" and 29+4, 20+2 and 11 + 1 % for the "step
down" studies during the low, mid and high periods
respectively.
The total recovery of PAH and AcPAH in relation to
the amount infused during each collection period were
100 + 5, 99 + 5 and 96 + 7 % for the low, mid and high
periods during the "step up" study and the corresponding
values for the step down study were 92+9, 118 + 21 and




These results show clearly that the renal clearance
of PAH changes significantly depending on its plasma
concentration. As the plasma concentrations of PAH
increased from 4.4 to 25 mg/1, the mean renal clearance
of PAH rose by 20 % and this was significantly related
to time and increasing plasma concentrations. At the
same time, the renal clearance of AcPAH decreased by
41%. Conversely, as the plasma PAH concentrations
decreased during the step down infusion, the clearance
of PAH decreased by 27% and the renal clearance of AcPAH
increased by 41%. As expected there were significant
correlations between the renal clearances of PAH and
AcPAH, except during the low period of the step up
infusion. The total body clearance of PAH during the
"step up" infusion remained constant over the three
collection periods and was significantly greater than
the renal clearance. The difference was greater at low
plasma PAH concentrations (26 %), than at high plasma
PAH concentrations (13 %).
The changes in renal clearances were clearly related
to plasma concentration of PAH and time can be excluded
as a significant factor. As steady state plasma
concentrations of PAH were achieved in the "step up"
infusion, the changes in PAH clearance cannot be due to
arterio-venous differences, as these should be minimal
under steady state conditions (Brun et al, 1949). This
may not hold for the "step down" study, as steady state
was not reached. A greater total body than renal
clearance of PAH during constant infusion (20-30 %) has
been reported previously (Statius Van Eps et al, 1967;
Cole et al, 1972). This difference was similar to that
found in the present study at low plasma PAH concent¬
rations, but greater than that found at high plasma
concentrations. However, the plasma concentrations in
these previous reports were similar to the high plasma
-233-
PAH concentrations achieved in the present study, and
the differences can probably be explained by their use
of subjects with impaired renal function. Other
investigators have not observed differences between the
total body and renal clearances of PAH during constant
infusion (Berger et al, 1948; Schnurr et al, 1980), but
this can be accounted for by the use of methods
involving hydrolysis. This would convert AcPAH back to
PAH.
The consistently higher total body clearance of PAH
indicates significant extrarenal clearance, which is
greater at low than at high plasma PAH concentrations.
This can be accounted for entirely by the acetylation of
PAH, as the total recovery of PAH and AcPAH was 100 % of
the amount infused during the step up study. These find¬
ings confirm the findings in the single injection study
that both PAH and AcPAH, were completely excreted by the
kidney. Under the conditions of constant infusion, AcPAH
was the major or even sole metabolite of PAH. During the
"step down" infusion, the total recovery exceeded the
amount infused after the high period and this reflects
redistribution with failure to reach steady state
conditions.
The reciprocal changes in the clearances of PAH and
AcPAH were directly related to the concentration
dependant clearance of PAH. No substance can have a
renal clearance greater than the renal plasma flow, but
the clearance can be lower if the extraction ratio is
reduced (Smith, 1951). It is possible that at low plasma
concentrations, PAH and AcPAH do not reflect the
clearance from whole blood due to uptake into
erythrocytes or increased plasma protein binding.
Uptake into erythrocytes
If concentrations of a substance are only measured
in plasma, irreversible uptake into erythrocytes could
cause an artificially low clearance. In this case the
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uptake of PAH and AcPAH into erythrocytes seems unlikely
as this does not occur, to a significant extent, "in
vitro" or "in vivo" (Smith et al, 1945).
Plasma protein binding
Increased plasma protein binding, at low plasma
concentrations has previously been put forward as an
explanation for the depression in diodrast clearance at
low plasma concentrations (Block & Burrows, 1960). There
is evidence that the fraction of PAH bound to plasma
proteins increases at low concentrations (Taggart,
1951). However, PAH is reported not to be strongly bound
to plasma proteins and to have a great affinity for the
tubular transport system (Moller & Sheikh, 1983). The
plasma protein binding of AcPAH does not seem to have
been investigated, but with decreasing plasma concent¬
rations, the extraction ratio is apparently constant
(Newman et al, 1949). Therefore, a change in plasma
protein binding seems an unlikely explanation for the
changes seen in the renal clearances of PAH and AcPAH.
The excretion of PAH is usually described by two
intrarenal processes, filtration and secretion. However,
there are 2 other major determinants of excretion that
can effect the clearance of a compound. These are reab-
sorption, and intrarenal metabolism (Weiner, 1985). If
either of these renal mechanisms are effecting the
excretion of PAH, the renal clearance of PAH will be
altered as it is the resultant of all intrarenal
processes. An effect on filtration seems unlikely as the
creatinine clearance remained unchanged, and would
therefore not explain the plasma concentration dependant
clearance of PAH.
As PAH and AcPAH are excreted via the same organic
anion transport system, it is possible that PAH
excretion is reduced due to competition for this system.
This seems unlikely considering the concentration
differences between them but it cannot be ruled out. The
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possible role that tubular reabsorptiort and intrarenal
metabolism may have on the renal clearance of PAH are
discussed below:-
Tubular reabsorption
Tubular reabsorption of PAH has been reported to occur
in dogs and rats (Cho & Gafruny, 1970; Moller & Sheikh,
1983). In man a rapid decline in renal clearance of two
cephalosporin antibiotics, (cephapirin and cephalorid-
ine) similar to that seen with PAH following a single
injection, has been shown to be due to saturable tubular
reabsorption (Arvidsson, 1982). Saturable tubular
reabsorption of PAH would be consistent with reduced
renal clearance, and proportionately reduced urinary
excretion of PAH at low plasma concentrations. However,
this will not explain the inverse relationship between
the renal clearances of AcPAH and PAH as plasma
concentrations decline. Bidirectional transport with
saturable tubular reabsorption of PAH cannot be ruled
out but this mechanism alone cannot account for the
findings.
Renal metabolism of PAH
Acetylation of PAH in the kidney would be consistent
with the lack of change in the total body clearance of
PAH during the "step up" infusion. This would also
explain why the AcPAH, clearance after administration of
PAH, was so much greater than reported in other studies
when given alone (Smith et al, 1945; Newman et al,
1949). The renal metabolism of PAH will increase the
amount of AcPAH and decrease the amount of PAH present
in the urine, irrespective of the plasma concentration.
In such circumstances, the apparent renal clearance of
AcPAH will be spuriously increased while the renal
clearance of PAH will be reduced. Such an effect would
also be consistent with the changing renal clearance of
PAH, whilst the total body clearance of PAH remained
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constant. The difference between total body and renal
clearance of PAH become less as the plasma con¬
centrations of PAH increased, and the apparent renal
clearance of AcPAH increased dramatically at low plasma
concentrations of PAH. Taken together, these findings
suggest saturable renal acetylation of PAH.
Renal metabolism should be suspected if the apparent
renal clearance of a metabolite, following administ¬
ration of the parent drug, is much greater than that
when the metabolite is given alone (Tucker, 1981). AcPAH
is only removed by renal excretion, and its clearance
cannot be greater than the renal plasma flow. In the
present study, the renal clearance of AcPAH at low
plasma PAH concentrations was greater than the expected
physiological renal plasma flow. In other studies, the
renal clearances of AcPAH given alone and PAH are
reported to be similar (Smith et al, 1945; Newman et al,
1949; Statius Van Eps et al, 1967). The reliability of
these findings must, however, be open to question
because of the indirect methods used for analysis. Stolk
et al, (1985), investigated a new HPLC technique for
measuring AcPAH, and during a constant infusion of AcPAH
(10 mg/min) in volunteers, described steady state plasma
concentrations, of 18, 21, and 23 mg/l> but
unfortunately no clearances were reported. On the
assumption that AcPAH has a maximal clearance and high
extraction ratio, it can be calculated from the cited
infusion rate and steady state concentrations that the
total body clearances of AcPAH were 555, 476 and 435
ml/min respectively. As no conditions were given, and
the clearance of PAH in their subjects is unknown, these
results are of limited value. However, AcPAH is totally
excreted by the kidney, as shown in the present study
and it is not deacetylated in man (Newman et al, 1949).
The clearance values for AcPAH calculated from the data
of Stolk et al, (1985), are well below those observed in
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the present study. This again suggests that the high
apparent AcPAH clearances found in the present study
reflect renal acetylation of PAH and are therefore, not
a true measure of the renal blood flow.
Acetylation of PAH has been demonstrated in animals
(Setchell & Blanch, 1961), and also "in vitro" in human
kidney slices (Frindt & Vial, 1968). In this latter
study, the kidney had a greater capacity for acetylation
of PAH in man than the liver, and saturation of acety¬
lation was demonstrated. Saturation of kidney metabolism
also occurs in mouse kidney slices (Carpenter & Mudge,
1980). Smith (1951) cited studies by Hamburger and
Ryckewaert in which the PAH clearances at plasma
concentrations below 10 mg/1 were very low, after single
injection and during constant infusion. This was
attributed to tubular conjugation, high plasma protein
binding or tubular "inertia". Newman et al,(1949), also
thought that PAH was metabolised in the kidney in man
because its renal clearance fell in man, but not in dogs
(who cannot acetylate) following a single injection. The
proportion of conjugate in urine increased as the plasma
concentrations of PAH decreased, as observed in the
present study. Grindt et al, (1974), also suggested that
PAH was metabolised in the kidney. On the other hand,
Smith (1951) stated that although conjugation in the
kidney could not be excluded, significant renal
conjugation at low plasma concentrations was unlikely,
and that extrarenal metabolism would have no effect on
the renal clearance of PAH. Pearson (1979) reports that
the presence of AcPAH does not interfere with the
estimation of ERPF.
The weight of evidence from the present studies,
supported in part by previous reports, indicate either
renal metabolism of PAH or interference with its
excretion as the cause of the significant decrease in
the renal clearance of PAH, at low plasma concent-
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rations. Either way, the reduced clearance of PAH at low
plasma concentrations seems to be related to its
metabolism to AcPAH.
Berger et al, (1948), proposed a constant infusion
method without urine collection, reporting similar total
body and renal clearances of PAH. They took into
consideration the metabolism of PAH and converted AcPAH
back to PAH by hydrolysis. This method has potential
problems due to the formation of degradation products
(Brown et al, 1976). However, the total body clearance
i.e. PAH + AcPAH (as PAH equivalents) can be estimated
by summing the PAH and AcPAH concentrations (as PAH
equivalents) in plasma and urine to give the total body
clearance of PAH + AcPAH and renal clearance of PAH +
AcPAH, without the errors involved with hydrolysis. In
this way, the total body and renal clearances of PAH +
AcPAH in the present "step up" infusion study were,
similar (Table 3.3.6).
TABLE 3.3.6
Mean (+ SD) clearances of PAH and total PAH + AcPAH during the
"step up" infusion study
PERIOD Rclt TBCt Rclt/TBCt Rclp Rclt/Rclp
PAH + AcPAH PAH
LOW 497 (73) 494 (75) 1.00 (0.07) 405 (48) 1.23 (0.09)
MID 525 (129) 540 (127) 0.97 (0.05) 468 (108) 1.12 (0.03)
HIGH 531 (109) 546 (92) 0.97 (0.08) 509 (93) 1.04 (0.02)
t = PAH + AcPAH p= PAH
Rcl = renal clearance TBC = total body clearance
If the renal clearance of total PAH + AcPAH is taken
as the best measure of the renal plasma flow it should
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be equal to the renal clearance of PAH, in the absence
of renal metabolism. This is not the case, as the renal
clearance of PAH is consistently less than the clearance
of PAH + AcPAH, at low PAH plasma concentrations (Table
3.3.6). This discrepancy becomes less as the plasma
concentrations of PAH rise. Presumably at some higher
plasma concentration, the renal clearance of PAH and PAH
+ AcPAH will become almost equal. At this point, the
renal acetylation of PAH would be saturated. PAH is
probably also metabolised extrarenally, presumably in
the liver.
The clearance of PAH is dependent upon its plasma
concentration and therefore, its use for measuring renal
plasma flow may only be valid over a narrow range of
plasma concentrations, where the clearance is maximal.
This range is above the point above where renal PAH
metabolism becomes saturated, and below the level of
saturation of its renal tubular transport. Thus the
classical representation of the renal clearance of PAH
in relation to plasma concentrations (shown on page 35),
should be redefined as follows:
Fig 3.3.9
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From the present data, it is not possible to define
the plasma concentrations at which there is complete
saturation of PAH metabolism (and possibly tubular
reabsorption), but with measurement of the renal
clearance of PAH by the constant infusion technique,
plasma concentrations should be kept above 20 mg/1.
The fall in PAH clearance following single injection
was more dramatic than observed in the present "step up"
and "step down" constant infusion, and this is probably
due to the much lower plasma concentrations in the 1-2 h
period. In addition, the fall in clearance may have been
exacerbated by other factors such as arterio-venous
differences or delay time. The results of the present
study suggest that at PAH plasma concentrations above 20
mg/1, the effects of renal metabolism are small. The
plasma concentrations achieved during the constant
infusion (section II, p 178) were above 20 mg/1 and the
clearances were similar to the 0-1 hour renal clearances
of PAH following single injection. Therefore, the 0-1
hour renal clearance of PAH is probably a better
estimate of the effective renal plasma flow than the
total body clearance. The major disadvantage of this
method is that accurate urine collections are still
required. This may be overcome by infusing to steady
state plasma concentrations and measuring the total body
clearance only. An appropriate correction factor could
be applied to correct for the fraction converted to
AcPAH extrarenally, providing the plasma concentrations
of PAH were above the point of significant renal
metabolism. Urine would still have to be collected but
all that is required is the fraction of the dose
converted extrarenally.
It is clearly time to reevaluate the role of PAH as
the standard for measurement of the renal plasma flow.
Its clearance is dependant on plasma concentration, and
it is probably metabolised as it passes through the
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kidney. In the present study there was no evidence of
genetically controlled acetylation of PAH as reported
for other arylamines (Weber & Hein, 1985), but the
number of subjects studied was small. If there is
genetic polymorphism of PAH acetylation, estimates of
renal plasma flow may depend on whether the subject is a
fast or slow acetylator. If AcPAH has a high maximal
extraction ratio and its total body and renal clearances
are similar (Smith et al, 1945; Newman et al, 1949;
Statius Van Eps, 1967), it should be a much better test
compound than PAH for measuring renal plasma flow. It
may not have been introduced previously because of the
lack of a specific assay.
SUMMARY
The renal clearance of PAH falls as the plasma
concentration declines, whilst the proportion of PAH
acetylated increases. The opposite is found to occur as
the plasma concentrations of PAH increase. The renal
clearance of AcPAH is inversely related to that of PAH.
The total body clearance of PAH and the total PAH +
AcPAH renal clearance remained relatively constant on
increasing the plasma concentration of PAH. Decreased
extraction due to plasma protein binding and uptake into
erythrocytes, are thought to be unlikely explanations
for the fall in the renal clearance of PAH. However,
saturable tubular reabsorption of PAH could contribute
to the decline in PAH renal clearance, but does not
explain all the results. The most plausible explanation
behind the plasma concentration dependant clearance of
PAH is saturable concentration dependant renal
acetylation.
The renal clearance of PAH is plasma concentration
dependant below 20 mg/1. Therefore, any method used to
measure the renal clearance of PAH below this level,
will be inaccurate. Above these levels urine must be
collected, due to significant extrarenal clearance.
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AcPAH should be investigated as a possible replacement






The disposition and kinetics of p-aminohippuric acid
(PAH) and its metabolite acetyl p-aminohippuric acid
(AcPAH) were investigated following single intravenous
administration and during constant infusion of PAH. PAH
and AcPAH were estimated using specific high performance
liquid chromatographic assays.
The results obtained and conclusions drawn can be
summarised as follows:-
1) Following single intravenous bolus administration
of PAH (10 mg /Kg) in 26 healthy males, the total body
and renal clearances of PAH fell significantly and
dramatically (a mean fall of 54 % in the case of the
renal clearance) in the second hour compared to the
first. Eighty two percent of the administered dose of
PAH was recovered in the urine as PAH, whilst the
remainder was recovered as AcPAH.
2) During "step up" and "step down" constant
infusions, the PAH renal clearance decreased
significantly as steady state plasma concentrations
decreased, well below the level of saturation of the
renal transport system. However, the total body clear¬
ance of PAH during the "step up" study did not alter,
suggesting an intrarenal mechanism behind the fall in
the PAH renal clearance.
3) The total body clearance of PAH was significantly
greater than its renal clearance following a single
injection (14 %, 0-1 h), and during constant infusion.
During the "step up" constant infusion, the difference
between total body and renal clearance of PAH was
greater at low (26 %) than at high (13 %) PAH plasma
concentrations. This difference between the total body
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arid renal clearances of PAH is due to its metabolism to
AcPAH.
4) AcPAH was present in plasma and urine following
both single intravenous injection and constant infusion
of PAH. In all studies, the renal clearance of AcPAH was
significantly greater than the corresponding renal
clearance of PAH. During the "step up" and "step down"
constant infusion, the changes in AcPAH clearance were
inversely related to the changes in PAH clearance.
6) The renal clearance of PAH + AcPAH (as PAH
equivalents) remained relatively constant during the
"step up" study, but was significantly greater than the
renal clearance of PAH at low plasma concentrations. The
differences between the two clearances decreased as the
PAH plasma concentration increased. This suggests that
the renal clearance of PAH is effected by its
metabolism, which is greater at low plasma
concentrations of PAH.
7) The renal clearance of PAH is clearly dependent
on the plasma concentration, and decreases progressively
as concentrations fall below 20 mg/1. This is unlikely
to be due to decreased renal extraction because of
increased plasma protein binding or uptake into
erythrocytes at low concentrations.
8) The effects of arterial-venous differences and
the delay time can also be ruled out as causes, because
the renal clearance changes significantly in the "step
up" infusion where these factors are minimal.
9) The concentration dependant decrease in the renal
clearance of PAH could be explained by saturable tubular
reabsorption. However, the weight of evidence suggests
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that PAH is metabolised as it passes through the kidney,
and such a mechanism is consistent with the results of
these studies.
10) The renal clearance of PAH was similar following
a single injection as during constant infusion, in the
same 10 healthy males.
11) The single injection method has limited
application for measurement of the renal clearance of
PAH because it undergoes significant metabolism. The
extent to which PAH is metabolised in the kidney could
not be determined in the present study, but this process
probably becomes saturated at high plasma
concentrations.
12) During the first hour following a single
intravenous injection of PAH, the renal clearance of PAH
is similar to that during constant infusion (465 v 444
ml/min/1.73 mz respectively), and the method can be used
as long as urine is collected.
13) The renal clearance of PAH decreases
progressively as the plasma concentrations fall below 20
mg/1 and this effect can be largely explained by
concentration dependant renal acetylation. Therefore,
any method used to measure the renal clearance of PAH
will be inaccurate at low plasma concentrations, and




THE EFFECTS OF TENOXICAM ON RENAL FUNCTION
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INTRODUCTION
Tenoxicam is a new non-steroidal anti-inflammatory
drug (NSAID). It is a thienothiazine derivative, and
belongs to the oxicam class (Fig. 4.1).
Fig 4.1
oh o
Structure of Tenoxicam MW 337.4
Chemical name: 4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno-
[2,3-e]-l,2-thiazine-3-carboxamide 1,1-dioxide.
Its anti-inflammatory and analgesic properties have
been demonstrated in animal models, and in patients with
rheumatoid arthritis and osteo-arthritis. Tenoxicam has
a long half life of about 72 hours, allowing once daily
administration and steady state plasma concentrations
are achieved by 12 to 15 days. The precise mode of
action of tenoxicam is unknown, but it inhibits
prostaglandin synthesis and reduces leucocyte
accumulation and phagocytosis (Gonzalez & Todd, 1987).
Prostaglandins are cyclic derivatives of the fatty
acid arachidonic acid and they are synthesised locally,
exerting their action near this site. Arachidonic acid
is oxygenated by cyclo-oxygenase enzymes present in the
endoplasmic reticulum to form the enderoperoxides PGG2
and PGH2, and these are then converted enzymatically to
the biologically active prostaglandins. Arachidonic acid
can also be converted to leukotrienes by lipooxygenase
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(Dunn, 1984).
The group of non-steroidal anti-inflammatory drugs
includes indomethacin, ibuprofen, naproxen and
piroxicam. These have all been linked with pathological
and physiological changes in renal function including
reduction in renal blood flow, chronic renal disease,
papillary necrosis and also unwanted sodium, potassium
and fluid retention. These effects are thought to be
mediated by inhibition of cyclo-oxygenase, and reduced
synthesis of renal prostaglandins (Fig.4.2) (Carmichael
& Shankel, 1985; Adams et al, 1986; Clive & Stoff,
1984).

















Changes in renal function following NSAID administration
ADH = antidiuretic hormone. (Carmichael & Shankel, 1985)
Tenoxicam has been reported to be as effective and
as well tolerated as indomethacin, ibuprofen and
naproxen in clinical studies, and in animal models of
inflammation, tenoxicam was as potent as piroxicam and
indomethacin (Gonzalez & Todd, 1987). However, it has
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been postulated that non-steroidal anti-inflammatory
drugs which have long elimination half lives, have a
greater potential for renal side effects than those with
short half lives (Adams et al, 1986).
The aim of this study, was to determine the effect
of tenoxicam on renal function in healthy volunteers as
assessed by measurement of the glomerular filtration
rate (GFR), effective renal plasma flow (ERPF), and
urinary prostaglandins and electrolyte excretion.
Urinary N-acetyl-glucosamidinase and B2 microglobulin
were also measured as indicators of acute renal tubular
damage (Prescott, 1982a). Studies were carried out
before, and during administration of tenoxicam over a
period of ten days.
METHODS
Volunteers
16 healthy male volunteers aged between 22 and 42
years (mean age 27+5 yrs) weighing 57 - 88 Kg (mean 70
+ 8 Kg), were recruited. A complete medical examination
was performed, and the results of routine blood
biochemistry and haematology screening were within
normal limits. The study was approved by the local
ethical committee, and written consent was obtained from
each volunteer. All subjects were instructed to avoid
alcohol and excessive salt intake during the study, and
to refrain from sexual activity 36 hours before each
study day, to avoid urinary contamination with
pros taglandins.
Study design
The study was a randomised, double blind, placebo-
controlled parallel group study. Each subject received
two tablets of tenoxicam (40 mg) or placebo on days one
and two, followed by one tablet of tenoxicam (20 mg) or
placebo for the next eight days. There were eight
subjects in each group. Detailed tests of renal function
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were performed before dosing, and on the third and tenth
day of drug administration (Fig 4.3).
On each study day, the volunteers had a light
breakfast without caffeine containing drinks before
attending hospital. On arrival, they emptied the
bladder, were weighed, and blood was taken for
biochemistry and estimation of plasma tenoxicam
concentrations. 500 ml of water was then drunk over 5
minutes, and on days 3 and 10 tenoxicam or placebo was
administered, at this time. After the initial water
loading, the volunteers drank 100 ml of water every half
hour for the next 6-8 hours. One hour after the initial
fluid load, the bladder was emptied again (basal period)
and the urine kept for measurement of B2 microglobulin
and N-acetyl-glucosamidinase (NAG) activity. Inulin
(Kerfoot, Barnsley, U.K (N=14) or "Inutest" (Laevosan-
Gesellschaft, Austria, (N=2)) and p-aminohippurate (PAH)
(Merck Sharp & Dohme, U.K) were then administered intra¬
venously for measurement of glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF), as
described on page 50 and 173 respectively.
Blood was also taken before dosing on days 8 and 17
for measurement of the plasma concentrations of
tenoxicam.
Sample collection
All blood samples were collected into 10 ml lithium
heparin tubes, centrifuged at 1500g for 10 minutes and
the plasma removed. The volume and pH of urine samples
were recorded, and aliquots kept for analysis. The
plasma and urine samples for measurement of inulin and
creatinine were kept at 4°C, and analysed within 72
hours of collection. For the determination of PAH,
samples were kept frozen at -20°C until analysis. An
aliquot of the 0-24 hour urine was collected for
measurement of PGE2 and 6 keto PGFIq; on each study day,
and stored at -20°C. The pH of urine aliquots for the
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Fig 4.3
Tenoxicam study design. The arrows indicate the
measurements made on different days.
TENOXICAM OR PLACEBO
i I
DAY -7 12 3456789 10 17
RENAL FUNCTION
( GFR, ERPF) 4 ♦ ♦
URINE ( VOL, Na+, 4 4 4
NAG, B2-MICRO., etc )
HAEMATOLOGY ^ 4
BIOCHEMISTRY
PLASMA TENOXICAM 4 4 4 4 4
DOSING!- 2 x 20 mg TENOXICAM days 1 6c 2
20 mg TENOXICAM days 3-10
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estimation of B2 microglobulin was adjusted to pH 7 with
1 M sodium hydroxide.
Plasma samples for the determination of tenoxicam
were stored in the dark at -20°C in plastic tubes
covered with tinfoil, as tenoxicam is light sensitive.
Analytical methods
Inulin and PAH were measured as described on page 51
and 147 respectively, and the Jaffe reaction was used
for determining plasma and urine creatinine by a
standard autoanalyser technique (Gemstar™ Electro-
Nucleonics). Urine sodium and potassium were estimated
by flame photometer (Corning 435), and prostaglandins
PGE2 and 6 keto PGFIq; were determined by
radioimmunoassay, as described previously (Mackay et al,
1984). Urine B2 microglobulin was estimated by
radioimmunoassay (Pharmacia, Sweden) and NAG by
spectrophotofluorimetry (Leaback & Walker, 1961).
Standard laboratory techniques were used for blood bio¬
chemistry and haematological screens.
Plasma tenoxicam concentrations were analysed by the
Clinical Pharmacology Unit, Royal Bath Hospital, Harro¬
gate using reverse phase HPLC (Dixon et al, 1984).
Data analysis
PAH and inulin clearance were calculated from the
area under the plasma concentration-time curves (AUC),
which were obtained by fitting the data to an open two
compartment model using the "MULTI" computer programme
(Yamaoka et al, 1981), as described in chapter two (p
53). The renal clearances of PAH and creatinine were
calculated using equations 4 (p 8). i.e. The renal
clearance is equal to the urinary excretion rate divided
by the corresponding AUC. The clearance of PAH was
determined on the 0-1 hour urine collection period only,
whilst the creatinine clearance was measured for the 0-
1, 1-2, 2-3, 3-4, 4-6 and 6-8 hour collection periods,
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and the weighted average calculated to give the
clearance for 0-8 hours. The inulin clearance was
calculated as the total body clearance using equation 8
(p 23), where the total body clearance of inulin is
equal to the dose of inulin injected divided by the AUC,
extrapolated to infinity. The AUC extrapolated to
infinity, was estimated from the 0-2 hour plasma data as
described in chapter 2 (p 52). All clearance values are
o
expressed as ml/min/1.73 m .
Urinary sodium and potassium excretion is expressed
as mmol/24 h, prostaglandins as ng/24 h and NAG as units
per mg of creatinine.
The plasma elimination half life of tenoxicam was
estimated from the tenoxicam plasma concentrations on
day 11 and seven days after termination of dosing, day
17, using equation 7 (p 21). The pre-dose level for day
10 was used as an estimate of the day 11 level as it was
assumed that steady state concentrations were achieved
and thus the pre-dose day 10 concentration would be
similar to that on day 11, 24 hours after the last dose.
The results from the day before treatment started is
referred to in the following text as pre, baseline or
control day.
Statistical methods
The statistical significance of differences within
and between the groups were determined by analysis of
variance. The null hypothesis was rejected if p< 0.05.
RESULTS
Renal function
The mean clearances of inulin, creatinine and PAH
are given in Tables 4.1 & 4.2, and the individual data
are shown in Figs 4.4 & 4.6. There were no significant
differences between the placebo and tenoxicam baseline
values for inulin, creatinine and PAH clearances.
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TABLE 4.1
0-2 h total body clearances of inulin (A) and 0-8 h renal
n
clearances of creatinine (B) (ml/rain/1.73 ra ) before (P) and on




SUBJECT P 3 10 SUBJECT P 3 10
2 127 119 106 1 97 95 96
4 101 96 94 3 95 92 85
5 98 103 101 6 114 97 106
8 98 107 96 7 115 96 103
10 113 104 113 9 117 120 122
12 127 130 131 13 99 107 104
16 98 85 90 14 117 116 124
19 105 110 115 20 98 107 103
MEAN 108 107 106 107 104 105
_+SD 13 14 14 10 10 13
B)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 119 131 126 1 104 104 113
4 99 98 100 3 116 102 101
5 125 131 130 6 113 146 170
8 126 127 117 7 115 113 109
10 119 106 123 9 116 133 127
12 135 143 125 13 117 118 119
16 103 97 107 14 119 116 113
19 137 116 124 20 112 110 118
MEAN 120 119 119 114 118 123
+SD 14 17 10 5 15 22




The 0-1 h renal clearance of PAH (ml/rain/1.73 m ) before (P) and on
days 3 and 10 of treatment with tenoxicara or placebo in 16 healthy
male subjects.
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 619 723 678 1 463 533 492
4 495 447 439 3 526 414 611
5 528 519 597 6 533 578 360
8 649 643 711 7 597 514 545
10 545 489 623 9 846 791 818
12 621 750 540 13 605 728 665
16 449 434 416 14 623 735 613
19 513 428 498 20 536 573 510
MEAN 552 554 563 591 608 578
+SD 70 132 108 115 130 135
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Fig 4.4
Individual 0-2 h total body clearances of inulin
(bottom) and 0-8 h renal clearances of creatinine (top)
in 16 healthy males, before (control) and on days 3 and
10 of treatment with placebo or tenoxicam. Clearances
O
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The mean total body clearances of inulin were 108,
107, and 106 ml/min/1.73 m in the tenoxicam group, and
o
107, 104 and 105 ml/min/1.73 m in the placebo group
before, and on days three and ten of treatment (Fig.
4.5). Thus, tenoxicam had no significant effect on the
glomerular filtration rate.
Similarly, there was no significant change in the
creatinine clearance. The mean creatinine clearances
were 120, 119, and 119 ml/min/1.73 m^ for the tenoxicam
group, and 114, 118 and 123 ml/min/1.73 m for the
placebo group before, and on days three and ten of
treatment (Fig. 4.5). The placebo group showed a rise
in mean creatinine clearance over the treatment period,
but this was attributable to subject No 6 whose
creatinine clearance rose markedly. On removal of this
subject's data, no rise is seen (Fig. 4.5).
There was considerable inter individual variation in
the PAH clearance (Fig. 4.6), but there were no
significant differences between the placebo and
tenoxicam groups. The mean PAH clearances were 552, 554,
and 563 ml/min/1.73 m^ in the tenoxicam group and 591,
o
608 and 577 ml/min/1.73 mz in the placebo group before,
and on days three and ten of treatment (Fig. 4.6). There
was no significant change in the mean PAH clearance over
the treatment period.
Urine volume and electrolyte excretion
The individual and mean values for the 24 hour
urinary excretion of sodium and potassium, and urine
volume are given in Tables 4.3 & 4.4.
There were no statistically significant changes in
sodium excretion or urine volume in the placebo or
tenoxicam groups (Fig. 4.7). The mean urinary potassium
excretion fell progressively in the tenoxicam group, but
this trend was not statistically significant (Fig. 4.7).
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Fig 4.5
Mean 0-2 h total body clearance of inulin (bottom) and
0-8 h renal clearances of creatinine (top) in 16 healthy
males, before (control) and on days 3 and 10 of
treatment with placebo or tenoxicam. (--0--) is the mean
clearance, omitting data from subject No 6). Clearances
O











Mean (top) and individual (bottom) 0-1 h renal
clearances of PAH in 16 healthy males, before (control)
and on days 3 and 10 of treatment with placebo or






























24 H urinary sodium (A) and potassium (B) excretion (mmol/24h)
before (P) and on days 3 and 10 of treatment with tenoxicam or
placebo in 16 healthy male subjects.
A)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 189 187 121 1 177 244 90
4 87 99 102 3 230 164 127
5 174 145 129 6 135 165 171
8 190 245 166 7 163 81 132
10 188 179 185 9 247 195 190
12 123 240 203 13 113 70 115
16 95 64 71 14 119 195 196
19 161 154 184 20 131 79 197
MEAN 151 164 145 164 149 152
jHSD 43 63 46 51 65 41
B)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 55 65 46 1 82 76 39
4 65 40 47 3 37 58 39
5 70 86 57 6 86 55 91
8 86 103 102 7 47 52 49
10 64 68 60 9 71 59 72
12 137 64 48 13 84 39 49
16 31 41 39 14 43 60 75
19 80 58 53 20 58 50 62
MEAN 73 66 57 64 56 59
+SD 31 21 20 20 11 19
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TABLE 4.4
24 H urine volume (ml) before (P) and on days 3 and 10 of treatment
with tenoxicam or placebo in 16 healthy male subjects.
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 3502 4334 2614 1 3255 3288 2952
4 3229 3229 3218 3 2653 3391 2522
5 3453 3795 3227 6 3090 3297 3186
8 3542 3580 3197 7 2973 2298 3092
10 2765 2633 3140 9 3065 2901 2906
12 3071 3488 3751 13 3338 2327 2186
16 2546 1864 2092 14 3559 3930 3676
19 2881 3091 2685 20 3113 2506 2756
MEAN 3124 3242 2991 3131 2992 2910
+SD 371 753 506 268 584 447
TABLE 4.5
0-1 H urinary NAG excretion before (P) and on days 3 and 10
treatment with tenoxicam or placebo in 16 healthy male subjects.
URINARY NAG EXCRETION (UNITS / MG CREATININE)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 48 45 70 1 72 82 51
4 163 273 134 3 92 129 92
5 43 44 35 6 227 139 191
8 68 68 99 7 112 144 122
10 138 82 121 9 80 73 71
12 264 131 288 13 109 97 115
16 50 72 75 14 75 107 92
19 126 75 84 20 136 133 132
MEAN 113 99 113 113 113 108
+ SD 77 75 77 51 27 43
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Fig 4.7
Mean 24 hour urine volume (top) and sodium and potassium
excretion (bottom) in 16 healthy males, before (B or
control) and on days 3 and 10 of treatment with placebo
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Urine Bj microglobulin and NAG concentrations.
Urinary E$2 microglobulin concentration was within
normal limits (<0.3 mg/1) throughout the study in all
subjects except in two cases (one in each group), where
the concentration rose to 0.4 mg/1. The mean urinary NAG
excretion did not change during the treatment period in
either group (Table 4.5).
Prostaglandins
The urinary excretion of prostaglandins PGE2 and 6
keto PGFIq; was very variable in both treatment groups
(Table 4.6 A & B ). The marked fluctuations in prosta¬
glandin output precluded any meaningful statistical
comparisons between the placebo and tenoxicam groups.
Plasma tenoxicam concentrations
The plasma concentrations of tenoxicam are given in
Table 4.7. The mean plasma concentrations of tenoxicam
were 4.68 + 0.92, 6.58 + 1.56, 6.53 + 1.87, and 2.50 +
1.61 mg/1 on days 3, 8, 10, and 17. In six subjects, the
plasma concentrations remained relatively constant from
day 8 to day 10, but in two (Nos 2 and 19)
concentrations were still rising (Fig. 4.8). By day 17
(seven days after stopping the drug), the plasma
concentrations were less than on day 3, except in
subject No 19. The mean plasma elimination half life as
calculated from the day 11 and 17 value was 105.5 + 50.1
hours. This was exceptionally long in subject No 19,
with a half life of 207.9 hours. The individual half
lives are given in Table 4.7.
Adverse effects
Tenoxicam was well tolerated by all except subject
No 19, who experienced persistent, intermittent
epigastric and central abdominal pain. It started on the
fourth day of treatment, and lasted for two weeks
ranging in severity from mild to severe. He completed
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TABLE 4.6
24 H urinary excretion (ng/24 h) of PGE2 (A) and 6 keto PGFIq; (B)
before and on days 3 and 10 of treatment with tenoxicam or placebo
in 16 healthy male subjects.
A)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 9890 3710 1281 1 570 612 266
4 5505 2005 3369 3 525 482 525
5 13311 1158 284 6 556 679 17924
8 900 695 1017 7 898 499 618
10 17397 5100 21324 9 18298 5437 3888
12 989 970 259 13 1008 251 643
16 812 725 318 14 1730 1662 890
19 1026 3743 781 20 >20235 383 1560
MEAN 6229 2263 3579 5478 1251 3289
+SD 6558 1695 7242 8535 1746 6026
B)
TENOXICAM PLACEBO
SUBJECT P 3 10 SUBJECT P 3 10
2 1684 1386 614 1 680 802 543
4 1450 1201 1210 3 446 536 446
5 1495 1450 600 6 717 692 2444
8 1031 795 1029 7 612 464 473
10 1366 487 1193 9 3307 2211 1485
12 1766 586 521 13 651 342 514
16 535 296 418 14 456 495 467
19 274 291 618 20 3054 356 659
MEAN 1200 812 775 1240 737 879
+ SD 543 476 317 1203 616 720
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TABLE 4.7
Plasma tenoxicam concentrations on days 3, 8, and 10 of treatment
in 8 healthy male subjects, and 7 days after treatment was stopped.
The plasma elimination half life (t%) is also shown.
PLASMA TENOXICAM CONCENTRATIONS (mg/1)
DAY
SUBJECT 3 8 10 17 *t\ (h)
2 5.19 8.38 9.12 3.52 104.8
4 6.44 7.95 7.74 2.91 102.0
5 4.21 4.63 4.35 0.74 56.4
8 4.11 6.82 5.51 2.74 142.9
10 3.37 5.67 5.35 1.04 60.9
12 4.42 5.62 5.60 2.04 98.8
16 4.52 5.01 5.41 1.31 70.4
19 5.15 8.53 9.18 5.68 207.9
MEAN 4.68 6.58 6.53 2.50 105.5
+SD 0.92 1.56 1.87 1.61 50.1
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the ten day course of tenoxicam, and the symptoms were
probably related to tenoxicam. No similar symptoms were
encountered in the placebo group.
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DISCUSSION
Under the conditions of this study, tenoxicam did
not have a demonstrable effect on GFR, ERPF or
electrolyte excretion in healthy subjects. Steady state
plasma concentrations were achieved in the majority of
subjects by the tenth day of treatment. The mean
concentration on day ten was 6.53 mg/1, and the mean
plasma half life was 105.5 + 50 hours. This is greater
than the reported average half life of tenoxicam
(Gonzalez & Todd, 1987). However, the half life was
considerably longer in subject No 19, and he was the
only subject to suffer adverse effects. The
gastrointestinal side effects of non-steroidal anti¬
inflammatory drugs have been well documented (Nickander
et al, 1979).
The lack of effect of tenoxicam on renal function in
these healthy individuals is not surprising, since
similar negative findings have been reported with other
non-steroidal anti-inflammatory drugs (indomethacin,
ibuprofen, asprin) under similar conditions, including
those of the same class (eg piroxicam) (Darragh, 1985;
Dibona, 1986; Patrono & Dunn, 1987). However, in other
studies reduced GFR, ERPF and sodium excretion have been
noted in healthy subjects who are sodium deplete (Clive
& Stoff, 1984; Raymond & Lifschitz, 1986).
Non-steroidal anti-inflammatory drugs are thought to
mediate most of their therapeutic and adverse effects
through inhibition of prostaglandin synthesis, and in
the kidney this can result in reduced RBF and GFR, with
adverse effects on renal function under certain con¬
ditions (Nickander et al, 1979; Clive & Stoff, 1984).
Renal prostaglandins are synthesised, act and are
degraded within the kidney. The major renal prostagland¬
ins are the powerful vasodilators prostacyclin (PGI2)
and PGE2, and thromboxane A2 which is a vasoconstrictor.
PGI2 and thromboxane are formed in the glomerulus,
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arterioles and juxtaglomerular apparatus (PGI2 only),
while PGE2 is formed within the medullary interstitial
cells and collecting tubules. One of the major roles of
the prostaglandins is the maintenance of renal cortical
and medullary function in patients with kidney, liver
and heart disease (Dunn, 1984; Patrono, 1986).
Experimental and clinical evidence has shown that
with increased amounts of circulating vasoconstrictors
(eg angiotensin II, vasopressin and catecholamine), the
renal circulation depends on a dynamic balance between
vasoconstriction and vasodilation. The prostaglandins
PGI2 and PGE2 maintain renal vasodilation by reducing
the effects of the vasoconstrictors on pre- and
postglomerular arterioles, and also by relaxing the
mesangium, which preserves the glomerular filtration
surface area. In this way, the renal blood flow and GFR
are maintained (Dunn, 1984). This protective mechanism
is of particular importance in patients with reduced
renal perfusion caused by cirrhosis with ascites,
diuretic induced volume and sodium depletion, congestive
cardiac failure and nephrotic syndrome, as well as in
the elderly (Prescott, 1982b). The use of non-steroidal
anti-inflammatory drugs in these situations, leads to
inhibition of renal prostaglandin synthesis and a
decrease in renal blood flow and GFR. This may cause
renal ischaemia and lead to acute or chronic renal
failure (Carmichael & Shankel, 1985). The acute effects
are usually reversible on stopping the non-steroidal
anti-inflammatory drug.
In normal healthy individuals, renal blood flow is
not dependent upon endogenous prostaglandin synthesis,
and non-steroidal anti-inflammatory drugs have little,
or no effect on renal function as other regulatory
mechanisms (eg adrenergic tone, renin secretion, and
dopamine) are also unstressed and therefore, compensate
when prostaglandins are inhibited (Patrono & Dunn,
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1987).
Inhibition of prostaglandin synthesis also has
effects on urinary electrolyte and water excretion. This
is due in part to a reduction in renal blood flow, and
thus the filtered load, and also to potentiation of the
effect of anti-diuretic hormone (ADH) (Clive & Stoff,
1984; Raymond & Lifschitz, 1986). Renal prostaglandins
also promote sodium and water excretion by a direct
action on the renal tubules, and their inhibition may
reduce sodium and water excretion without necessarily
changing the ERPF or GFR (Haylor, 1980). No significant
effects on sodium or water excretion were seen in the
present study, but the subjects were fluid loaded on the
day of study, and had been on tenoxicam for two days
before the first observations were made. A small initial
transient effect could have been missed.
Retention of potassium with hyperkalaemia has also been
reported after administration of non-steroidal anti¬
inflammatory drugs. This is thought to be mediated
through inhibition of renin release, which in turn
reduces circulating aldosterone (Staszewska-Barczak,
1978). PGI2 has been reported to be involved in the
release of renin (Clive & Stoff, 1984). No significant
changes in 24 hour urinary potassium excretion were
seen, in the present study.
The long term use of non-steroidal anti-inflammatory
drugs may cause chronic renal injury including papillary
necrosis and chronic interstitial nephritis (Adams et
al, 1986; Prescott, 1982b). The proximal tubule has a
high metabolic activity, and is particularly vulnerable
to nephrotoxicity. Toxic effects on the proximal tubules
can be detected by abnormal urinary excretion of
compounds which undergo tubular transport at this site,
and by the release of specific enzymes from tubular
cells. Increased excretion of B2 microglobulin reflects
impaired tubular reabsorption of this low molecular
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weight protein, while excessive urine NAG activity,
indicates leakage from damaged tubular cells (Prescott,
1982a). No increase in the excretion of either B2
microglobulin or NAG was detected in this study.
Measurement of the urinary excretion of prosta¬
glandins and their metabolites, is thought to reflect
renal prostaglandin synthesis (Patrono, 1986). With the
possible exception of sulindac, all non-steroidal anti¬
inflammatory drugs reduce urinary prostaglandin
excretion by at least 50 % when administered in full
anti-inflammatory doses (Patrono & Dunn, 1987). Urine
prostaglandin E2 is primarily derived from medullary
sites, and the metabolite of prostacyclin, 6-keto PGFlce,
from the cortex (Patrono, 1986). Unfortunately, the
variation in the urinary excretion of PGE2 and 6-keto
PGFlo; in the present study was such, that no conclusions
could be drawn concerning the effects of tenoxicam. The
reason for this large variability is probably
contamination with prostatic fluid. This is common in
men, and urinary prostaglandin measurements in men are
probably uninterpretable (Patrono & Dunn, 1987).
SUMMARY
The short term administration of a new non-steroidal
anti-inflammatory drug, tenoxicam in healthy hydrated
males, had no significant effects on renal function
under these conditions, but inhibition of renal
prostaglandin synthesis could not be demonstrated.
However, adverse renal effects in patients predisposed
to nephrotoxicity and the elderly cannot be excluded.
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CHAPTER FIVE
FINAL DISCUSSION AND CONCLUSIONS
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DISCUSSION
A single injection method for measuring glomerular
filtration rate (GFR) and renal plasma flow (RPF) has
been examined, using appropriate pharmacokinetic
analysis. The use of single injection methods for
measuring GFR and RPF are today widely accepted as
accurate and reproducible, if appropriate pharmaco¬
kinetic methods of analysis are used (Cohen, 1974;
Brochner-Mortensen, 1985). The standard methods for
measuring GFR and RPF by constant infusion (Schuster &
Seldin, 1985) are inconvenient for both patient and
investigator. Short accurately timed urine collections
are needed, the patient is immobilised for several
periods, and forced diuresis or catheterization are
required for accurate urine collections. These
techniques are therefore not practicable for routine
clinical use (Kampmann & Molholm-Hansen, 1981). One
important advantage of the single injection method is
that urine collection is not necessary. This eliminates
the greatest source of error and inconvenience in
constant infusion methods. In addition there is no need
to wait for steady state to be reached.
Inulin and p-aminohippuric acid (PAH) are the
standard substances for estimation of the GFR and RPF
respectively (Schuster & Seldin, 1985). Their clearances
are believed to be constant at plasma concentrations
achieved in the present studies and independent of the
urine flow rate, but the clearance of PAH decreases
above 80 mg/1 due to saturation of the renal transport
system (Smith, 1951). These properties should make
inulin and PAH ideal for use in single injection
methods, but most data related to their clearance refers
to the standard constant infusion methods. The
independence of the PAH and inulin clearance of their
respective plasma concentrations is a major assumption,
which is made in their use as reference compounds.
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The results from the present studies clearly show
that this assumption does not hold at low plasma
concentrations. The clearance of both inulin and PAH
were found to be significantly lower at low than at high
plasma concentrations, regardless of whether the plasma
concentrations were at steady state or falling. In the
case of inulin, the renal clearance fell in subjects
with both normal and impaired renal function. For both
compounds the significant changes in clearance were
related to plasma concentration. To elucidate, the
possible mechanisms involved it is necessary to remember
that the renal clearance of any substance is the
resultant of 4 processes (Arvidsson, 1982):-
1) Glomerular filtration.
2) Active secretion into tubular fluid.
3) Active reabsorption from tubular fluid.
4) Renal Metabolism.
The use of the renal clearance of inulin as a
measure of the GFR over any period of time, depends on
the assumption that it reflects glomerular filtration
only (Smith, 1951). In the case of PAH, there is both
filtration and active proximal tubular secretion with 90
7o extraction in one passage through the kidney, so, it
is ideal for measurement of the effective renal plasma
flow (Smith et al, 1945). However, the results of the
present studies show, that there are fundamental changes
in the clearance of both PAH and inulin as the plasma
concentration declines. In the case of inulin the renal
clearance falls progressively as the plasma concent¬
ration decreases below 100 mg/1 in subjects with normal
renal function. This threshold level is higher in
patients with renal impairment. The decrease in PAH
clearance becomes significant when plasma concentrations
fall below 20 mg/1.
These changes in the clearances of inulin and PAH
cannot be explained by effects such as delay time
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errors, plasma protein binding, uptake into
erythrocytes, arterial-venous differences, selective
filtration of the low molecular weight polymers of
inulin, or time itself, as shown by the "step up" and
"step down" studies. Similar results have been reported
by Smith, 1951; Newman et al, 1949; Ferguson et al,
1950; Mogensen, 1968. The observed falls in clearances
were greater following a single injection than during
constant infusion. Some of the above effects could have
contribute to some extent to the changes following a
single injection, as they are more likely to occur with
declining plasma concentrations than at steady state
(Pihl, 1973).
With inulin, three observations must be taken into
account, in relation to possible mechanisms for the
decreasing clearance:-
1) The renal clearance of inulin was less than the
glomerular filtration rate at low plasma concentrations,
since there was no corresponding fall in the
simultaneously determined creatinine clearance. If the
clearance of any substance is less than the glomerular
filtration rate, tubular reabsorption is possible
(Rowland & Tozer, 1980).
2) The total body clearance of inulin is signif¬
icantly greater than the renal clearance of inulin after
a single injection. Significant extrarenal clearance of
inulin is unlikely since it is quantitatively recovered
in the urine. Underestimation of the area under the
plasma concentration-time curve following a single
injection,could account for the difference, (Rehling et
al, 1984) and this may have occurred, since it is
impossible to define the early part of the AUC
accurately. However, the same differences in clearance
were seen during the constant infusion studies.
3) A plot of the urinary excretion rate of inulin
against the plasma concentration shows a negative
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deviation from the origin. This indicates that the
observed rate of inulin excretion lags behind the plasma
concentration (Tucker, 1981). Such an effect could be
explained by the delay time, a progressive increase in
the time taken for inulin to pass through the kidney, or
its retention within the renal tract because of
increasing residual urine as the flow rate declines.
These mechanisms seem unlikely to have caused the
decreased clearance of inulin, as they cannot account
for the changes in inulin clearance during the "step up"
and "step down" constant infusion studies. Under these
conditions the high urine flow rates minimise the
effects of delay time and errors caused by residual
urine (Pihl, 1973). Perhaps the most likely explanation
is saturable tubular reabsorption.
This possibility was first raised by Ferguson et al,
(1950), but similar studies by Laake, (1954), and
Kennedy & Kleh, (1953) gave different results. These
authors concluded that there was no evidence to support
tubular reabsorption and this appears to be confirmed by
micropuncture studies in the rat (Harris et al, 1974).
Uptake of inulin into the renal tubules has been
reported to occur in animals (Balint & Forgacs, 1958;
Gayer et al, 1961) and the results of the present
studies are entirely consistent with low capacity
saturable tubular reabsorption of inulin, which only
becomes evident at low plasma concentrations. Further
studies are required to elucidate the kinetics of this
reabsorption process.
The circumstances of the decrease in the renal
clearance of PAH are different since it is metabolised
to AcPAH. The following evidence points to a possible
mechanism for the decline in PAH clearance at low plasma
concentrations:-
1) As the renal clearance of PAH falls with
decreasing plasma concentrations, the proportion of the
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dose recovered in the urine as AcPAH increases. The
opposite occurs as the plasma concentrations of PAH
increase.
2) The total body clearance of PAH is significantly
greater than the renal clearance following single
injection and constant infusion studies. This difference
can be accounted for entirely by metabolism as the
administered dose is quantitatively recovered in the
urine as PAH and AcPAH.
3) The renal clearance of AcPAH is greater than the
renal clearance of PAH, after intravenous administration
of PAH. The clearance of any substance cannot be greater
than the renal blood flow, unless it is synthesised
within the kidney, or unless the measured plasma
concentration differs significantly from the whole blood
concentration, because of uptake into erythrocytes
(Smith, 1951). At low plasma concentrations of PAH, the
apparent clearance of AcPAH is greater than would be
expected if AcPAH was given alone (Smith et al, 1945;
Newman et al, 1949). This is consistent with renal
metabolism of PAH (Tucker, 1981).
4) The total body clearance of PAH does not change
during constant infusion, but the difference between the
total body and the corresponding renal clearance,
diminishes at high plasma concentrations of PAH. This
suggests that the change in PAH clearance is related to
its metabolism by the kidney.
5) The renal clearance of total PAH + AcPAH (as PAH
equivalents) is relatively constant at different plasma
concentrations of PAH and it is significantly greater
than the renal clearance of PAH. Again this difference
diminishes as the plasma concentration of PAH increases.
Taken together these observations cannot be
explained by a change in the renal extraction of PAH or
in its extrarenal metabolism. The findings could
conceivably be explained in part by bidirectional renal
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tubular transport of PAH as has been reported for the
cephalosporin, cephapirin. This also shows a similar
decline in renal clearance as its plasma concentrations
decline (Arvidsson, 1982). There is indeed evidence for
the tubular reabsorption of PAH "in vitro" and "in
vivo", in animals (Cho & Cafruny, 1970; Moller & Sheikh,
1983). However, as the clearance of PAH is much greater
than the glomerular filtration rate, secretion must
still be the major excretory mechanism at low plasma
concentrations (Rowland & Tozer, 1980). Saturable
tubular reabsorption of PAH at low concentrations is
inconsistent with the fact that the renal clearance of
AcPAH, is significantly greater than the renal clearance
of PAH, even at high plasma concentrations, under these
conditions, the renal clearance of PAH is considered to
be an accurate measure of the renal blood flow (Schuster
& Seldin, 1985), and it cannot exceed it. The renal
clearance of AcPAH increases significantly as the plasma
concentrations of PAH decline and this could be due to
saturable concentration-dependant renal acetylation of
PAH.
Renal acetylation of PAH has been reported "in vivo"
in animals (Setchell & Blanch, 1961), "in vitro" in man
(Frindt & Vial, 1968) and possibly "in vivo" in man
(Newman et al, 1949; Grindt et al, 1974). The metabolism
of PAH has been reported not to effect its renal clear¬
ance (Smith, 1951; Pearson, 1979). This may be true at
high plasma concentrations, if the renal acetylation
becomes saturated, but this appears not to be the case
at low plasma concentrations of PAH (below 20 mg/1). The
renal tubular transport of PAH becomes saturated at high
plasma concentrations, causing a depression in its renal
clearance (Schuster & Seldin, 1985) and therefore if PAH
is to be used as a measure of the RPF, the plasma
concentrations must be maintained, in the range in which
both these effects are minimal. Thus the renal clearance
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of PAH is not an accurate measure of the renal plasma
flow at low plasma concentrations and this is probably
due to significant saturable renal acetylation. This
holds for both single injection and constant infusion
methods.
Are the renal clearances of inulin and PAH valid
measures of GFR and RPF following single intravenous
administration ?
The single injection technique is clearly applicable
to inulin, as its total body and renal clearances are
similar to those measured by the constant infusion and
they are significantly more reproducible, in repeated
studies. However, the plasma concentrations of inulin
must be above the levels where inulin reabsorption
becomes significant. In the present study, this
threshold level was about 100 mg/1 and this is reached
approximately 2 hours following a dose of 70 mg/Kg, in
subjects with normal renal function.
Today the endogenous creatinine clearance is the
most widely used measure of the GFR; in most hospitals.
An accurate 24 hour urine collection is usually
required, but creatinine clearance can also be estimated
from the plasma creatinine concentration, using a
nomogram based on age, sex and body weight (Brochner-
Mortensen, 1985). However, the renal clearance of
creatinine is an overestimate of the GFR because of
tubular secretion and this increases as the renal
function declines (Bauer et al, 1982). Thus, the
creatinine clearance is not an ideal measure of the GFR.
1 1^1CrJX EDTA and I-1-0-1- iothalamate have also been used but
the former underestimates the renal clearance of inulin
by 5-15 % (Brochner-Mortensen, 1985) and iothalamate is
believed to undergo extrarenal clearance and renal
tubular secretion (Odlind et al, 1985; Prueksaritanont
et al, 1986). These radiolabelled compounds are probably
not as accurate as inulin for measurement of the GFR and
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there are inherent dangers with the use of radioactive
materials, especially if repeated estimates are
required. This is a particular problem in children and
here the inulin single injection technique has been used
successfully (Muller-Suur et al, 1983).
The results of the present studies show that in
adults, the inulin single injection method is as
accurate and more reproducible than the constant
infusion method. It is also comfortable for the patient,
and fluid loading, catheterisation and prolonged
immobilization are not required. It is an ideal
technique for the single estimation of GFR, but if
dynamic studies are required, the constant infusion
method is probably still the best method. With the
single injection technique, the numerous blood samples
required to define the plasma concentration-time curve,
are a drawback.
The validity of the renal clearance of PAH,
following single injection as a measure of the RPF, is
more complicated since it is acetylated both renally and
extrarenally. Therefore, the total body clearance may be
an overestimate or the renal clearance may be an under¬
estimate of the true RPF. The extrarenal metabolism
influences the total body clearance, while the renal
metabolism influences the renal clearance. It is there¬
fore necessary to know the contribution of each process.
In the present studies, it appears that the renal
metabolism of PAH becomes saturated and is insignificant
at high plasma concentrations. Therefore, in constant
infusion studies with plasma concentrations of the order
of 30 mg/1 the renal clearance of PAH is a more accurate
measure of the RPF than the total body clearance, as the
intrarenal metabolism is probably insignificant. The
renal clearance of PAH during the first hour following a
single injection in the present study was of the same
order as that achieved during constant infusion. This
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suggests that after a single injection, the renal
clearance of PAH is not initially influenced to any
great extent by renal metabolism. Thus under the
conditions of this study the single injection method
gives an estimate of the renal clearance of PAH, which
is probably a close approximation to the ERPF, when
sampling is limited to the first hour. The single
injection method of measuring the renal clearance of PAH
has the advantages described previously and, as it is
very quick, repeated estimates can be made on the same
day. Although it is a safe and simple method, urine
collections are required and at low plasma concent¬
rations, major errors are likely, because of the renal
metabolism.
At low plasma concentrations of PAH, it is not
possible to correct the total body clearance for
extrarenal clearance, because the contribution of the
renal acetylation is unknown. However, provided the
plasma concentrations are kept above the point where the
renal metabolism becomes significant, it should be
possible to apply the appropriate correction factor to
the total body clearance. Thus, to eliminate the errors
involved in achieving accurate urine collections,
infusion to steady state plus a correction factor for
extrarenal PAH metabolism, would probably be the best
method for estimating the ERPF. This method would still
require urine collections, but only to acertain the
fraction of the dose infused which is converted
extrarenally to AcPAH.
The effective renal plasma flow has been measured
using the single injection method before, with
1 ^1radiolabelled compounds such as, IiJi diodrast and
Hippuran (Pihl, 1973; Pearson, 1979). The results with
these substances are not as accurate as with PAH, and at
low plasma concentrations, their clearances also decline
(Block & Burrows, 1960; Pihl, 1973). With radioactive
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iodine it is necessary to pre-treat the patient with
potassium iodide to inhibit the uptake of radioactive
iodine into the thyroid (Pearson, 1979). In comparison
with these other test compounds, the use of PAH by
single injection methods may be no worse. However, it is
not ideal and there is a need for better agents for
measuring the renal plasma flow. AcPAH would make a
better test compound for the measurement of the renal
plasma flow, as it is totally cleared via the kidney, it
is not metabolised, and can be measured accurately and
specifically using HPLC (Newman et al, 1949; Statius Van
Eps, 1967).
The single injection methods described here for
determining the GFR and ERPF, were used to establish the
effects of tenoxicam, (a new non-steroidal anti¬
inflammatory drug) given for 10 days, on the renal func¬
tion of healthy males. There was no significant changes,
and, this is not entirely unexpected, as the GFR and RPF
would not have been reduced in healthy subjects, unless
they are sodium or fluid depleted (Carmichael & Shankel,
1985). Inhibition of the synthesis of renal prosta¬
glandins only has an adverse effect when renal perfusion
is reduced (Patrono & Dunn, 1987). To show such an
effect with tenoxicam, studies should be carried out in




In these studies, the single intravenous injection
of inulin and p-aminohippuric acid (PAH) have been
investigated as a valid measure of the GFR and ERPF. The
conclusions are summarized as follows:-
1) The total body and renal clearances of inulin
decline progressively, two hours after a single
intravenous bolus (70 mg/Kg) of inulin in 23 healthy
male volunteers. The mean renal clearance fell from 97
ml/min/1.73 at 0-1 hours to 47 ml/ min/1.73 m^ by 6-8
hours.
2) The total body clearance of inulin was
significantly greater than the corresponding renal
clearance (6 %) following single injection.
3) The total body and renal clearances of inulin
were significantly lower at low, than high, steady state
plasma concentrations.
4) The plot of the urinary excretion rate of inulin
against its plasma concentration showed a negative
deviation from the origin.
The results clearly show that at low plasma concent¬
rations, the clearance of inulin is dependant on the
plasma concentrations. It appears that there is low
capacity saturable renal tubular reabsorption of inulin
in addition to glomerular filtration, which becomes
significant below plasma concentrations of 100 mg/1 in
normal subjects.
5) The total body and renal clearances of PAH fell
after one hour, following a single intravenous injection
of PAH (10 mg/Kg). The mean renal clearance of PAH fell
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dramatically from 526 ml/min/1.73 m at 0-1 hours to 241
O
ml/min/1.73 m by 1-2 hours in 26 healthy male
volunteers. Eighty two percent of the administered dose
was recovered as PAH, and the remainder was recovered as
its metabolite AcPAH.
6) The total body clearance of PAH was significantly
greater than its corresponding renal clearance by 14 %,
following single intravenous administration.
7) The renal clearance of PAH was significantly
lower at low, than high, steady state plasma
concentrations.
8) The metabolite of PAH, AcPAH was present in both
plasma and urine, following intravenous administration
of PAH during constant infusion studies and following a
single injection. The renal clearance of AcPAH was
significantly greater than that of the parent compound
and was significantly greater at low, than high, plasma
concentrations of PAH. The fractional urinary excretion
of AcPAH decreased with increasing plasma concentrations
of PAH.
The results clearly show that at low plasma concent¬
rations, the renal clearance of PAH is highly dependant
on the plasma concentration. There is evidence for
saturable renal acetylation of PAH during the process of
excretion. This effect significantly limits the renal
clearance of PAH at plasma concentrations below 20 mg/1.
The total body clearance of PAH is significantly greater
than the renal clearance because of renal and extrarenal
metabolism.
10) The single injection method for measuring the
total body and renal clearances of inulin gave results
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which were similar to those obtained by the standard
constant infusion method in the same subjects when
sampling was restricted to the first two hours following
the single injection.
11) The renal clearance of PAH following a single
injection was in the same order as that achieved during
constant infusion in the same subjects, when sampling is
restricted to the first hour.
12) These two single injection techniques were
applied to the investigation of renal function during
administration of tenoxicam, in 8 healthy hydrated males
for 10 days. Tenoxicam had no significant effect on GFR
or ERPF in these subjects
The single injection methods are limited by the
depression of clearance at low plasma concentrations.
However, if the sampling times are restricted, both the
renal and total body clearances of inulin and the renal
clearance of PAH, can be used as estimates of the GFR
and RPF respectively. In the case of PAH, the renal
clearance must be measured, but the total body clearance
of inulin without urine collection, is a valid estimate
of the GFR. The single injection methods are more
convenient for the patient and investigator than the
constant infusion methods and are ideal for single
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DETAILS OF HEALTHY SUBJECTS STUDIED DURING CONSTANT INFUSION AND
FOLLOWING SINGLE INJECTION OF p-AMINOHIPPURIC ACIO (PAH) AND INULIN
CONSTANT SINGLE DOSE ADMINISTERED
INFUSION INJECTION SINGLE INJECTION
SUBJECT AGE HEIGHT WEIGHT S/A WEI6HT S/A INULIN PAH
(Y) (11) (KG) (M) (K6) (M) (N6) (HG)
RH 26 1,81 72,0 1,92 72,0 1,92 4870 715
LP 50 1,79 76,3 1,95 76,3 1,95 5020 704
GS 28 1,75 71,9 1,87 71,9 1,87 5188 674
JN 24 1,82 75,5 1,97 75,5 1,97 4990 727
ON 23 1,75 73,5 1,89 73,5 1,89 4840 710
MK 23 1.72 63,0 1,75 63,0 1,75 4807 643
CP 22 1,77 63,5 1,79 63,5 1,79 4850 581
BH 22 1.87 77,3 2,02 77.3 2,02 5320 712
BS 21 1.85 78,5 2,02 78,5 2,02 5201 715
PL 22 1,84 82,9 2,06 85,7 2,08 4967 -
S/A = Surface Area
SINGLE
INJECTION
SUBJECT AGE WEIGHT HEIGHT S/A INULIN PAH
(Y) (Kg) (M) (H) (M6) (HG)
PF 25 68,9 1,76 1,84 4838 628
GS 1 28 68,3 1.75 1,82 5032 -
JN 1 25 77,5 1,82 1,98 5249 -
TN 31 87,1 1,79 2,06 5280 812
GH 32 66,4 1,73 1.79 4927 647
AT 24 67,0 1,79 1,84 4918 636
EC 29 67,0 1,67 1.75 4631 640
WW 30 56,6 1,66 1,72 4677 548
AB 24 73,5 1.79 1,92 4970 720
RJ 27 57,2 1,65 1.62 4313 544
AD 29 65,4 1,71 1,77 4830 639
JA 29 88,5 1,87 2,14 5022 816
RF 24 76,9 1,73 1,92 5050 735
PD 22 67.7 1.74 1,81 4925 634
MS 25 74,8 1,73 1,88 5030 732
SA 24 67,5 1.72 1,79 4906 638
J6 29 70,4 1.79 1,88 5042 647
AH 28 74,9 1,87 1,99 - 719
SB 42 69,0 1,74 1,82 - 631
-309-
APPENDIX I.la





PERIOD (hours) PERIOD (hours)
SUBJECT BLANK 1 1.5 2 2,5 3 1 1.5 2 2,5 3
RM <10 205 205 198 195 195 75 80 70 75 80
LP <10 185 180 175 170 175 80 85 80 85 90
6S <10 150 150 155 155 155 100 100 95 95 100
JN <10 150 160 160 165 170 110 105 110 110 110
DM <10 160 155 153 160 160 95 90 95 90 95
MK <10 185 178 175 170 173 90 90 90 95 95
CP <10 195 190 190 188 180 90 90 90 90 95
BH <10 170 170 170 165 160 85 85 85 88 90
BS <15 175 175 170 170 175 100 100 100 100 100
PL <10 145 145 145 150 145 86 86 87 84 93
APPENDIX I,lb
p-AMINQHIPPURIC ACID (A) AND ACETYL p-AMINQHIPPURIC ACID (B) PLASMA CONCENTRATIONS 0URIN6 A




B) ACETYL p-AMINOHIPPURIC ACIO
PLASMA CONCENTRATION (M6/L)
PERIOD (hours)
SUBJECT BLANK 1 1.5 2 2,5 3 1 1,5 2 2,5 3
RM 0 24,95 27,84 27,66 27,61 27,53 3,40 3,88 4,18 3,89 3,67
LP 0 25,67 27,64 29,34 26,30 30,17 2,32 3,03 3,29 3,39 3,34
6S 0 27,67 28,35 28,68 31,30 29,94 2,30 2,54 2,77 2,93 2,94
JN 0 23,42 25,15 25,71 27,81 30,22 2,49 2,88 3,17 3,24 3,33
DM 0 24,92 25,77 28,05 29,2 30,21 2,01 2,35 2,24 2,57 2,62
MK 0 27,88 27,92 28,72 28,33 29,30 2,87 3,33 3,26 3,46 3,22
CP 0 33,60 35,40 37,50 37,54 35,41 3,08 3,47 3,56 3,39 3,40
BH 0 24,87 27,20 27,55 28,54 29,52 2,71 2,95 3,21 3,16 3,10
BS 0 26,06 29,33 34,21 33,40 33,41 3,10 4,08 4,33 4,46 4,41
RJ 0 24,80 28,31 28,40 29,40 29,60 2,57 2,82 2,88 2,99 3,06
-310-
APPENDIX 1,2
fifty URINARY DATA RELATING TO INULIN, CREATININE, p-AINOHIPPURIC ACID (PAH)
AND ACETYL-p-AHINOHIPPURIC ACID (AcPAH) DURING CONSTANT INFUSION STUDIES,
COLLECTION PERIOD URINARY CONCENTRATIONS
SUBJECT PERIOD TINE VOLUME INULIN CREATININE PAH AcPAH
hour nins »1 tag/1 unol/1 »g/l tag/1
MK 1-1.5 29,60 275 2850 1600 1886,5 208,0
1,5-2 30,00 270 2250 1200 1714,5 195,9
2-2,5 29,60 134 3550 2050 2884,2 373,8
2,5-3 29,95 245 2050 1200 1714,5 223,6
DH 1-1,5 30,38 231 2200 1650 1852,1 205,8
1.5-2 30,32 200 2350 1700 2138,8 259,7
2-2,5 30,43 122 4250 3000 4008,1 490,2
2,5-3 30,50 215 2425 1550 2184,7 312,8
JN 1-1,5 29,25 226 1700 1850 1760,3 214,9
1,5-2 29,58 110 3400 3150 3514,9 495,2
2-2,5 30,07 102 4000 3600 4168,6 592,4
2,5-3 29,67 146 2750 2400 2758,1 418,5
6C 1-1,5 29,33 206 1950 1900 1409,4 235,5
1.5-2 29,83 240 1750 1500 1594,5 217,4
2-2,5 29,67 130 3000 2550 2746,6 415,6
2,5-3 29,67 134 2950 2500 2881,9 390,8
BH 1-1.5 29,42 143 2950 2300 2471,4 294,1
1.5-2 29,60 146 3425 2850 3125,0 371,6
2-2,5 29,67 192 2650 1900 2299,4 280,7
2,5-3 33,01 180 2900 2150 2563,1 339,2
BS 1-1.5 29.37 170 3050 2500 2238,7 361,8
1.5-2 29,92 108 4450 3250 3416,6 654,8
2-2,5 29,60 180 2700 2100 2049,9 402,5
2,5-3 29.55 206 2200 1700 1812,6 360,1
LP 1-1.5 29,40 282 1950 1050 1439,4 180,0
1,5-2 29,93 263 2000 1000 1310,8 199,1
2-2,5 29,93 136 3700 2050 3050,7 519,7
2,5-3 29,96 144 3550 1950 2919,4 515,6
RH 1-1.5 30,00 234 2450 1500 1801,8 247,3
1,5-2 30,00 211 2575 1460 2191,1 286,7
2-2.5 30,50 356 1575 880 1347,6 140,6
2,5-3 30,25 256 2200 1260 1791,8 256,8
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APPENDIX 1.2 CONTINUE
COLLECTION PERIOD URINARY CONCENTRATIONS
SUBJECT PERIOD TINE VQLUNE INULIN CREATININE PAH AcPAH
hour sins •1 ■g/1 ueol/1 «g/l »g/l
CP 1-1.5 29.50 65,5 7400 4600 5814,1 697,0
1.5-2 29.57 206 2250 1400 1857,5 251,3
2-2.5 29.75 206 2200 1400 1989,9 264,4
2,5-3 29,80 210 2300 1400 1975,4 257,9
PL 1-1.6 30,47 46 12450 8480 - -
1.5-2 30,30 63 9150 6480 - -
2-2.5 30,18 151 3750 2680 - -
2.5-3 30,37 234 2300 1460 - -
RJ 1-1.5 31.00 141 - - 3066,7 424,2
1,5-2 30,50 128 - - 3499,0 511,7
2-2.5 30.55 108 - - 3579,9 606,8
2.5-3 28,48 74 - - 5253,5 869,8
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RAW URINARY DATA C0NCERNIN6 INUL1N, CREATININE, p-AMINOHIPPURIC ACID
(PAH) AND ACETYL-p-AMINQHIPPURIC ACID (AcPAH) DURING SINGLE INJECTION
STUDIES IN SUBJECTS WITH NORMAL RENAL FUNCTION
PERIOD VOLUME TIME INUL1N CREATININE PAH AcPAH
hi nin »g/l unol/1 #g/l «g/l
0-1 105 71 21500 5860 4459 454
1-2 590 60 1700 650 70 57
2-3 370 60 1400 1410 26 45
3-4 340 60 1000 1600 14 30
4-6 710 120 550 1480 - 13
6-8 340 120 500 2750 - 10
8-24 800 960 185 10500 - -
0-1 482 80 5283 1686 1014 141
1-2 285 60 3900 2380 89 141
2-3 445 60 1100 1400 11 24
3-4 375 60 690 1660 8 12
4-6 365 120 70S 3980 - 8
6-8 770 120 210 1980 - -
8-24 780 960 645 13070 - -
0-1 570 68 4859 1285 857 118
1-2 346 60 2700 1630 69 95
CO1Cs| 326 60 1600 1730 22 48
3-4 325 60 990 1720 11 25
4-6 144 120 2100 7250 - 56
oo1co 34 120 1750 13800 - 38
8-24 908 960 465 9410 - -
0-1 618 74 4130 946 710 106
1-2 256 60 3200 1720 66 129
CO1CN 350 60 1400 1340 17 42
3-4 230 60 1300 1900 - 30
4-6 360 120 750 2250 - 16
6-8 480 120 350 1920 - -
8-24 935 960 250 6930
0-1 751 69 4133 1096 829 89
1-2 330 60 2650 1850 73 99
2-3 320 60 1600 1940 28 48
3-4 345 60 850 1990 15 19
4-6 238 120 1200 6020 - 20
6-8 325 120 350 5000 - 7
8-24 1144 960 SO 8850 - -
0-1 528 69 4259 1245 881 120
1-2 405 60 1750 1360 37 77
2-3 156 60 2200 3380 24 87
3-4 309 60 900 1700 7 21
4-6 384 120 735 3460 - 14
6-8 159 120 765 7530 - 2













































TIME INULIN CREATININE PAH AcPAH
win ng/1 utol/l ng/1 »g/l
79 3898 1012 741 89
60 2700 1480 49 90
60 1550 2100 17 52
60 850 1800 11 20
120 500 2120 - 8
120 250 2960 - -
960 250 12060 - -
71 5906 1241 2060 149
60 2950 1850 177 118
60 1550 1960 49 93
60 650 1500 15 37
120 350 1850 7 12
120 450 4340 - -
960 300 12270 - -
89 - - 1021 126
60 - - 60 89
60 - - 17 62
60 - - 12 25
120 - - - 35
120 - - - 12
76 - - 3161 498
60 - - 122 222
60 - - 18 48
60 - - 7 32
120 - - - 14
120 - - - 19
73 5511 1812 1406 139
60 2950 2470 124 128
60 1200 1960 28 41
60 1050 3100 15 32
120 500 2340 - 7
120 315 2610 - -
960 195 6290 - -
72 3439 1030 788 101
60 2600 1750 79 119
60 1450 1840 17 52
60 1600 3880 IS 42
120 555 2610 - 12
120 420 3770 - -















































TIME INULIN CREATININE PAH AcPAH
Kin eg/1 UIOl/1 eg/1 eg/1
72 5387 1334 1009 142
60 4350 1490 79 105
60 2450 2500 20 105
60 1350 2520 26 53
120 405 4190 - 40
120 390 2900 - -
960 345 9430 -
67 10098 5298 1922 275
60 1750 1530 59 81
60 2050 3490 26 88
60 700 1770 - 22
120 950 4660 - 23
120 900 9630 - 21
960 285 12750 - -
69 4797 1449 982 131
60 2350 1990 72 105
60 1550 2140 15 87
60 950 2300 3 30
113 650 3100 - 19
131 300 2640 - 5
949 480 15240 - -
91 4100 2050 - -
60 2100 1600 - -
60 1500 1700 - -
60 1000 1600 - -
120 1150 3950 - -
120 400 2250 - -
960 750 21000 - -
84 5500 2300 - -
60 2100 1500 - -
60 1300 1850 - -
60 960 2050 - -
120 1800 6850 - -
120 445 3550 - -
960 400 11500 - -
73 2898 1411 713 39
60 2250 1790 160 90
60 1750 3000 47 60
60 1600 4290 12 40
120 345 1830 7 32
120 270 2600 - 4




PERIOD VOLUME TIME INULIN CREATININE PAH
al ain ng/l uaol/1 «g/l
0-1 1130 86 2612 1267 822
1-2 415 60 2250 1730 312
2-3 385 60 1400 1880 78
3-4 374 60 915 2080 36
4-6 480 120 675 2940 22
6-8 315 120 585 5270 -
8-24 518 960 630 19460 -
0-1 774 90 3816 1369 960
1-2 304 60 3450 2360 392
2-3 350 60 1550 1850 102
3-4 258 60 1250 2570 19
4-6 500 120 700 2970 8
6-8 238 120 600 6540 -
8-24 1620 960 250 6920 -
0-1 160 100 16000 7500 3119
1-2 340 60 2900 2000 105
2-3 275 60 1800 2550 36
3-4 360 60 890 2000 22
4-6 620 120 500 2450 -
6-8 171 120 857 8300 -
8-24 2240 960 174 4854 -
0-1 560 ND 3400 1700 768
1-2 425 60 2125 1600 161
2-3 340 60 1600 2100 42
3-4 202 60 1150 2900 2
4-6 345 120 670 3850 -
6-8 238 120 283 3200 -
8-24 645 960 380 12884 -
0-1 55 88 44500 19500 7646
1-2 100 60 9500 5900 344
2-3 500 60 900 1200 14
3-4 363 60 890 1600 2
4-6 900 120 420 1600 -
6-8 134 120 1075 8800 -

































1-2 348 60 2850 1800 61
2-3 344 60 1325 1700 12
3-4 238 60 1475 2600 7
4-8 262 240 1600 9200 -
8-24 451 960 425 -
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APPENDIX 1,4 CONTINUE
SUBJECT PERIOD VOLUME TIME INULIN CREATININE
al nin rg/1 ufiol/1
0-1 467 ND 5150 1800
1-2 426 60 2150 1250
2-3 325 60 1550 1750
3-4 94 60 2950 5700
4-8 151 240 3300 15600
8-24 1156 960 492 8006
0-1 450 75 5400 2600
1-2 430 60 2300 1750
2-3 360 60 1350 1850
3-4 340 60 940 2050
4-6 112 120 2800 11600
6-8 186 120 900 8300
8-24 4470 960 60 2750
0-1 1068 100 2400 1350
1-2 380 60 2575 2050
2-3 260 60 1950 2700
3-4 300 60 1080 2350
4-6 202 120 1730 15200
6-8 170 120 1050 9200
8-24 3040 960 160 4450
0-1 405 ND 5550 2900
1-2 555 60 1575 1350
2-3 336 60 1250 2050
3-4 280 60 825 2550
4-8 735 240 600 3950
8-24 746 960 372 15009
0-1 430 ND 4450 3300
1-2 435 60 2050 1950
2-3 345 60 1400 2000
3-4 328 60 1050 2350
4-8 1130 240 530 2900
































DETAILS OF SUBJECTS STUDIED USING REPEAT ESTIMATES OF INULIN SINGLE INJECTION METHOD
OAY ONE TWO THREE
DOSE DOSE DOSE
OF OF OF
SUBJECT A6E HEIGHT WEIGHT S/A INULIN WEIGHT S/A INULIN WEIGHT S/A INULIN
(Y) (M) (KG) (M ) (M6) (K6) (M ) (MG) (K6) (M ) (MG)
GM 32 1,73 66,4 1,79 4927 67,4 1,92 5204 66,2 1,79 4953
EC 29 1,67 67,0 1.75 4631 67,6 1,95 4712 66,5 1,75 4598
AB 24 1,78 72,9 1,90 4930 72,5 1,87 5056 72,5 1,90 4882
RJ 27 1,65 57,2 1,62 4313 56,0 1,97 4310 56,9 1,62 4278
AO 29 1,71 65,4 1.77 4830 66,3 1,89 4793 66,8 1,78 4863
JA 29 1,87 88,5 2,14 5022 88,2 1.75 4918 89,0 2.14 4821
MS 25 1,73 74,8 1,88 5030 75,4 1,79 5100 76,8 1,92 5100
SA 24 1,72 67,5 1,79 4906 67,6 2,02 4942 68,0 1,80 4999
S/A = SURFACE AREA
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APPENDIX 11,1
INULIN PLASMA CONCENTRATIONS (M6/L) FOLLOWING REPEATED ESTIMATES OF THE
INULIN SINGLE INJECTION METHOD
TIME (Min)
SUBJECT 0 3 5 10 15 20 30 40 50 60 75 90
6N 1 15 150 520 740 615 520 400 335 290 245 205 175
6M 2 20 300 560 720 600 500 380 325 280 250 210 180
6M 3 20 130 390 760 820 540 400 325 280 235 185 150
EM 1 5 700 1185 800 620 560 380 310 250 230 180 160
EM 2 IS 710 855 860 680 550 375 315 265 220 190 155
EM 3 15 700 1035 840 680 550 395 325 265 240 200 175
AB 1 20 490 840 780 600 440 295 235 195 160 130 110
AB 2 10 700 750 860 700 500 360 295 255 205 175 145
AB 3 15 700 1080 780 600 480 325 270 230 190 160 135
RJ 1 10 350 690 660 540 470 350 280 220 185 135 125
RJ 2 5 690 1035 700 580 540 375 295 230 185 145 130
RJ 3 5 330 750 620 520 470 360 270 205 170 130 115
AD 1 15 260 735 860 600 480 335 260 215 180 140 120
AD 2 10 480 795 760 560 450 320 250 200 175 140 120
AD 3 5 330 645 720 600 470 320 255 210 180 145 115
JA 1 5 280 660 740 560 460 320 245 190 160 125 110
JA 2 2,5 350 690 600 500 460 315 255 195 160 120 85
JA 3 5 190 450 640 500 400 280 220 180 155 125 125
SA 1 5 310 900 680 540 450 325 275 235 205 165 135
SA 2 15 500 765 740 540 490 345 275 230 205 165 140
SA 3 5 290 600 660 540 440 335 265 210 180 155 120
MS 1 10 120 255 780 600 365 350 290 235 215 170 150
MS 2 5 390 615 720 620 520 355 275 235 205 160 140
MS 3 5 330 585 740 600 490 335 270 225 195 165 140




























INULIN URINARY DATA FROM REPEATED ESTIMATES OF INULIN SINGLE INJECTION METHOD
DAY ONE TWO THREE
SUBJECT PERIOD TIME VOLUME INULIN TIME VOLUME INULIN TIME VOLUME INULIN
»in nl ig/I min nl ig/1 sin nl »g/l
6M 0-1 71 105 21500 67 615 4500 51 594 4050
1-2 60 590 1700 60 445 2150 60 340 2850
EC 0-1 68 570 4859 66 670 5781 70 612 3876
1-2 60 346 2700 60 495 1850 60 315 2850
AB 0-1 90 652 3657 69 670 3112 67 310 5276
1-2 60 290 3100 60 495 2400 60 237 4200
RJ 0-1 69 528 4259 65 407 4975 69 653 3391
1-2 60 405 1750 60 235 2550 60 237 2550
AD 0-1 71 530 5906 71 169 20077 69 448 8500
1-2 60 290 2950 60 315 2800 60 268 3350
JA 0-1 73 491 5511 66 382 7113 70 479 5424
1-2 60 278 2950 60 140 4900 60 270 2800
SA 0-1 72 691 3439 66 750 3384 70 609 3588
1-2 60 310 2600 60 494 1650 60 460 1750
MS 0-1 69 546 4796 67 404 6500 73 344 7341
1-2 60 334 2350 60 540 1300 60 345 2400
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APPENDIX III
SUBJECT DETAILS OF PATIENTS WITH RENAL IMPAIRMENT
DOSE
OF
SUBJECT AGE WEI6HT HEI6HT S/A INULIN
(Y) (Kg) (M) (M ) (H6)
JB 46 76,7 1.76 1,92 5070
EC 63 86,3 1.74 2,00 5108
AO 61 74,0 1,61 1,78 5124
EH 65 78,8 1,67 1.87 5120
WA 65 64,0 1.70 1,74 5048
JH 65 61,0 1,68 1,75 5081
CP 56 87,5 1.81 2,08 5101
S/A = SURFACE AREA
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INULIN AND CREATININE URINARY DATA FOLLOWING A SIN6LE































































































0-1 420 68 3450 2220
1-2 465 74 1750 1790
2-3 290 48 1250 1880
3-4 224 58 950 1840
4-6 560 122 1100 2880
6-8 738 120 500 2080
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APPENDI* IV
DETAILS OF SUBJECTS INVOLVED IN THE STEP UP AND STEP DOWN CONSTANT INFUSION
INCLUDING, AGE, HEIGHT, SURFACE AREA (S/A),AND INFUSION CONCENTRATIONS,
STEP UP INFUSION STEP DOWN INFUSION
INFUSION INFUSION
CONCENTRATION CONCENTRATION
SUBJECT AGE HEIGHT WEI6HT S/A INULIN PAH WEIGHT S/A INULIN PAH
(V) («) (K6) (H ) mm (M6) (KG) (H ) (M6/X) (MB)
JN 26 1,82 77,2 1,37 1500 12776 77,4 1.97 1550 12469
6S 29 1,75 70,1 1,84 1750 12897 71.0 1,86 1500 13128
SB 42 1.74 71,6 1,85 1679 12669 71.6 1,85 1600 10227
AO 30 1,71 64,5 1,75 1650 12323 64,9 1,75 1650 12036
SN 28 1,64 55,2 1,59 1650 12994 55,6 1,59 1650 12347
WW 27 1,86 75,1 1,98 1600 12707 73,9 1,97 1650 12203
BB 36 1.62 69,0 1,73 1950 12179 68,5 1,73 1650 11724
BW 25 1,72 70,1 1,82 1650 12807 69,0 1.81 1500 12162
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APPENDIX IV.la
INIJLIN PLASMA CONCENTRATIONS DURING STEP UP AND DOWN CONSTANT INFUSIONS OF
INULIN
INULIN PLASMA CONCENTRATIONS (M6/L) ACHIEV1ED DURING THE STEP UP INFUSION
TIME (hours)
SUBJECT 0 1 1,5 2 2,5 3 3,5 4 4,5 5 5,5 6 6,5
JN <10 25 25 23 23 60 55 50 45 130 US 105 100
GS <10 35 40 35 40 75 75 75 75 210 190 185 185
SB <10 25 25 30 25 65 60 55 60 145 145 140 140
BB <10 35 40 43 35 80 65 65 75 195 173 170 170
AD <10 30 30 30 30 60 55 55 55 185 170 165 160
WW 10 50 40 40 40 75 65 60 60 170 153 153 155
SM 10 45 45 45 45 85 85 85 80 235 210 210 205
BW 15 40 38 38 38 85 75 75 70 230 190 185 185
INULIN PLASMA CONCENTRATIONS (M6/L) ACHIEVIED DURIN6 THE STEP DOWN INFUSION
TIME (hours)
SUBJECT 0 1 1,5 2 2,5 3 3,5 4 4,5 5 5,5 6 6,5
JN <10 215 200 195 190 145 125 110 105 85 75 80 55
GS <10 220 200 190 175 130 100 100 no 75 80 80 60
SB <10 165 155 ISO 155 120 95 85 80 75 65 60 55
BB 10 215 185 185 175 140 110 105 95 75 70 65 65
AD <10 195 180 175 175 115 100 95 90 65 55 50 35
WW <10 175 150 150 150 105 90 85 75 55 45 45 4S
SM 10 300 265 250 235 170 145 130 125 105 9S 90 85
BW <10 230 230 190 185 130 115 IOS too 85 75 70 6
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APPENDIX IV,lb
CREATININE PLASMA CONCENTRATIONS DURIN6 STEP UP AND DOWN CONSTANT INFUSIONS
OF INULIN
CREATININE PLASMA CONCENTRATIONS (UMQL/L) DURIN6 THE STEP UP INFUSION
TIME (hours)
SUBJECT 0 1 1.5 2 2,5 3 3,5 4 4,5 5 5,5 6 6,5
JN 107 103 101 103 99 95 90 99 97 100 97 97 93
6S 93 100 89 87 93 92 97 92 91 93 96 91 91
SB 71 60 67 68 63 67 63 67 68 56 58 72 72
AD 77 78 81 79 75 75 71 76 69 74 75 80 83
BB 73 74 86 73 79 70 65 67 77 72 72 74 73
WW 79 78 76 76 73 72 75 75 74 68 73 74 75
SM 76 88 90 85 85 88 81 84 73 78 71 102 98
BW 79 85 87 82 80 78 78 76 78 78 77 73 80
CREATININE PLASMA CONCENTRATIONS (UMOL/L) DURIN6 THE STEP DOWN INFUSION
TIME (hours)
SUBJECT 0 1 1.5 2 2,5 3 3.5 4 4,5 5 5,5 6 6,5
JN 107 103 101 103 99 95 90 99 97 100 97 97 93
6S 85 83 71 77 84 80 76 89 90 88 91 89 83
SB 47 56 58 57 58 53 55 55 56 59 59 55 58
BB 81 76 73 81 74 76 75 78 77 75 73 73 74
AD 68 78 85 81 86 78 78 78 74 80 82 79 81
WW 69 70 72 69 70 70 69 66 65 71 72 71 71
SM 81 83 80 79 79 79 76 77 79 79 76 74 75
BW 80 81 81 85 76 83 88 76 85 88 71 79 77
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RAW URINARY CONCENTRATIONS OF INUL1N, CREATININE, p-ANINOHIPPURIC ACID
ACETYL-p-AMINOHIPPURIC ACID DURING STEP UP AND DOWN CONSTANT INFUSIONS
STEP DOWN INFUSION STUDY
COLLECTION PERIOD URINARY CONCENTRATIONS
SUBJECT PERIOD TIME VOLUME INULIN CREATININE PAH AcPAH
hour tins «1 tg/1 unol/1 eg/1 lug/1
JN 1,5-2 28,8 292 2050 1340 1109,4 173,9
2-2.5 29,5 268 2200 1460 984,2 157,8
3,5-4 32,0 159 2400 2570 847,9 280,9
4-4,5 30,5 210 1470 1940 600,9 192,7
5,5-6 30,5 310 615 1280 193,3 132,0
6-6,5 29,5 296 585 1250 192,2 199,2
GS 1,5-2 29,5 245 2300 1490 1356,4 199,9
2-2,5 30,5 241 2400 1590 1490,2 227,4
3.5-4 29,0 284 990 1370 448,9 138,5
4-4,5 29,5 270 1035 1340 430,8 127,7
5,5-6 29,0 242 720 1440 234,8 112,6
6-6.5 29,5 195 810 1910 271,3 137,8
SB 1,5-2 31,2 178 4750 2070 2407,4 365,0
2-2,5 29,5 69 5000 2320 2872,1 629,5
3,5-4 29,6 135 2500 1930 798,2 228,7
4-4,5 29,8 152 2600 2160 865,1 286,5
5,5-6 29,8 210 1150 1630 306,4 159,1
6-6,5 29,7 240 800 1300 213,5 157,7
AD 1,5-2 29,7 210 3300 1520 1891,0 289,7
2-2,5 30,4 290 2300 1240 1280,2 218,4
3,5-4 29,9 265 1450 1250 488,6 168,6
4-4,5 29,3 240 1250 1340 491,1 158,2
5,5-6 29,9 279 650 1210 196,6 101,9
6-6,5 28,4 225 650 1360 222,2 121,4
BB 1,5-2 29,5 235 2650 1210 1492,5 229,8
2-2,5 29,9 330 2100 920 1215,4 191,1
3,5-4 29,8 134 2550 2060 933,5 262,7
4-4,5 29,9 282 1380 1300 581,7 148,8
5,5-6 30,2 259 690 1150 162,4 71.7
6-6,5 30,1 253 660 1130 247,9 108,5
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APPENDIX IV,2 CONTINUE
STEP DOWN INFUSION STUDY
COLLECTION PERIOD URINARY CONCENTRATIONS
SUBJECT PERIOD TIME VOLUME INULIN CREATININE PAH AcPAH
hour tins ill mg/1 utol/1 •g/1 mg/1
SN 1.5-2 29,9 280 2300 960 1290,4 198,6
2-2,5 30,4 240 2350 1180 1523,1 165,6
3,5-4 29,9 215 1480 1320 635,3 187,4
4-4,5 30,4 200 1375 1390 634,1 152,6
5,5-6 30,5 255 700 1180 263,0 108,1
6-6,5 30,4 255 650 1030 253,2 106,8
vu 1,5-2 29,6 275 2000 1070 1083,5 121,9
2-2,5 29,6 451 1900 1040 1063,9 121,4
3,5-4 29,4 370 1500 1330 584,5 136,3
4-4,5 29,4 355 1200 1120 482,2 116,3
5,5-6 29,5 342 525 930 164,5 60,2
6-6,5 30,6 420 500 880 161,1 56,4
BU 1,5-2 29,9 210 3350 1330 1765,4 240,5
2-2,5 30,2 243 3150 1370 1489,3 215,2
3,5-4 29,6 203 1850 1560 594,6 173,7
4-4,5 29,6 160 2100 2280 727,2 229,1
5,5-6 29,8 152 1500 2000 273,6 203,8
6-6,5 29,5 208 800 1440 269,1 144,5
STEP UP INFUSION STUDY
COLLECTION PERIOD URINARY CONCENTRATIONS
SUBJECT PERIOD TIME VOLUME INULIN CREATININE PAH AcPAH
hour • ins ll ng/1 uiol/1 •g/1 •g/1
JN 1,5-2 29,5 170 450 2240 288,3 145,3
2-2,5 29,5 256 315 1580 192,2 93,9
3,5-4 29,0 186 920 2100 548,7 179,7
4-4,5 28,0 263 640 1540 391,7 121,2
5,5-6 29,0 256 1950 1470 1283,4 213,5
6-6,5 28,0 244 1800 1510 1332,1 223,9
6S 1,5-2 30,0 263 345 1550 214,6 90,0
2-2,5 29,7 218 405 1800 248,0 105,2
3,5-4 29,7 260 680 1500 480,4 113,0
4-4,5 29,6 255 660 1510 473,9 113,5
5,5-6 29,5 283 2150 1350 1353,3 151,4
6-6,5 28,5 212 2400 1740 1706,9 197,1
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APPENDIX IV.2 CONTINUE






































INULIN CREATININE PAH Ac PAH
»g/l utol/1 og/1 #g/l
400 1380 227,8 173,6
225 750 128,0 99,2
2850 4440 1953,4 566,8
1100 1630 604,6 277,6
1450 770 944,4 191,5
2350 1420 1836,8 395,3
420 1180 209,7 101,6
600 1530 281,0 145,4
750 1100 385,1 129,9
945 1520 513,5 172,9
4450 2340 2913,2 440,2
2650 1300 1641,7 266,9
345 970 187,2 75,2
300 810 178,7 71,2
720 1010 469,7 159,1
645 870 397,4 102,4
2100 900 1268,4 196,9
2050 950 1266,0 206,8
375 1480 222,1 97,9
500 2070 291,3 108,8
950 1920 593,8 180,9
950 1380 590,1 180,6
3050 1520 2022,6 305,3
2750 1420 1890,1 303,2
275 1150 157,4 77.9
725 1550 472,4 131,4
2175 1570 1633,3 210,2
400 1170 213,9 86,9
700 2550 454,7 175,9
1050 1660 594,6 157,3
1950 2970 1213,1 306,2
2400 1180 1577,6 203,3
2650 1410 1688,1 241,5
-336-
PUBLICATIONS
The following are the titles of published abstracts of
papers presented to the British Pharmacological Society,
which contained data included in this thesis.
FREESTONE, S., McAUSLANE, J.A.N., MACKAY, I.G., COWIE,
J., WATSON, M.L., and PRESCOTT, L.F. (1986). Comparison
of total body clearance and renal clearance of inulin and
p-aminohippuric acid during constant infusion. British
Journal of Clinical Pharmacology, 21, 96P - 97P.
FREESTONE, S., McAUSLANE, J.A.N., MACKAY, I.G., COWIE,
J., WATSON, M.L., and PRESCOTT, L.F. (1986). Inulin
clearance after single intravenous injection : A re-
evaluation. British Journal of Clinical Pharmacology, 21,
97P.
McAUSLANE, J.A.N., FREESTONE, S., BARRON, W. , and
PRESCOTT, L.F. (1987). Disposition and kinetics of PAH
following a single intravenous injection : Measurement of
renal plasma flow. British Journal of Clinical
Pharmacology, 24, 277P.
McAUSLANE, J.A.N., FREESTONE, S., COWIE, J., and
PRESCOTT, L.F. (1987). Tenoxicam : Effect on renal
function in normal man. British Journal of Clinical
Pharmacology, 25, 93-94P.
McAUSLANE, J.A.N., FREESTONE, S., and PRESCOTT, L.F.
(1988). Concentration dependent metabolism and renal
clearance of p-aminohippurate. British Journal of
Clinical Pharmacology, in press.
-337-
